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Ian M. McDonald: Exploring the Controversial Role of MELK in Cancer 
(Under the direction of Lee M. Graves) 
 
 The kinase MELK (maternal embryonic leucine zipper kinase) is upregulated in 
numerous cancers, and high expression levels are correlated with tumor grade, aggressiveness, 
radioresistance, and poor prognosis.  Depletion of MELK with RNAi causes slowed proliferation 
and induces apoptosis in triple-negative breast cancer (TNBC) and other cancers, and these 
antiproliferative effects can be rescued by exogenous MELK expression, indicating they are due 
specifically to MELK loss.  Recently, it was demonstrated that CRISPR/Cas9-mediated MELK 
knockout has no effect on the proliferation of TNBC and other cancer cells.  These disparate 
results have called into question the purported requirement for MELK in cancer, and have 
underscored the need for a deeper understanding of MELK functions in cancer. 
 In this dissertation, I demonstrate that the antiproliferative effects of MELK silencing 
extend to pancreatic cancer (PC), and that treatment of PC cells with the chemotherapeutic agent 
gemcitabine upregulates MELK expression.  Multiple novel MELK inhibitors are characterized 
and determined to impair PC cell viability, but the lead compound, UNC2025, fails to sensitize 
cells to gemcitabine and exhibits only moderate selectivity for MELK. 
 Next, I characterize the selectivity of the MELK inhibitors OTSSP167 and NVS-
MELK8a (8a) in TNBC cells, revealing that OTSSP167, the leading MELK inhibitor in the field, 
is poorly selective, while 8a is highly selective for MELK.  I next demonstrate that MELK 
iv 
inhibition with 8a causes delayed mitotic entry in cancer cells, in parallel with delayed activation 
of CDK1 and Aurora A and B.  Cells overcome this delay to enter and complete mitosis after 
approximately 2h.  8a also causes an induction of the DNA double strand break marker p-H2AX 
(S139) and activation of Chk2, suggesting MELK inhibition causes a transient activation of the 
G2/M DNA damage checkpoint.  I investigate protein-protein interactions using the technique 
BioID, and identify CDK1/cyclin B1 and the MCM complex as putative novel MELK 
interactors.  Collectively, this work provides the field with the rationale to use 8a instead of 
OTSSP167 in future studies, on the basis of greatly improved selectivity, and establishes that 
MELK inhibition causes delayed mitotic entry in cancer cells, illuminating a function of MELK 
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 During the entirety of my thesis studies (from early 2015 to early 2020), my project was 
focused on the kinase MELK.  While the singular protein of study remained constant, the 
perspective from which I approached these studies certainly did not.  To say the least, the 
opinions of the field on the requirement of MELK in cancer, and thus the validity of targeting 
MELK for therapeutic purposes has become quite controversial.  Numerous studies published 
during the course of my thesis project made it necessary for me to drastically change my 
approach towards studying MELK.  I address, in detail, the controversy surrounding the 
requirement of MELK in cancer in chapter 1.  Here, I would like to orient the reader as to when 
the studies in each chapter took place, with regards to the prevailing attitude of those in the 
MELK field at that particular time. 
 Chapters 2, 3, and 4 contain research results from my thesis project.  The experiments 
shown in chapter 2 were completed primarily between early 2015 and early 2017.  At this point 
in time, MELK was widely considered a relatively new, attractive therapeutic target in multiple 
cancers.  There was substantial interest in developing novel MELK inhibitors for therapeutic 
purposes, and accordingly, my project centered around identifying and characterizing a new 
MELK inhibitor with therapeutic potential.  In early 2017, the notion of targeting MELK in 
cancer was challenged.  We subsequently abandoned our drug discovery efforts and turned our 
focus to elucidating biological functions of MELK, which were, and still are, quite unclear. 
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 The results shown in chapters 3 and 4 are from experiments completed after early 2017.  
The abrupt change in experimental approach and model system (from pancreatic to triple-
negative breast cancer) were a result of the publications challenging the requirement of MELK in 
breast cancer.  We sought to address this controversy by contributing to the understanding of the 
biological functions of MELK in cancer.   
While the arrival of this paradigm-shifting controversy in the middle of my thesis work 
certainly made for a tumultuous, and at times seemingly hopeless project, I believe it illustrates 
the dynamic nature of academic research quite well.  The MELK story has made it clear that it is 
exceedingly difficult and rare to establish any absolute truth.  The lesson that everything should 
be challenged, and that assumptions and paradigms can always be upended, both in science and 
broadly in other disciplines, is a great one to have learned through experience at a young age.  I 
hope that this work illustrates these principles, and contributes towards a more true 
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CHAPTER 1: INTRODUCTION1 
 
A Brief Overview of MELK: From Discovery to Controversy 
 Throughout this chapter, it will become clear that the essentiality of MELK in cancer has 
recently come under scrutiny.  Some have even questioned whether MELK has any role in 
cancer.  Before deeply analyzing that controversy, I will begin with a brief chronological history 
of MELK to provide context (see Fig. 1.1 for an accompanying timeline).   
In 1997, MELK cDNA was cloned for the first time, in two studies published in rapid 
succession.  The first group sought to identify genes that were important in embryonic genome 
activation.  They ultimately cloned the cDNA of a gene containing a kinase domain sharing 
significant sequence identity with the Snf1/AMPK family kinases.  The cloned kinase also 
contained a leucine zipper motif, and transcription of this gene was increased in mouse 
preimplantation embryos.  Accordingly, the kinase was named MELK (maternal embryonic 
leucine zipper kinase) (1).  Shortly after this, another group cloned the same gene from mice and 
named it MPK38 (murine protein serine/threonine kinase 38) (2).  Five years later, the MELK 
homolog was characterized in Xenopus and named pEg3 (3), not to be confused with PEG3 
(paternally expressed gene 3) (4).  In this study, pEg3 was demonstrated to be phosphorylated in 
a cell cycle-dependent manner to regulate its activity, which is maximal in mitosis (3).  Naming 
 
1A minor portion of this chapter was originally published in the Journal of Biological Chemistry.  The original 
citation is as follows: McDonald, I. M., Grant, G. D., East, M. P., Gilbert, T. S., Wilkerson, E. M., Goldfarb, D., 
Beri, J., Herring, L. E., Vaziri, C., Cook, J. G., Emanuele, M. J., and Graves, L. M. (2020) Mass spectrometry-based 
selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer 
cells. J. Biol. Chem. 295, 2359–2374 
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conventions converged on MELK within a few years, though the name MPK38 is still used 
sporadically in the literature. 
 In 2005, the first study characterizing MELK as a promising cancer target was published.  
Here, it was noted that MELK RNA levels were elevated in a panel of 20 cancer tissues, relative 
to matched normal samples, and that siRNA-mediated MELK knockdown decreased 
proliferation of cervical, breast, colorectal, and pancreatic cancer cell lines (5).  This publication 
spawned dozens of subsequent studies over the next 15 years, demonstrating increased MELK 
expression in numerous cancers, including glioblastoma, breast, prostate, and gastric, and slowed 
proliferation of these and other cancers as a result of RNAi-mediated MELK depletion (6–9).  As 
the body of literature implicating MELK as a promising therapeutic target grew, the first MELK 
inhibitor (OTSSP167 (OTS), also called OTS167) was developed in 2012 (10).  OTS effectively 
impairs growth and induces apoptosis of numerous cancer types, including breast cancer, acute 
myeloid leukemia, and small cell lung cancer, and is currently in four clinical trials (10–12).  
Because of its status as the leading MELK inhibitor, OTS has been used in nearly all functional 
studies of MELK since its development.  It has recently been definitively demonstrated that OTS 
has extremely poor selectivity for MELK (13–16), yet unfortunately, it is still routinely used as a 
tool compound to investigate MELK function. 
 The start of the controversy currently surrounding MELK can be traced back to a 
comprehensive 2014 study, in which MELK was demonstrated to be essential for the 
proliferation of basal-like breast cancer (BLBC) cells, one of the most aggressive subtypes of 
breast cancer.  This study utilized RNAi-mediated MELK knockdown to demonstrate slowed 
proliferation and essentiality, and even showed that growth effects in cells and tumors could be 
rescued with exogenous wild-type MELK expression, but not with kinase-dead MELK (17).  
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Three years later, in 2017, another group used CRISPR/Cas9 genomic knockout to show that 
MELK is not required in triple-negative breast cancer (TNBC) and other cancer types (18).  This 
publication was quickly followed by a study from the group that originally showed essentiality, 
now also claiming that MELK is not required for TNBC cell proliferation, based upon genomic 
MELK knockout and other experimental techniques (16).  To further complicate the situation, 
members of this same group published another study in 2018, asserting that TNBC cells actually 
have a conditional dependency on MELK for proliferation (19).  One could forgive the reader for 
being somewhat confused at this point; the majority of the MELK field likely is as well.  We will 
next more closely examine the evidence on both sides of the controversy concerning the 
requirement of MELK in cancer cells. 
 
Examining the Requirement for MELK in Cancer 
Evidence supporting the requirement for MELK in cancer 
 Perhaps the most robust evidence implicating MELK as an important mediator of cancer 
progression comes in the form of expression analyses between cancerous and normal tissues and 
cells.  Numerous studies have used microarray and TCGA analysis or immunoblotting methods 
to demonstrate that expression of MELK RNA or protein is significantly increased in neoplastic 
cells.  This effect seems to be a characteristic that broadly defines many cancer types, as it has 
been described in breast (17, 20, 21), brain (glioma (6, 22), astrocytoma (23), and neuroblastoma 
(24)), liver (25), prostate (8), bladder (26), and endometrial cancers (27), among others (5).  
Further, high levels of MELK expression correlate with high-grade tumors, increased 
aggressiveness, poor patient outcomes, and radioresistance (17, 20, 21, 24–28).  Increased 
MELK expression has been linked to concurrent upregulation of genes important or essential for 
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cell cycle progression including CDK1, CCNB1/2, TOP2A, AURKB, PLK1, and BUB1 (8, 23, 
29–32), suggesting MELK likely also plays a role in this process. 
 The effects of RNAi-mediated MELK knockdown have resolutely indicated that MELK 
expression is vital to the proliferation and survival of cancer cells.  In cancers including basal-
like breast (17), endometrial (27), glioma (6), acute myeloid leukemia (11), high-risk 
neuroblastoma (24), and hepatocellular carcinoma (25), MELK depletion has been shown to 
slow or halt proliferation of cancer cells and tumors.  Some studies have additionally 
demonstrated that knockdown of MELK sensitizes cells to radiation (17, 21, 33, 34) and impairs 
migration (8, 9, 27, 35).  Crucially, a number of studies have rescued the antiproliferative effects 
of RNAi-mediated MELK knockdown with ectopic MELK expression, indicating that these 
effects are specifically due to loss of MELK (6, 17, 22, 25, 36, 37).  These results were extended 
by two studies that demonstrated that complementation of knockdown with kinase-dead MELK-
D150A or -T167A does not restore normal growth, indicating that catalytic activity is required 
for rescue (17, 37).  Additionally, the oncogenic potential of MELK has been shown using rodent 
fibroblasts that expressed a dominant negative form of p53 (Rat1-p53DD), which necessitate 
only one oncogenic event for neoplastic transformation.  When wild-type, but not kinase-dead, 
MELK was overexpressed, these cells gained the ability to grow in an anchorage independent 
manner and form tumors in vivo, evidence of transformation indicating that MELK may function 
as a driver oncogene (17). 
It was recently demonstrated that CRISPR/Cas9-mediated MELK knockout impaired 
proliferation and induced apoptosis in chronic lymphocytic leukemia cells (35).  It should be 
noted that this is the only study that has shown a growth effect resulting from MELK knockout.  
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Other studies that demonstrate no phenotype in MELK knockout cells will be discussed in the 
next section. 
 Multiple MELK inhibitors have been developed as potential cancer therapeutics 
(discussed in more detail later in this chapter).  The molecules OTS (10), NVS-MELK8a (8a) 
(14, 38), HTH-01-091 (16), MELK-T1 (39), IN17 (40), and C1 (22) have all demonstrated 
preclinical efficacy in slowing cancer cell proliferation, with OTS exhibiting such potent, broad 
anti-neoplastic effects that it has advanced to phase I/II clinical trials (11, 12, 24, 35, 41–43).  
Certainly, all small-molecule inhibitors exhibit some degree of polypharmacology, so the 
antiproliferative effects of these compounds cannot be solely attributed to MELK inhibition.  For 
the inhibitor 8a, the cell viability of TNBC cells has been shown to be reduced at concentrations 
at which 8a is highly selective for MELK, suggesting that inhibition of MELK is a major 
contributor to its antiproliferative effects (14). 
 
Evidence against the requirement for MELK in cancer 
On the other side of the controversy are a series of studies that used CRISPR/Cas9 to 
genetically knockout MELK, revealing no growth phenotype in MELK null cell lines.  The first 
of these studies used both single and double guide RNA (gRNA) strategies to genetically delete 
MELK from a panel of TNBC cell lines, with some experiments additionally completed in other 
cancers.  For the single gRNA strategy, seven independent gRNAs were used to generate clonal 
MELK null A375, Cal51, and MDA-MB-231 cell lines, and these lines were compared to 
Rosa26 (a non-essential, non-coding gene) knockout control lines in growth assays.  Both cell 
proliferation and anchorage independent growth were unaffected by MELK knockout.  The 
double gRNA strategy was used to induce DNA cutting in two places, excising a portion of the 
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MELK gene that encodes for residues essential for ATP binding in two TNBC cells lines.  Long-
term growth assays were repeated with these MELK knockout cell lines, and again they were 
found to proliferate normally, indicating that MELK is not required for TNBC proliferation (18). 
Reasoning that signaling pathway adaptations may have occurred during the extensive 
time required for clonal selection, which could restore normal cell proliferation, the authors 
employed a GFP dropout assay to assess cell proliferation more proximal to MELK deletion.  
Briefly, seven Cas9-expressing TNBC cell lines were transduced with seven independent gRNAs 
targeting MELK or three gRNAs targeting Rosa26, RPA, or PCNA.  Transductions were done at 
a low MOI to ensure that some portion of cells remained untransduced.  gRNA plasmids 
additionally expressed GFP, which allowed for the proportion of GFP+ to GFP- cells to be 
monitored over five passages to assess the relative fitness of cells that had been transduced with 
MELK or control gRNA relative to their untransduced counterparts.  Less than 2-fold dropout of 
MELK and Rosa26 knockout cells was observed, compared to 5- to 100-fold dropout of the 
positive control RPA or PCNA knockout cells, again suggesting that MELK is not a requirement 
for TNBC proliferation.  Crucially, the methods for this study indicate that the baseline 
GFP+/GFP- measurement was not taken until 3 days post-transduction, with the first reading 
assessing GFP dropout measured 3-4 days later.  While the authors state that this GFP dropout 
assay was used in an effort to test the effects of MELK knockout immediately following MELK 
loss, the 3 days that passed between gRNA transduction and baseline readings could certainly 
still allow ample time for cellular reprogramming that restores normal growth (18). 
The next CRISPR study replicated many of the results described above, while also using 
additional techniques to test MELK dependency (16).  Again, MELK null MDA-MB-468 cells 
were observed to have no growth phenotype relative to control cells.  A chemical-induced 
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protein degradation approach was additionally employed to show that MELK loss had no 
immediate or prolonged effects on BLBC proliferation.  The authors state that MELK expression 
was maintained throughout the process of creating these cell lines, by first stably expressing a 
FKBP12-MELK fusion that could be selectively degraded with an engineered degrader 
molecule, then deleting endogenous MELK with CRISPR.  Importantly, it was never 
demonstrated that this MELK fusion is similarly functional to endogenous MELK (i.e. 
interactions and substrate phosphorylations are unperturbed by FKBP12 fusion).  It therefore 
cannot be ruled out that this cell line is simply another MELK knockout line, which has had 
ample time during clonal selection for reprogramming of signaling pathways, that additionally 
expresses a non-functional MELK fusion. 
This study also demonstrated quite convincingly that MELK knockdown with CRISPR 
interference (CRISPRi) has no effect on BLBC cell proliferation.  MDA-MB-468 cells were 
transduced with KRAB-dCas9, a catalytically dead version of Cas9 that allows for 
transcriptional repression of the gRNA-targeted gene.  Multiple gRNAs targeting the MELK 
promoter were shown to efficiently decrease MELK transcript and protein levels, and five of 
these gRNAs were cloned into a doxycycline-inducible vector and stable cell lines were 
generated.  Using this system, MELK knockdown by doxycycline treatment was not found to 
significantly decrease cell proliferation in any of the five cell lines.  It should be noted that, while 
not statistically significant, all cell lines did exhibit slightly decreased growth (~5-20%) when 
treated with doxycycline, compared to untreated controls (16). 
A follow-on study to the first MELK CRISPR paper was completed by the same group 
roughly a year later, in which they expanded upon their previous results (44).  In stark contrast to 
previous results by Wang et al. (17), MELK overexpression was found to be insufficient for 
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neoplastic transformation of immortalized cell lines as measured by anchorage-independent 
growth assays (44).  Multiple cell models were used to test transformation potential, including 
the Rat1-p53DD system used in the study by Wang et al.  Similarly, MELK knockout TNBC, 
melanoma, and colorectal cell lines did not exhibit impaired anchorage-independent growth.  
This study additionally found that genetic deletion of MELK did not impair proliferation of 
cancer cells plated at varying densities in crystal violet assays, and had no effect on cancer cell 
sensitivity to five common chemotherapeutic agents or to metabolic stresses including hypoxia, 
glucose limitation or exposure to reactive oxygen species.  CRISPR-mediated MELK knockout 
also had no effect on the proliferation of tumor xenografts in mice (44). 
 
Commentary on the MELK Requirement Controversy 
I will first discuss the specific evidence supporting a requirement for MELK in cancer, 
then the evidence rebutting a MELK requirement, before providing overall commentary on the 
controversy, including gaps in knowledge that should be addressed to improve our understanding 
of the role of MELK in cancer. 
 Some of the results suggesting that MELK is a cancer requirement have been recently 
refuted or can now be viewed with added perspective.  Specifically, neoplastic transformation of 
immortalized cells was demonstrated with MELK overexpression in one model (17), but these 
results were later convincingly refuted by another group using the same and additional models 
(44).  Multiple MELK inhibitors have demonstrated antiproliferative effects, but it is not possible 
to conclude that any of the observed effects are due solely to MELK inhibition.  The possibility 
of off-target inhibition contributing to observed phenotypes cannot be discounted.  Results from 
dozens of studies have demonstrated that MELK expression is upregulated in cancer, and that 
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higher levels of MELK correlate with tumor grade and poor prognosis.  However, these results 
are purely correlative in nature.  It has been suggested that MELK may be upregulated as part of 
a cell cycle/mitotic cluster of genes in cancer cells simply due to the fact that these cells 
proliferate more rapidly than their non-neoplastic counterparts (44).  None of these results 
provide strong evidence that MELK is a cancer dependency. 
 Other results provide more convincing evidence of MELK’s importance in cancer.  
Numerous studies have demonstrated that RNAi-mediated MELK knockdown slows 
proliferation, induces apoptosis, and decreases migration and radioresistance of cancer cells, 
providing quite compelling evidence that MELK is required in cancer cells.  While it has been 
documented that RNAi approaches often have off-target silencing effects (45), the use of 
multiple sh- or siRNA in a single study that cause similar phenotypes suggests that depletion of 
the common target of the sh/siRNA (i.e. MELK) was responsible for the observed phenotypes.  
When this is expanded to a large number of studies (~30) completed by separate groups, all 
showing evidence of similar phenotypes in varied cancers, it provides quite strong evidence that 
the phenotypes observed are due to MELK loss.  Even stronger evidence that the observed 
proliferative effects are due specifically to MELK loss were provided by the studies showing 
successful rescue experiments.  Six studies, all completed by different groups, have rescued the 
effects of MELK knockdown with exogenous MELK expression (6, 17, 22, 25, 36, 37), 
including at least two that demonstrated a failure to rescue with kinase-dead MELK (17, 37). 
 The only partially contrasting results come from the study that used CRISPRi to show 
that depletion of MELK transcript had no significant growth effect in TNBC cells (16).  This has 
only been demonstrated in one study, compared to a large body of work demonstrating that 
MELK depletion with RNAi has antiproliferative effects.  Further, it is important to note that 
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CRISPRi is an orthogonal approach to RNAi, not an identical one.  Differences in observed 
effects could therefore be due to technical differences between the approaches.  This CRISPRi 
result also does not account for or explain the results observed with rescue experiments.  The 
only effort ever made to rebut rescue experiment results appeared in the discussion of the paper 
that showed no growth phenotype following CRISPRi-mediated MELK depletion.  The authors 
stated that, “Since the previous study was able to rescue the antiproliferative activity observed 
for shMELK-2 using an shRNA-resistant MELK (Wang et al., 2014), we postulated that the 
potential off-target of shMELK-2 might only manifest its effect in the presence of MELK 
knockdown, a so-called ‘synthetic lethal’ interaction.”  Absent any data to support this claim, we 
find this to be an extremely unlikely scenario to have occurred in one study, and a near-
impossibility when considering that six independent groups, all using different RNAi knockdown 
and rescue reagents, have successfully rescued growth phenotypes with exogenous MELK. 
 On the other side of the controversy, there are three studies that have demonstrated that 
CRISPR-mediated MELK knockout has no effect on proliferation of TNBC and other cancer 
cells (16, 18, 44).  Recently, contrasting results have been presented, indicating that MELK 
knockout induces apoptosis and slows proliferation of chronic lymphocytic leukemia cells (35), 
though the former three studies were more thorough in their analyses of MELK deletion and 
subsequent growth assays.  It is possible that technical or cell line-dependent differences account 
for the conflicting results between these studies.  Importantly, in the studies that showed no 
growth phenotype as a result of MELK knockout, the methods used do not preclude the 
possibility that cellular reprogramming of signaling pathways occurred to circumvent MELK 
loss and restore normal growth. 
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While these studies showed compelling evidence that MELK is not a cancer cell 
dependency, efforts should be made to more comprehensively characterize MELK knockout cell 
lines.  There is at least one documented instance of purported knockout cell lines actually still 
expressing splice variants of the targeted protein.  Bub1 was thought to be essential for proper 
functioning of the spindle assembly checkpoint (SAC), until CRISPR-mediated Bub1 knockout 
cells were shown to have a functional SAC.  Recently, however, RT-PCR and MS-based 
approaches were used to show that these Bub1 “knockout” cells still expressed low levels of 
alternatively spliced Bub1 or Bub1 protein with a small deletion.  Subsequent experiments 
demonstrated that Bub1 is indeed essential to the SAC, and that very low levels of Bub1 were 
sufficient to restore normal SAC functioning (46–48).  This level of evasion of CRISPR-
mediated gene deletion is likely more of an exception than a rule.  Nonetheless, MS-based 
approaches should be used to exclude the possibility that MELK knockout cell lines express 
alternatively spliced MELK, or other gene- or protein-level adaptations that evade complete 
MELK knockout. 
Overall, assuming no technical shortcomings, CRISPR-based results indicate that MELK 
is not a strict requirement for cancer cell proliferation.  The abundant RNAi studies, however, 
indicate that MELK does play an important, yet poorly defined role in cancer.  How does the 
field rectify this apparent paradox?  One possible explanation is that MELK is dispensable under 
some conditions, but required, or at least highly important, under others.  In this vein, members 
of the group that initially labeled MELK essential for BLBC cell proliferation (17), and later said 
it was not necessary for proliferation of these cells (16), recently published a study indicating 
that TNBC cells have a conditional dependency on MELK for growth (19).  In this study, TNBC 
cells were transduced with a gRNA (plus Cas9) that caused efficient reduction of MELK 
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expression, and selected for infected cells with antibiotic.  This approach, which utilized a 
heterogeneous population of cells instead of clonal selection, is more akin to depletion of MELK 
expression than total knockout.  CRISPR-mediated depletion of MELK was shown to have no 
effect on the proliferation of TNBC cells in short-term growth assays, in which cells were seeded 
at medium to high density (MDA-MB-231 cells, 50,000 cells/well seeded on a 12-well plate, 3-
day assay).  However, when MELK was depleted and cells were seeded at low density (MDA-
MB-231 cells, 500 cells/well seeded on a 12-well plate, 10-day assay), they exhibited markedly 
slower proliferation relative to control cells.  These experiments were also completed with 
gRNAs targeting the essential mitotic genes AURKB and PLK1, and the oncogenes KRAS and 
MYC.  CRISPR-mediated depletion of AURKB and PLK1 slowed proliferation of cells seeded 
at high or low densities, indicating that the effects of knockout of truly essential genes occur 
independently of assay conditions.  Depletion of KRAS and MYC caused moderate decreases in 
proliferation (50%) when cells were seeded at high densities, and more markedly impaired 
proliferation (>90%) when seeded at lower densities (19).  Collectively, these results suggest that 
MELK is likely not universally essential in cancer cells, but under specific growth conditions 
MELK expression seems to be important.  MELK may conditionally function as an oncogene 
without being a strict essentiality for cancer cells. 
Authors of some of the CRISPR studies have suggested that MELK does not play an 
important role, or may not even play any role, in mammalian biology and the cell cycle 
progression of cancer cells (18, 44).  However, the fact that MELK expression is cell cycle 
regulated (17, 27, 49, 50), and that the upregulation of MELK in cancer correlates with 
upregulation of many other important or essential mitotic genes, including CDK1, CCNB1/2, 
TOP2A, AURKB, PLK1, and BUB1 (8, 23, 29–32), suggests that MELK plays a role in cancer 
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cell proliferation despite negative results from CRISPR studies.  Why would MELK be cell cycle 
regulated and consistently upregulated in concert with many essential mitotic proteins if it did 
not contribute to these processes?  There are a few possible explanations for the observations that 
MELK expression is tightly correlated with the cell cycle, yet MELK knockout does not perturb 
growth.  In line with the conditional dependency hypothesis, it is possible that MELK acts as a 
functional redundancy for a specific cell cycle pathway, such that MELK is nonessential during 
normal cell cycling, but becomes required under certain conditions.  Conversely, there may be a 
functional redundancy for MELK, such that total loss of MELK (i.e. CRISPR knockout) allows 
for compensatory reprogramming of signaling networks, while RNAi-mediated partial MELK 
depletion does not trigger the reprogramming necessary to shift to this redundant pathway. 
The recent controversy concerning the requirement for MELK in cancer has underscored 
a few important scientific principles.  First, it is imperative not to overinterpret negative results, 
as there are a wide variety of potential explanations for the lack of any observed phenotype, 
ranging from functional or biological to purely technical or methodological, as the Bub1 
CRISPR story illustrates.  Second, technical considerations, while often only given cursory 
attention in publications, are vitally important.  The observation that CRISPR-mediated MELK 
depletion has differing effects in TNBC cells depending upon cell density serves as an 
illustration of this.  Third, when orthogonal approaches do not give identical results, it does not 
necessarily mean that one result is correct, while the other is incorrect.  Rather, a more complex 
and interesting biological explanation may be underlying the seemingly discordant results. 
To expand upon the third principle in the context of the MELK controversy, authors of 
the CRISPR studies have attempted to conclude that MELK is not important to cancer cell 
proliferation, and that MELK is not a viable therapeutic target.  Neither of these assertions are 
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definitively supported by their results demonstrating no growth phenotype following CRISPR-
mediated MELK deletion.  While these studies have provided strong evidence that MELK is not 
essential to cancer cells, they have done nothing to rebut the studies that coupled RNAi depletion 
with rescue, indicating that MELK is important for proliferation, and the therapeutic viability of 
inhibiting MELK should not yet be fully discounted, particularly in combination with other 
chemotherapeutic agents.  It is vitally important to recognize that CRISPR-mediated genetic 
knockout, RNAi-mediated transcript depletion, and pharmacological inhibition are three 
orthogonal, but fundamentally different approaches.  While some view CRISPR technologies as 
a universal improvement over RNAi-based approaches, this view is not entirely accurate.  Off-
target effects are less prevalent with CRISPR than RNAi, but both techniques still have their 
advantages and limitations (51–54).  Results obtained with RNAi knockdown and subsequent 
rescue, long considered the gold standard for functional studies, still hold tremendous value, as 
this approach mitigates the off-target effects of RNAi.  Further, while CRISPR technologies are 
undeniably powerful, they are also still relatively new, with CRISPR first being used for genome 
editing in 2013 (55).  Some aspects of CRISPR/Cas9 gene editing are still not entirely 
understood, including central parts of the technology such as prediction of the on- and off-target 
DNA cutting efficiency of specific gRNAs (51, 52).  The scientific community is still uncovering 
some of the intricacies of this powerful, yet complex approach.  As such, negative results 
obtained with CRISPR should be continually re-evaluated as new information becomes 
available.  Finally, the advent and widespread implementation of CRISPR for functional studies 
does not render RNAi-based approaches obsolete, particularly when coupled with exogenous 
complementation. 
15 
The field should continue to investigate the controversy concerning the requirement of 
MELK in cancer.  Future efforts to better understand the functions of MELK in cancer will likely 
shed light on the mechanism underlying discordant results observed with CRISPR and RNAi, 
which could be broadly applicable to functional studies of other proteins using these techniques.  
Some studies have begun to investigate the specific conditions under which MELK expression 
seems to be required, but the conditions tested thus far are certainly not comprehensive (19, 44).  
Efforts to elucidate the specific conditions under which MELK is important for cancer cell 
proliferation will be a crucial step towards a more complete functional understanding of this 
kinase.  There are seemingly more questions than answers in the MELK field at the present 
moment.  In subsequent sections, we will discuss the small-molecule tools available to study 
MELK and what is known about MELK functions, regulation, and substrates. 
 
The MELK Inhibitor Landscape 
 The first MELK inhibitor to be developed, and far and away the most widely-used 
MELK inhibitor, is OTSSP167 (OTS) (10).  This inhibitor has demonstrated potent anti-
proliferative effects against numerous cancers including TNBC (17), multiple myeloma (42), 
acute myeloid leukemia (11), neuroblastoma (28), and small cell lung cancer (12).  
Consequently, OTS has advanced to phase I/II clinical trials for patients with advanced TNBC or 
refractory or relapsed leukemia (NCT01910545, NCT02795520, NCT02768519, 
NCT02926690).  It has recently been demonstrated that OTS has extremely poor selectivity for 
MELK, both in biochemical assays and in cells, and exerts its antiproliferative effects through 
inhibition of many kinases, some of which are vital mitotic kinases (13–16).  Nonetheless, the 
polypharmacology that is characteristic of OTS is clearly effective at halting cancer cell 
proliferation and inducing apoptosis, and thus the rationale for its inclusion in clinical trials 
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remains sound, provided that MELK expression levels are not used to set patient 
inclusion/exclusion criteria or to stratify experimental groups. 
 OTS should not be used as a tool compound to study the specific effects of MELK 
inhibition on cellular processes, as the potential to misattribute observed phenotypes to specific 
MELK inhibition is high.  In the original study that described the development of OTS, this 
molecule was described as a highly selective MELK inhibitor, despite a complete dearth of data 
to support this claim (10).  Unfortunately, this has caused a multitude of groups to subsequently 
use OTS for functional MELK studies.  This includes multiple studies that have primarily or 
exclusively used OTS to draw conclusions about MELK biology (28, 43, 56–58).  Additionally, 
many studies continue to claim that OTS is highly selective, also without supporting data, and 
despite the fact that multiple studies have been published definitively demonstrating the opposite 
(13–16).  Conclusions about MELK function drawn solely through experiments using OTS must 
be interpreted with extreme caution, and should be repeated with RNAi or CRISPRi approaches, 
or other MELK inhibitors, for validation. 
 Additional MELK inhibitors have been described and characterized since the 
development of OTS, although none have garnered serious attention as potential therapeutic 
options for cancer treatment.  Cpd1 and Cpd2 exhibit nanomolar potency for MELK with good 
selectivity against a panel of 50 kinases, and treatment of multiple cancer cell lines with Cpd2 
induces PARP cleavage (59).  Compound C1 also showed nanomolar potency for MELK in in 
vitro assays, though it is a noted multi-kinase inhibitor and was originally designed to inhibit the 
Aurora kinases.  Treatment of glioma stem cells with this inhibitor caused mitotic arrest, induced 
apoptosis, and sensitized cells to radiation (22, 60).  MELK-T1 (61) and MELK-T2 (62) both 
have demonstrated nanomolar potency for MELK.  The former compound is the more selective 
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of the two, with only 6 kinases (including MELK) out of 235 tested using an in vitro assay 
inhibited greater than 50% at 1 μM.  Phenotypic effects of these inhibitors were not explored in 
these studies.  The inhibitors NVS-MELK8a (8a) and NVS-MELK8b exhibited low nanomolar 
potency and high selectivity for MELK, as determined using an in vitro assay against a panel of 
456 kinases.  These molecules had antiproliferative effects against TNBC cells, causing 
increased apoptosis, polyploidy, and G2/M accumulation, but not luminal breast cancer cells 
(38).  Another low nanomolar inhibitor of MELK, HTH-01-091 (HTH), showed fairly good 
selectivity, with only 4% of 141 kinases inhibited greater than 90% by 1 μM compound, 
determined using an in vitro assay.  HTH was described as being cell permeable and having 
moderate antiproliferative effects (in the low μM range) against breast cancer cells (16).  
Compound 17, or IN17, was shown to also have nanomolar potency for MELK, but selectivity 
was only moderate against a panel of 5 closely related kinases.  This molecule additionally 
impaired proliferation of TNBC cells, though potency in growth assays was notably cell type-
dependent (40). 
A series of low nanomolar MELK inhibitors were published in 2017, with extensive 
selectivity data presented from in vitro assays (63).  The effects of these inhibitors on cancer cell 
growth were not demonstrated.  Another series of inhibitors was published a year later, though 
the potency of this series for MELK was rather low compared to other published inhibitors.  The 
most potent molecules from this series, compounds 4 and 16, have low micromolar to high 
nanomolar potency for MELK.  No selectivity data were presented, and cancer cell proliferation 
was unaffected by these compounds (64).  In 2018, yet another series of MELK inhibitors was 
described, with compounds 52 and 29 presented as the most promising for future studies based 
upon potency and selectivity for MELK, respectively.  The effects of these compounds on cancer 
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cell growth were not investigated (65).  Finally, the compound 16h was published in 2020.  This 
molecule was found to be a highly potent (low nanomolar), but poorly selective inhibitor of 
MELK, that exhibited antiproliferative effects against breast cancer cells (66).  The majority of 
these studies present extensive structure-activity relationship data, and many additionally show 
inhibitor binding modes based upon crystallography or computer modeling.  This wealth of 
information could be used for further MELK inhibitor optimization for improved potency and 
selectivity. 
 Of these MELK inhibitors, only MELK-T1, HTH, and 8a have been used in studies by 
groups other than the one responsible for development of the inhibitor.  MELK-T1 was found to 
impair proliferation of breast cancer cells by inducing replication fork stalling and DNA double-
strand breaks, resulting in a senescence-like phenotype (39).  Despite HTH being previously 
described as a cell permeable molecule, recent results suggest it does not engage and inhibit 
MELK in TNBC cells.  A chemical proteomics approach called competition MIB/MS (described 
in chapter 3) was used to show that treatment of TNBC cells with 1 μM HTH did not prevent the 
subsequent capture of MELK by immobilized pan-kinase inhibitors.  In the same study, the 
competition MIB/MS technique was used to demonstrate that 1 or 3 μM 8a treatment of TNBC 
cells significantly prevented MELK binding to inhibitor beads, and did not substantially prevent 
the binding of over 200 other kinases.  These results indicated that 8a is a moderately potent, 
highly selective inhibitor of MELK in cells.  8a was subsequently used to show that MELK 
inhibition in HeLaS3 or U2OS cells caused a delay in mitotic entry consistent with transient 
activation of the G2/M checkpoint (14). 
 In summation, data from biochemical and cellular assays indicate unequivocally that OTS 
should not be used as a tool compound to investigate MELK function.  NVS-MELK8a is a 
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suitable alternative for functional MELK studies, based upon strong biochemical selectivity data 
and recent selectivity profiling results completed in TNBC cells.  There are a number of 
additional MELK inhibitors that appear to have good potency for MELK and favorable 
selectivity profiles in biochemical assays, most notably MELK-T1.  Future studies should use 
cellular selectivity profiling approaches to further characterize these inhibitors, with the goal of 
identifying additional highly selective molecules suitable for interrogating MELK function. 
 
Processes Regulated by MELK in Cancer 
 MELK has been implicated in various processes, but a comprehensive understanding of 
its overarching function in cancer cells is still lacking.  In this section I will discuss some of the 
major processes to which MELK has been linked. 
 
Proliferation and cancer aggressiveness 
 The connection to these processes was discussed in detail previously, in the section 
examining the requirement of MELK in cancer.  In brief, high MELK expression levels have 
been consistently correlated with increased proliferation, aggressiveness, and tumor grade of 
cancers (67).  It is unclear whether MELK acts as a driver of these processes; there is some 
speculation that MELK is simply upregulated as part of a mitotic cluster of genes (44). 
 To expand upon these results mechanistically, recent studies have suggested that the 
proliferative effects of MELK may be mediated through the NF-κB pathway.  In melanoma cells, 
MELK knockdown or inhibition with OTS or 8a decreased NF-κB pathway signaling, which 
decreased cell proliferation.  MELK was found to phosphorylate SQSTM1 (also called p62), a 
known regulator of NF-κB, to drive these effects.  Depletion of SQSTM1 also decreased NF-κB 
signaling.  Overexpression of constitutively active IKKβ, a downstream activator of NF-κB, 
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partially rescued the NF-κB signaling and anti-proliferative effects caused by OTS or 8a 
treatment, indicating that these effects were driven by loss of MELK-SQSTM1 signaling through 
the NF-κB pathway (37).  It has also been reported that MELK phosphorylates and activates 
EZH2, which subsequently methylates NF-κB.  This methylation caused increased transcription 
of NF-κB target genes, and loss of MELK/EZH2-mediated methylation impaired glioblastoma 
cell and tumor proliferation (68).  Other studies have reported that the anti-proliferative effects of 
MELK knockdown or inhibition with OTS are due to decreased signaling through the mTOR 
pathway.  In endometrial carcinoma and clear cell renal cell carcinoma, MELK may interact with 
MLST8 and phosphorylate PRAS40, respectively, to regulate proliferation of cells via activation 
of the mTOR signaling pathway (27, 69).  Additional studies are needed to clarify the 
mechanism underlying the role of MELK in cancer cell proliferation and aggressiveness. 
 
Cell cycle progression 
 A substantial number of studies have linked MELK with cell cycle progression, but the 
specific functions of MELK in this process have not been well-elucidated.  There is not a 
consensus as to which phases of the cell cycle are most affected by MELK perturbation. 
 The largest body of evidence suggests that MELK regulates G2 and M phases of the cell 
cycle.  MELK expression is partially regulated by the transcription factors E2F1 and FoxM1 (17, 
27, 37, 70, 71).  Accordingly, MELK expression oscillates during the cell cycle, increasing 
throughout S phase, reaching maximal levels around the G2/M transition, and declining upon 
mitotic exit (17, 49, 50, 72).  Multiple studies have reported that MELK knockdown causes a 
G2/M accumulation of cells, though these studies have frequently used DNA quantification by 
flow cytometry to draw this conclusion (5, 9, 35, 38, 41).  This approach does not allow for 
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differentiation between cells in G2 and M phases.  Overexpression of MELK may also induce a 
G2/M accumulation of cells (5, 73).   
Some studies have used methods that distinguish between G2 and M phenotypes resulting 
from MELK perturbation.  MELK knockdown has been reported to impair mitotic progression 
by varied mechanisms, including by decreasing activity and expression of the oncogenic mitotic 
transcription factor FoxM1 (39, 74), by regulating MCL1 synthesis in mitosis (75), by inducing 
mitotic catastrophe (22), and by causing cytokinetic defects (17, 76, 77).  A role for MELK 
specifically in G2 has also been demonstrated.  Overexpression (73) or selective inhibition of 
MELK with 8a (14) has been shown to increase the length of G2 phase, consistent with 
activation of the G2/M DNA damage checkpoint.  Collectively, these results suggest that MELK 
likely functions as a regulator of both the G2/M checkpoint and mitosis, similar to other crucial 
cell cycle-regulated kinases including CDK1, PLK1, and Aurora A (78). 
 A few studies have also described a role for MELK in G1 and S phases of the cell cycle.  
MELK knockdown has been shown to induce an accumulation of cells in G1 in glioblastoma 
(79) (retracted) or bladder cancer (26).  Both studies depleted MELK with RNAi for 48h or more 
before quantifying DNA content by flow cytometry, which leaves open the possibility that G1 
accumulation was a secondary effect of MELK loss following mitotic defects.  Progression 
through S phase is impaired by MELK knockdown (39, 79) (latter paper retracted) or inhibition 
with MELK-T1 (39) or OTS (26).  Specifically, these treatments caused replication fork stalling, 





DNA damage response and therapeutic resistance 
 Reduction of MELK expression or activity (with MELK-T1) has been reported to cause 
DSBs and induce the DDR specifically through activation of the ATM/Chk2 pathway (26, 39).  
Induction of p53 expression has been reported following MELK inhibition with OTS, but has not 
been replicated with more selective inhibitors (80).  Another study showed that MELK silencing 
in glioblastoma cells induced p53 expression, while overexpression had the opposite effect, and 
apoptotic effects caused by MELK depletion could be partially rescued by p53 knockdown or 
inhibition (81).  An increase in p53 phosphorylation, with no change in expression, has been 
demonstrated with MELK-T1 treatment (39).  In a separate study by this group (which was later 
retracted for immunoblot image duplication) MELK knockdown was demonstrated to not affect 
total p53 levels in glioblastoma cells, but rather caused downregulation of MDMX, an inhibitor 
of p53, and this effect could be rescued by exogenous MELK expression (79).  Clearly, while 
perturbation of MELK activity or expression results in some sort of DDR, the precise 
mechanisms remain elusive. 
MELK has been implicated as a mediator of radio- and chemotherapeutic resistance.  
Treatment of colorectal cancer cells with radiation or the DNA damaging agent 5-fluorouracil 
caused an upregulation of MELK, and pre-treatment with MELK siRNA sensitized cells to 5-
fluorouracil (34).  Similarly, MELK expression is correlated with radioresistance in breast cancer 
cell lines.  Knockdown or inhibition of MELK (with OTS) in combination with radiation induced 
the DNA damage marker p-H2AX (S139) in vitro, and markedly sensitized cells to radiation 
both in vitro and in tumor xenografts (21).  While MELK has been linked to DNA damage 
response pathways by numerous studies, our understanding of its function in the DDR still 
requires further characterization. 
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Migration and invasion 
Knockdown of MELK has been shown to decrease migration of various cancer types, 
while overexpression has the opposite effect, as measured by wound healing and transwell 
migration assays (9, 26, 27, 41, 69).  The mechanism underlying suppressed migration as a result 
of MELK knockdown was investigated further in gastric cancer.  MELK depletion reduced the 
number of actin stress fibers and filopodia, while overexpression increased stress fibers, 
indicating that MELK regulates cytoskeletal organization.  The effect of MELK silencing on the 
activity of RhoA-GTPases, major regulators of cell migration, was subsequently measured.  
RhoA activity was decreased, while Rac1 and Cdc42 activity was unaffected.  Modulation of 
RhoA activity is likely mediated through the FAK/paxillin pathway.  Decreased phosphorylation 
of both FAK and paxillin was observed in response to MELK silencing, and increased migration 
induced by MELK overexpression was suppressed by treatment with FAK inhibitor I.  A direct 
physical interaction between MELK and FAK or paxillin was not demonstrated, however, so 
observed differences in phosphorylation may be indirect effects (9).  Another study demonstrated 
that MELK knockdown or inhibition with OTS suppressed invasion both in vitro and in vivo, and 
that resulting changes in cell morphology were consistent with epithelial-mesenchymal transition 
(EMT).  MELK depletion altered expression of proteins involved in the EMT process.  
Specifically, E-cadherin was upregulated, and N-cadherin, vimentin, and snail were observed to 
be downregulated by immunoblotting (41). 
 
Apoptosis 
 While the vast majority of studies indicate that MELK is a pro-survival kinase (see 
proliferation and cell cycle progression sections, above), results from one group suggest that it 
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may also function in a pro-apoptotic role.  This pro-apoptotic function may be redox-dependent, 
and is purportedly mediated through direct interaction with and phosphorylation of ASK1 (82), 
p53 (83), STRAP (84), and SMAD2, -3, -4, and -7 (85).  The studies implicating MELK in pro-
apoptotic and pro-survival functions have been reviewed previously (67, 86).  Future studies 
should aim to clarify the inputs controlling these disparate functions. 
 
Cancer stem cell phenotype 
 The role of MELK in tumor initiation and maintenance of cancer stem cell state has been 
studied fairly extensively.  MELK expression has been shown to be increased in breast (36) and 
glioma (72, 81, 87, 88) cancer stem and tumor initiating cells relative to non-stem cancer cells.  
In breast cancer, cells with higher levels of MELK expression were found to form increased 
tumorspheres in vitro and exhibited enhanced tumor initiation in mice.  MELK depletion with 
shRNA decreased tumorsphere formation, which could be rescued completely with exogenous 
MELK expression (36).  MELK knockdown in multipotent neural progenitor cells impaired 
neurosphere formation, while overexpression enhanced formation, indicating that MELK 
functions in tumor initiation (72).  In glioma stem cells (GSCs), treatment with siomycin A, an 
inhibitor of FoxM1, decreased MELK expression and inhibited self-renewal, proliferation, and 
invasion.  Overexpression of MELK partially rescued these effects, suggesting they are mediated 
at least in part through MELK.  Importantly, treatment of non-stem tumor cells or normal neural 
progenitor cells with siomycin A had little effect on growth (88).  Treatment with compound C1, 
an inhibitor of MELK and other kinases, impaired the proliferation of GSCs moreso than their 
non-stem counterparts (22). 
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 Mechanistically, the function of MELK in cancer stem cells is mediated in part through 
the oncogenic transcription factors FoxM1 and c-JUN.  The expression of FoxM1 has been 
shown to be important for neural progenitor cell growth and neurosphere formation using 
knockdown and overexpression studies.  In this system, MELK phosphorylates FoxM1 to 
increase its transcriptional activity in a PLK1-dependent manner, which results in increased 
mitotic gene expression.  Proliferation of GSCs was again shown to be more sensitive to 
siomycin A than neural progenitor cells.  Antiproliferative effects of this compound could be 
rescued with overexpression of both FoxM1 and MELK, but not with overexpression of either 
protein alone, suggesting that disruption of the MELK-FoxM1 interaction mediated growth 
effects (74).  MELK-driven activation of FoxM1 in GSCs may contribute to radioresistance via 
transcriptional upregulation of the histone methyltransferase enhancer of zeste homolog 2 
(EZH2) (33).  Recently, it was reported that MELK phosphorylates EZH2 to induce methylation 
and activation of the transcription factor NF-κB.  Signaling through this MELK-EZH2-NF-κB 
axis was observed moreso in GSCs than non-stem tumors, and suppression of this signaling by 
EZH2 knockdown or inhibition, or MELK inhibition (with OTS), reduced GSC self-renewal 
(68). 
In another study, MELK silencing in GSCs impaired self-renewal capacity in vitro and 
slowed tumor growth in vivo.  MELK expression was found to be regulated by JNK2, via the 
transcription factor c-JUN, specifically in GSCs and not normal progenitors.  Further, MELK 
formed a protein complex with c-JUN only in GSCs, and these cells were dependent upon the 
JNK2-MELK/c-JUN signaling axis for their survival and maintenance of stemness (81).  These 
studies collectively suggest that MELK is important for cancer stem cell self-renewal, and has 
different functions in tumor initiating and cancer stem cells relative to normal tumor cells. 
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Asymmetric cell division and cytokinesis 
 The involvement of MELK in the control of asymmetric cell division and cytokinesis has 
been studied primarily in Caenorhabditis elegans (89–93) and Xenopus (76, 94), respectively.  
For this reason, I will not cover these processes in depth here.  In brief, MELK has been 
demonstrated to regulate asymmetric cell division in part through interactions with snail (92), 
STOX (93), and LKB1 (90) homologs in C. elegans.  In Xenopus, MELK overexpression caused 
failed cytokinesis and impaired accumulation of active RhoA at cell division furrows (76).  The 
importance of proper control of asymmetric cell division and cytokinesis in cancer has been 
well-documented (95, 96); thus, a future examination of the role of MELK in these processes in 
cancer may be useful. 
 
Regulation of MELK Expression and Activity 
 Regulation of MELK transcription has predominantly been reported to be controlled by 
the transcription factors E2F1 and FoxM1.  E2F1 expression levels peak at the G1/S phase 
transition to control the transcription of genes crucial for DNA replication and cell cycle 
progression, among other processes (97).  MELK was first reported as an E2F target gene in 
2005 (70), and has since been identified as being regulated specifically by the E2F1 isoform 
(37).  In melanoma, control of E2F1-driven MELK transcription seems to be downstream of the 
MAPK pathway.  Direct binding of E2F1 to the MELK promoter has been observed by 
chromatin immunoprecipitation (ChIP), and decreased MELK expression as a result of E2F1 
knockdown was detected by immunoblot and transcriptional reporter assays, suggesting that 
E2F1 is required to maintain MELK expression (37).  Similar results were later reported in 
endometrial cancer as well (27). 
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FoxM1 is an oncogenic transcription factor that controls the transcription of numerous 
genes important for mitotic entry and progression, including cyclin B, Aurora B, and PLK1 (98, 
99).  Much like MELK, the overexpression of FoxM1 has been noted in many cancers, and 
higher expression levels are correlated with increased migration and invasion, and poor 
prognosis for patients (17, 100–102).  Furthermore, the overexpression of FoxM1 and MELK are 
tightly correlated in breast cancer, with higher expression levels significantly correlated with the 
more aggressive basal-like subtype.  Direct binding of FoxM1 to the MELK promoter has been 
observed by ChIP, and FoxM1 depletion or inhibition with thiostrepton has been demonstrated to  
decrease MELK expression (17). 
Recently, a study was published linking the regulation of MELK by both E2F1 and 
FoxM1 in breast cancer, in a manner dependent upon p53 mutational status.  This study reported 
that MELK expression is increased in p53-mutant breast cancer cell lines (often TNBC) 
compared to those with wild-type p53 (often non-TNBC).  Mechanistically, E2F1 exhibits 
reduced binding to the FoxM1 promoter in breast cancer cell lines with wild-type p53, resulting 
in lower expression of FoxM1, which subsequently causes decreased MELK expression.  Wild-
type p53 also directly bound FoxM1 to block its recruitment to the MELK promoter.  
Conversely, in p53-mutant TNBC cell lines, mutant p53 acted as a dominant negative to reverse 
the wild-type p53-mediated decrease in E2F1 binding to FoxM1 promoters, and to suppress the 
binding of wild-type p53 to FoxM1 that impaired recruitment to MELK promoters.  This resulted 
in increased E2F1 binding to FoxM1 promoters, driving higher levels of FoxM1, which 
increased MELK expression levels.  This study also reported a novel FoxM1 binding site on the 
MELK promoter (71). 
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As discussed above in the cancer stem cell phenotype section, the oncogenic transcription 
factor c-JUN has also been reported to control MELK expression specifically in GSCs (81).  This 
has not been corroborated by other cancer studies, and may serve as an example of highly cell-
type specific regulation. 
 Regulation of MELK degradation is not well understood.  No E3 ubiquitin ligases have 
been thoroughly validated to regulate MELK turnover, though evidence suggests that the 
anaphase promoting complex/cyclosome (APC/C) plays a role in this process.  MELK 
expression is cell cycle regulated, with expression rising in S phase, peaking in late G2 and M 
phases, and decreasing sharply around mitotic exit (17, 49, 50, 72).  This expression pattern 
mirrors that of other APC/C substrates, including cyclin B and Aurora A and B (103).  One study 
reported that MELK is ubiquitinated by the APC/C-Cdh1 complex (104).  Collectively, this 
information suggests that the APC/C regulates MELK degradation, though further studies are 
needed to definitively validate this interaction.  Separately, thioredoxin may recruit the E3 ligase 
MDM2 to induce MELK degradation in a redox-dependent manner, but more experimentation is 
required to determine the relevance of this in cancer (105).   
 It has been reported that phosphorylation by an unknown kinase, possibly on the C-
terminal non-catalytic domain, stabilizes MELK in mitosis (3, 49).  Multiple studies have also 
reported that pharmacological inhibition of MELK induces its degradation.  This seems to be a 
general effect caused by multiple MELK inhibitors, including OTS, MELK-T1, 8a, and HTH, 
and has been used to conclude that MELK is inhibited in cells in functional experiments (16, 39, 
44).  The mechanism underlying inhibitor-induced degradation is not at all understood, and could 
be due to general cell cycle perturbation rather than a MELK-specific effect, among other 
possible explanations.  For this reason, inhibitor-induced MELK degradation should be used 
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cautiously as a cellular readout of MELK activity, and a more reliable and specific marker for 
MELK activity in cells must be pursued. 
 Unlike other AMPK family members, regulation of MELK activity is not controlled by 
LKB1 phosphorylation (106).  Rather, MELK autophosphorylation of its activation loop at T167 
and S171 regulates its kinase activity (107).  The C-terminal noncatalytic domain of MELK is 
regarded as an autoinhibitory domain, is it has been shown to inhibit MELK activity in a dose-
dependent manner in vitro (107).  The function of this domain in cells has not been elucidated.  
Furthermore, a reducing environment is required for MELK catalytic activity in vitro (107), 
which may be due to an intramolecular disulfide bridge that forms between C154 and C168 of 
the activation loop under oxidative conditions (108).  It is unclear whether this disulfide 
represents a physiologically relevant mechanism of redox regulation of MELK activation state in 
cells.  An additional regulatory mechanism may involve the redox-dependent binding of ZPR9 
and thioredoxin.  These proteins have been reported to bind MELK via two disulfide bridges that 
form under oxidative conditions, thereby positively and negatively regulating MELK activity, 
respectively (105, 109).  Further characterization of these redox-dependent interactions are 
necessary to determine their functions in cancer. 
 
MELK Substrates  
 Despite substantial interest in MELK as a potential therapeutic target in cancer since 
2005, MELK substrates remain poorly characterized.  MELK was originally reported to have 
broad substrate specificity.  Using a peptide array chip, it was determined that MELK strongly 
phosphorylated multiple peptides with varied sequence composition surrounding the 
phosphorylated residue (107).  More recently, a positional scanning peptide library screen was 
used to determine the preferred MELK phosphorylation motif to be X-basic-X-X-S/T, with a 
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strong preference for arginine at the -3 position, a strong selection against hydrophobic residues 
at the -3 position, and a moderate preference for arginine at the -2 and -4 positions (75).  It 
should be noted, however, that multiple reported MELK substrates do not conform to this 
phosphorylation consensus sequence, including p53 (Ser15, EPPLS*) (83), ASK1 (Thr838, 
PCTET*) (82), ZPR9 (Thr252, AIPIT*) (109), and STRAP (Ser188, MSVSS*) (84). 
 The most well-characterized MELK substrates to date are FoxM1, EZH2, and eIF4b.  
The phosphorylation of FoxM1 by MELK causes increased transcriptional activity.  This 
phosphorylation is reported to be essential for proliferation of GSCs, and to be dependent upon 
phosphorylation by the known FoxM1 kinase PLK1 (74).  As noted in the previous section, the 
regulation of MELK transcription by FoxM1 is well-validated.  Therefore, the observation that 
MELK activates FoxM1 transcriptional activity suggests that this interaction creates a positive 
feedback loop, perhaps to enhance the rapidity of mitotic FoxM1 target gene expression in late 
G2 phase.  Various additional studies have reported decreased transcription of FoxM1 targets in 
response to MELK knockdown (33, 110) or inhibition with OTS (11, 12, 35, 57) or MELK-T1 
(39).  Importantly, while studies have observed decreased phosphorylation of FoxM1-S35 (57, 
111) and -T600 (110) in response to MELK targeting, the specific FoxM1 phosphorylation sites 
regulated by MELK remain unclear. 
 A MELK-EZH2 relationship was first described in 2015, where this signaling axis was 
shown to contribute to the radioresistance of GSCs.  No direct binding or phosphorylation of 
EZH2 by MELK was shown, but rather MELK was demonstrated to control EZH2 expression 
through phosphorylation of FoxM1 (33).  MELK was later reported to directly bind and 
phosphorylate EZH2, regulating its methyltransferase activity, and EZH2 to purportedly 
methylate MELK in medulloblastoma stem-like cells (112) and GSCs (68).  The MELK-EZH2 
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interaction was further elucidated in extranodal natural killer/T-cell lymphoma.  Here, MS was 
used to observe a concurrent increase in phosphorylation of EZH2 (S220) and decrease in 
ubiquitination of EZH2 (K222) with MELK overexpression.  Notably, this phosphorylation site 
in EZH2 (S220, RKFPS*) conforms with the reported MELK consensus sequence described 
previously.  Knockdown or inhibition of MELK with OTS caused increased ubiquitination and 
degradation of EZH2, suggesting that MELK regulates the stability of this protein.  Knockdown 
or overexpression of FoxM1 altered EZH2 transcript and protein, but did not affect 
ubiquitination of K222, suggesting that MELK-mediated regulation of EZH2 stability is not 
FoxM1-dependent (111).   
Phosphorylation of eukaryotic translation initiation factor 4b (eIF4b) at S406 has been 
reported to be regulated by MELK by one study.  This study demonstrated decreased 
phosphorylation of eIF4b (S406) in response to OTS treatment or MELK knockdown.  In BLBC 
cells, the phosphorylation of eIF4b (S406) by MELK was required for synthesis of the 
antiapoptotic protein MCL1 in mitosis, which regulated cancer cell survival, as demonstrated by 
knockdown and inhibition studies (75).  In another study, it was reported that CRISPR-generated 
MELK knockout breast cancer cell lines had normal levels of eIF4b (S406) phosphorylation and 
maintained normal expression of MCL1, suggesting that MELK may not be required for 
phosphorylation of eIF4b at this site (44). 
 Numerous additional proteins have been reported to be MELK substrates, including 
CDC25B (73, 113), SQSTM1 (37), ASK1 (82), p53 (83), SMAD2, -3, -4, and -7 (85), PDK1 
(114), ZPR9 (115), thioredoxin (105), STRAP (84), PRAS40 (69), stathmin (116), DBNL, and 
PSMA1 (10).  Some of these studies additionally describe specific phosphosites purported to be 
regulated by MELK, but none have been well-validated to date.  Future studies should focus on 
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further validating these putative MELK substrates and identifying new substrates, as the field 










CHAPTER 2: MELK KNOCKDOWN AND PHARMACOLOGICAL INHIBITION 
IMPAIR PANCREATIC CANCER CELL VIABILITY 
 
Introduction 
 Pancreatic cancer (PC) is among the most deadly and difficult-to-treat forms of cancer.  
In the US in 2019, an estimated 56,770 new cases were diagnosed, with an estimated 45,750 
deaths occurring as a result of this disease.  While PC was only the eleventh most frequently 
occurring type of cancer in the US in 2019, it accounted for the third most cancer deaths 
according to the most recent data in the SEER (Surveillance, Epidemiology, and End Results) 
database (117, 118).  Further, the 5-year survival rate for PC is only 9% in the US, lowest 
amongst all cancers (117).  Survival rates are anticipated to rise more slowly in PC than other 
cancers, and accordingly, PC is projected to surpass colorectal cancer as the second leading 
cause of cancer deaths in the US by 2030 (119). 
 One of the major contributors to the poor survival rate for PC patients is the limited 
efficacy of treatment options.  While surgical resection of the pancreas is the best therapeutic 
strategy, only 15-20% of patients are diagnosed early enough in disease progression to be 
candidates (120).  Even in patients that receive surgery to remove the tumor, recurrence rates can 
be as high as 80% (121).  In these cases, and in the numerous instances of non-resectable disease, 
patients are treated with chemotherapeutics.  The current chemotherapeutic standards of care for 
PC are FOLFIRINOX (a combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) 
and gemcitabine/nab-paclitaxel (122).  Both therapeutic options offer increased survival versus 
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gemcitabine alone, the previous standard of care for PC, though FOLFIRINOX has a higher 
incidence of serious adverse events than gemcitabine/nab-paclitaxel (122–124).  Therefore, when 
considering new treatment combinations to enhance PC survival, it is likely unrealistic to 
consider adding another treatment to the toxic four-drug cocktail FOLFIRINOX.  A more 
feasible approach, potentially, would be to identify a treatment that increases the efficacy of the 
gemcitabine/nab-paclitaxel combination.   
Gemcitabine, a cytidine analog, was the standard of care for PC treatment for over a 
decade, despite only conferring a median survival time of approximately 5.6 months for patients 
(125).  Often, patients initially respond favorably to gemcitabine therapy, only to rapidly develop 
drug resistance.  A number of resistance factors have been identified, including variation of 
expression of nucleoside transporter-1 and downstream gemcitabine processing enzymes, 
changes in expression of apoptosis-related genes, and increased activation of numerous kinase 
signaling pathways, including PI3K/AKT, FAK, c-SRC, and c-MET (126).  Given the potential 
importance of activation of kinase networks in drug resistance, we sought to characterize 
perturbations of the kinome in response to gemcitabine in an effort to identify putative, novel 
therapeutic targets for combatting gemcitabine resistance and increasing the effectiveness of PC 
treatment with gemcitabine/nab-paclitaxel. 
The MIB/MS (multiplexed kinase inhibitor beads/mass spectrometry) technology is a 
useful approach for identifying global changes in the kinome in response to cellular 
perturbations.  Briefly, this approach utilizes pan-kinase inhibitors immobilized on agarose beads 
to capture kinases from cell lysates, allowing for comparisons of global kinase expression 
between treatment and control conditions.  This technique has previously been used to define the 
kinome response of breast cancer cells to MEK inhibition and lapatinib treatment, which 
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subsequently allowed for the rational design of strategies to combat and overcome resistance to 
these therapeutic approaches (127, 128).  MIB/MS kinome profiling was also used to identify 
kinase pathways driving resistance in imatinib-resistant chronic myelogenous leukemia cells 
(129).    We sought to employ a similar approach to identify kinome changes in PC cells in 
response to gemcitabine treatment.  A slight adaptation of this strategy, termed competition 
MIB/MS, combines short-term treatment of cells or drug addition to cell lysates with MIB/MS to 
identify direct kinase inhibitor binding targets (130). 
 In this chapter, we used MIB/MS to characterize the kinome response of PC cells to 24h 
gemcitabine treatment, in an effort to identify putative resistance mechanisms.  This analysis and 
immunoblotting revealed that expression of the kinase MELK is upregulated by gemcitabine.  
RNAi-mediated MELK knockdown was found to slow proliferation of PC cells.  To identify 
novel inhibitors of MELK, we screened a small-molecule library using a MELK kinase assay 
and subsequently identified 18 compounds with similar or greater potency than the leading 
MELK inhibitor OTSSP167 (OTS).  These hit compounds were further evaluated using MTS 
and crystal violet assays, to measure their effects on PC cell viability.  A lead compound, 
UNC2025, was selected for selectivity profiling using competition MIB/MS, which revealed 
relatively low selectivity for MELK.  PC cells were not sensitized to gemcitabine with MELK 
inhibition using either OTS or UNC2025, or MELK knockdown.  Collectively, the results 
showing that MELK knockdown and inhibition decrease PC cell viability suggest that this kinase 
is a putative therapeutic target in PC, though upregulation of MELK may not truly act as a 





Gemcitabine causes increased MELK expression in pancreatic cancer cells 
PANC-1 cells were treated with 1 μM gemcitabine for 24h, at which point they were 
harvested for MIB/MS to assess changes in kinase expression.  A total of 128 kinases were 
quantified using MaxQuant (Fig. 2.1A).  Five kinases were captured with at least 2-fold 
decreased abundance (MTOR, ULK3, STK24, MP2K3, and M3K4), and 2 kinases were captured 
with greater than 2-fold increased abundance (MELK and KCC2G), indicating that gemcitabine 
treatment had caused a decrease and increase in expression of those kinases, respectively.  
Generally, drug resistance factors are induced in response to exposure to a given drug; thus, we 
were most interested in the two kinases that exhibited an increase in expression.  Of those, the 
kinase with the largest magnitude change was MELK, which was quantified with nearly 5-fold 
increased abundance by MIB/MS.  We confirmed that 24h treatment with 0.5 or 2 μM 
gemcitabine caused a 5- to 10-fold increase in MELK expression in MIA PaCa-2 and PANC-1 
cells (Fig. 2.1B).  To test whether PC cells were sensitive to loss of MELK, we next used an 
shRNA targeting MELK to deplete this kinase.  Indeed, we found that MELK depletion caused a 
decrease in proliferation in PANC-1 cells, measured using a 21-day crystal violet cell viability 
assay (Fig. 2.2, A and B) 
 
Screening of UNC small-molecule library reveals novel MELK inhibitors 
These observations led us to focus subsequent experiments on investigating the approach 
of targeting MELK in PC cells, particularly in combination with gemcitabine.  At the time these 
studies were conducted, OTS was universally used in MELK studies.  Despite numerous studies 
describing OTS as a highly selective inhibitor of MELK, no data had ever been presented to 
support this claim (9, 10, 116).  Publicly available data (http://www.kinase-
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screen.mrc.ac.uk/screening-compounds/594372) and preliminary data from our lab (shown in 
chapter 3) indicated that OTS was actually quite poorly selective for MELK.  Further, while 
other MELK inhibitors had been published, none had been thoroughly validated or used in 
MELK functional studies (38, 39, 61). Thus, we initiated a drug discovery effort in search of a 
selective MELK inhibitor with potential for both therapeutic use and functional studies. 
Through a collaboration with Drs. Stephen Frye and Xiaodong Wang (UNC CICBDD), 
we obtained access to a library of small-molecule inhibitors of the TAM (TYRO3-AXL-
MERTK) family of kinases (131, 132), known to have moderate affinity for MELK (unpublished 
data).  From this library, we tested 53 compounds for their ability to inhibit MELK activity using 
the ADP-Glo™ (Promega) kinase assay.  All compounds, in addition to OTS, were tested at 50 
nM, which was previously determined to be the IC50 of OTS for MELK in this assay (data not 
shown).  A total of 18 compounds were found to inhibit MELK with similar or greater potency 
than OTS (Fig. 2.3).  These compounds were thus selected for further evaluation using PC cell 
viability assays. 
 
Novel MELK inhibitors impair pancreatic cancer cell viability 
First, inhibitors were tested at concentrations ranging from 0.3 nM to 10 μM in MIA 
PaCa-2 cells using a 72h MTS assay.  The IC50 of each inhibitor was determined (Table 2.1).  
The top five inhibitors of MIA PaCa-2 cell viability were found to be OTS, UNC3778, 
UNC2371, UNC2025, and UNC3875 (Fig. 2.4A).  The effects of these compounds, in addition 
to UNC1170, UNC570, UNC3906, and UNC4200, were additionally tested against PANC-1 cell 
viability using a long-term (28-day) crystal violet assay.  In order to quantify the IC50 of each 
compound, crystal violet stain was solubilized with Sorenson’s buffer and absorbance measured 
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at 570 nm (Table 2.1).  Similar to MTS assay results, the most potent inhibitors of proliferation 
in crystal violet assays, besides OTS, were UNC3778, UNC2371, and UNC2025 (Fig. 2.4B). 
Notably, there appeared to be a moderate correlation between potency in the MELK 
kinase assay (Fig. 2.3) and potency for inhibiting MIA PaCa-2 (MTS assay) and PANC-1 
(crystal violet) cell viability (Table 2.1).  This trend does not hold true for OTS, which is known 
to significantly inhibit a number of kinases more potently than MELK, including vital regulators 
of proliferation (chapter 3) (13, 15).  Despite being the most potent inhibitor of cell viability, 
OTS is a less potent MELK inhibitor than many of the UNC compounds tested.  These results 
suggest that inhibition of MELK by the UNC compounds was at least partially responsible for 
impaired PC cell viability, while providing further evidence that OTS does not impair cancer cell 
proliferation primarily through inhibition of MELK activity. 
 
MIB/MS kinome profiling reveals low selectivity of UNC2025 for MELK 
Amongst the top three inhibitors of PC cell viability, UNC2025 has the most favorable 
permeability and pharmacokinetic profile ((131) and unpublished data).  We therefore decided to 
use this compound for subsequent experiments rather than UNC3778 or UNC2371.  We utilized 
competition MIB/MS to determine the kinase selectivity of UNC2025.  In brief, we incubated 
DMSO or 10, 100, or 1000 nM UNC2025 with equal volumes of PANC-1 lysate for 30 min.  
Lysates were then applied to chromatography columns containing MIBs, columns were washed, 
and bound kinases were eluted and quantified by MS.  The fundamental principle underlying this 
assay is that kinases in the lysate which are bound by UNC2025 are subsequently unable to bind 
to MIBs; thus, these specific kinases are quantified in lower abundance relative to the DMSO 
control condition.  It is important to note that this particular application of MIB/MS is distinct 
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from the technical setup used previously to study kinome changes resulting from 24h treatment 
with gemcitabine (Fig. 2.1A), as only direct inhibitor binding is assessed with this competition 
MIB/MS approach. 
Using competition MIB/MS, we determined the selectivity of UNC2025 for 223 total 
kinases (Fig. 2.5).  A total of 31 kinases, including MELK, exhibited decreased binding to MIBs 
in a dose-dependent manner, with greater than 2-fold (UNC2025 / DMSO <0.5) decreased 
binding with 1 μM treatment.  The additional kinases that met these criteria were LATS1, 
PRKCG, RPS6KA4, PIK3C2A, CAMK2B, CAMK2D, CAMK2G, MARK3, NUAK1, SIK1, 
SIK2, SIK3, STK17A, CLK1, CLK2, CLK4, DYRK1A, AAK1, BMP2K, ULK3, AXL, 
FGFR1/2, MERTK, PTK2B, MAP3K2, MAP4K3, MAP4K5, MINK1, SLK, and STK10.  Of 
note in this list are the TAM family kinases AXL and MERTK (TYRO3 was not detected).  
Moreover, MERTK was the only kinase with more than 5-fold decreased binding (UNC2025 / 
DMSO <0.2) at the lowest concentration tested (10 nM).  These results are in agreement with 
previous studies that described MERTK as the primary target of UNC2025 (131, 133).  While 
MELK binding was decreased more than 5-fold at 1000 nM, it was only slightly decreased (less 
than 2-fold) at 10 and 100 nM UNC2025.  Additionally, 21 other kinases in addition to MELK 
exhibited greater than 5-fold decreased binding to MIBs with 1000 nM UNC2025 treatment.  
These results indicated that UNC2025 has relatively low selectivity for MELK, and that the 
effects of this compound cannot be solely attributed to MELK inhibition. 
 
MELK inhibition or knockdown does not sensitize pancreatic cancer cells to gemcitabine 
While neither OTS nor UNC2025 appeared highly selective, these compounds still 
strongly inhibited MELK.  We therefore next tested whether these inhibitors sensitized PC cells 
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to gemcitabine.  MIA PaCa-2 cells were treated with 0.3 nM to 10 μM gemcitabine, plus either 
DMSO, 10 nM OTS, or 250 nM UNC2025 (the IC25 concentration for each compound), and the 
resulting cell viability was measured using a 72h MTS assay (Fig. 2.6A).  MIA PaCa-2 cells did 
not exhibit increased sensitivity to gemcitabine with either OTS or UNC2025 treatment, as the 
IC50 remained at or above 20 nM for all conditions.  Given the prominent off-target kinase 
inhibition for both compounds, we further tested our hypothesis that decreased MELK activity 
would increase susceptibility to gemcitabine using RNAi-mediated knockdown.  MELK was 
depleted with shRNA in MIA PaCa-2 cells, and sensitivity to gemcitabine was again measured 
with a 72h MTS assay (Fig. 2.6B).  While MELK depletion itself caused decreased viability, as 
with inhibitor treatment, it failed to sensitize cells to gemcitabine. 
 
Discussion 
Our results are the first to demonstrate that MELK expression is upregulated by 
gemcitabine treatment (Fig. 2.1).  This observation was not entirely surprising, as others have 
shown that treatment with the nucleoside analog 5-fluorouracil or radiation also cause 
upregulation of MELK in colorectal cancer (34).  These findings have largely been ignored by 
the MELK field, and along with our results here, may suggest a role for MELK in response to 
impaired DNA replication or DNA damage.  MELK has been linked to the DNA damage 
response previously by our group (chapter 4) and others (26, 39).  Further studies are needed to 
more clearly define the role of MELK in these processes, as this is currently an understudied area 
of investigation in the MELK field.  
While the drug discovery efforts undertaken in this study did not ultimately unearth a 
highly selective inhibitor of MELK (Fig. 2.5), UNC2025 has certainly shown promise as an 
anticancer agent.  This inhibitor has been demonstrated to induce cell death and suppress tumor 
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growth in melanoma, glioblastoma, leukemia, and non-small cell lung cancer primarily through 
inhibition of MERTK (132–135).  Nonetheless, it is possible that partial MELK inhibition by 
UNC2025 contributes to the favorable polypharmacology displayed by this inhibitor.  Further, no 
results have yet been published showing the efficacy of UNC2025 or related UNC compounds 
for the treatment of PC.  Our results (Fig. 2.4) indicate that these compounds display anticancer 
properties in PC cells, and may provide a rationale for further investigation of the role of the 
TAM family of kinases in PC.  While the approach of targeting AXL in PC has been 
investigated, MERTK has not yet garnered significant attention (136, 137).  UNC2025 could 
thus serve as a useful tool compound for preliminary studies, and may also hold therapeutic 
potential.  Finally, the results of our MELK kinase assay screen of 53 small-molecules (Fig. 2.3) 
could be used to define the structure-activity relationship for these scaffolds.  This information 
could potentially be used to modify UNC2025, or other inhibitors, in an effort to improve their 
potency towards MELK. 
As discussed in chapter 1, many groups have shown that RNAi-mediated MELK 
knockdown causes slowed proliferation of various cancers, including TNBC, glioma, leukemia, 
and others (6, 11, 17, 24, 25).  In many studies, this effect has been shown to be due specifically 
to MELK loss using complementation experiments (6, 17, 22, 25, 36, 37).  The role of MELK in 
PC, however, has not yet been the focus of any studies.  Results from this chapter suggest that 
MELK may play a role in the proliferation of PC cells, albeit without complementation to 
demonstrate specificity in knockdown experiments.  Given that the prognosis for PC is extremely 
poor, and the need for targeted therapies is undeniably dire, MELK may warrant further attention 
as a potential target. 
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We observed that MELK inhibition with OTS or UNC2025, or MELK knockdown, did 
not sensitize PC cells to gemcitabine (Fig. 2.6).  Here, we used the IC25 concentration of each of 
these compounds.  Given that both OTS and UNC2025 exhibit significant kinase inhibition with 
similar or greater potency than that for MELK, MELK activity may not have been substantially 
inhibited at these concentrations.  After the completion of the studies shown in this chapter, 
additional MELK inhibitors were developed, including NVS-MELK8a (8a), IN17, and HTH-01-
091 (16, 38, 40).  8a in particular has excellent selectivity for MELK and inhibits TNBC cell 
proliferation (chapter 3), making this compound suitable for functional MELK studies.  In future 
studies, it would be interesting to test whether this inhibitor sensitizes pancreatic or other cancers 
to chemotherapeutics, including gemcitabine.  Lastly, given that MELK expression oscillates in 
the cell cycle (17, 49), it is possible that gemcitabine treatment, which perturbs the cell cycle, 
causes an acute upregulation of MELK independent of resistance mechanisms.  Future efforts to 
identify drug resistance mechanisms with MIB/MS may be more successful when applied to 
cells that have been persistently treated (i.e. for weeks) with chemotherapeutic agents. 
 
Experimental Procedures 
Reagents and cell culture 
Gemcitabine (cat. # S1714) and OTSSP167 (cat. # S7159) were purchased from 
SelleckChem.  The small-molecule compound library of putative MELK inhibitors was a 
generous gift from Drs. Stephen Frye and Xiaodong Wang of the UNC CICBDD.  PANC-1 and 
MIA PaCa-2 cell lines were kindly provided by Dr. Jen Jen Yeh (UNC).  Both cell lines were 
cultured in RPMI 1640 (Gibco) supplemented with 5% fetal bovine serum (Millipore) and 1% 
antibiotic-antimycotic (Sigma).  Cells were maintained in a humidified chamber with 5% CO2.  
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Short hairpin RNA (shRNA) reagents used in these studies were purchased from Dharmacon™ 
(ID: TRCN0000001642, sequence: 5’-ACAAAGAGACATAGTTAAGAG-3’). 
 
Immunoblotting 
Immunoblotting was completed exactly as described previously (14).  The following 
primary antibodies were used in this study: MELK (Cell Signaling Technologies, cat. # 2274, 
1:1000) and β-actin (Santa Cruz Biotechnology, cat. # SC47778, 1:1000). 
 
Kinase assays 
Active MELK (1-340) was purchased from SignalChem Lifesciences Corporation (cat. # 
M50-11G).  ZIPtide substrate (KKLNRTLSFAEPG) was purchased from AnaSpec (cat. # AS-
63366).  Tris base (cat. # BP152-500), magnesium chloride hexahydrate (cat. # M33-500), and 
dithiothreitol (DTT) (cat. # R0861) were purchased from Thermo Fisher Scientific.  Bovine 
serum albumin (BSA) (cat. # A2153) was purchased from Sigma-Aldrich. 
ADP-Glo™ (Promega) kinase assays were completed in 96-well white, round bottom 
plates, according to the Promega protocol.  Briefly, the kinase reaction was initiated by adding 
25 ng active MELK to a well containing 10 μM ATP, 200 μg/mL ZIPtide, 50 nM MELK 
inhibitor or DMSO, and kinase reaction buffer (40 mM Tris, pH 7.5, 20 mM MgCl2, 0.1 mg/mL 
BSA, and 15 mM DTT).  This reaction was allowed to proceed for 30 min at room temperature.  
ADP-Glo reagent was added to terminate the kinase reaction and deplete remaining ATP in 
solution.  The plate was incubated for 40 min at room temperature.  Kinase detection reagent was 
added to produce luminescence proportional to the amount of kinase activity (MELK 
phosphorylation) that occurred in the first step.  The plate was incubated for 30 min at room 
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temperature.  All incubations were completed with the plate protected from light.  Luminescence 
was measured using a PHERAstar (BMG Labtech) plate reader with luminescence module. 
 
Cell viability assays 
 For MTS assays, MIA PaCa-2 cells were plated on a 96-well plate at a density of 3000 
cells/well.  Media was aspirated and replaced, after 24h, with media containing compound 
(MELK inhibitor or gemcitabine) at concentrations ranging from 0.3 nM to 10 μM, or DMSO.  
MELK inhibitor conditions were tested in technical duplicate, and gemcitabine conditions were 
tested in technical triplicate.  Cells were incubated in a humidified chamber for 72h.  After 72h, 
0.6 mM resazurin dye (Acros Organics, cat. # 62758-13-8) was added, cells were incubated for 
2h, and fluorescence was measured using a PHERAstar plate reader with fluorescence module 
(FI: 540-20, 590-20).  GraphPad Prism was used to generate dose-response curves and calculate 
IC50 values. 
 Crystal violet cell viability assays were completed by plating 300 PANC-1 cells/well on a 
6-well cell culture-treated plate.  Media was replaced the following day with fresh media 
containing DMSO or MELK inhibitor at concentrations ranging from 10 to 1000 nM.  
Throughout the duration of the assay, media was refreshed at least every 3 days.  After 28 days, 
media was aspirated and cells were stained by incubating 10 min at room temperature with 
crystal violet solution (0.5% crystal violet (w/v) (Sigma), 20% methanol (Fisher)).  Plates were 
imaged using a Canon LiDE 110 document scanner.  For quantification of relative cell number, 
crystal violet stain was solubilized using Sorenson’s buffer (0.1 M sodium citrate, pH 4.2, 50% 
ethanol), and the absorbance (570 nm) of each solubilized stain solution was measured using a 
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SpectraMax microplate reader.  GraphPad Prism was used to generate dose-response curves and 
calculate IC50 values. 
 
Kinome analysis and selectivity profiling by MIB/MS 
 For standard MIB/MS to determine kinome remodeling following gemcitabine exposure, 
PANC-1 cells were treated with 1 μM gemcitabine for 24h.  Cells were lysed and MIB 
enrichment was completed exactly as previously described (138), with the only exception being 
the kinase inhibitor bead mix.  In this study, a mix of the following kinase inhibitors, 
immobilized on beads, was used: CTx-0294885, PP58, Purvalanol B, UNC2147A, VI-16832, 
UNC8088A.  Following MIB kinase enrichment steps, MS and MS/MS data acquisition with 
MALDI TOF/TOF 5800 (AB SCIEX), MS/MS spectra search against a reviewed human Uniprot 
database, and quantification and data analysis using ProteinPilot™ were completed as previously 
described (129). 
Competition MIB/MS, used for selectivity profiling of UNC2025, was also completed as 
previously described (14) with one exception.  Here, the inhibitor was incubated with PANC-1 
cell lysate on ice for 30 min, rather than being added to cells prior to lysis.  Following MIB 
kinase enrichment, the samples were analyzed by LC/MS/MS using a Q Exactive HF mass 
spectrometer.  Data acquisition, search against a reviewed human Uniprot database, 
quantification using MaxQuant label-free quantification, and data analysis were completed as 
previously described (14). 
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Tables and Figures 
Table 2.1. MELK inhibitor potency in PC cell viability assays.  The 18 compounds that 
inhibited MELK activity with equal or greater potency than OTS in kinase assays (Fig. 2.3) were 
tested in PC cell viability assays.  For MTS assays, MIA PaCa-2 cells were exposed to inhibitor 
for 72h prior to quantification of viability by addition of resazurin and measurement of 
fluorescence.  For crystal violet (CV) assays, PANC-1 cells were exposed to inhibitor for 28 







Figure 2.1. Treatment of PC cells with gemcitabine causes MELK upregulation.  A, PANC-
1 cells were treated with 1 μM gemcitabine for 24h.  Cells were harvested and MIB/MS was 
completed to assess changes in kinase expression.  B, MIA PaCa-2 and PANC-1 cells were 






Figure 2.2. MELK knockdown slows proliferation of PANC-1 cells.  A, PANC-1 cells were 
transfected with empty vector (vehicle) or an shRNA targeting MELK.  Cells were stained with 
crystal violet after 21 days.  B, PANC-1 cells were transfected as in A and MELK expression 





Figure 2.3. Screening of a small-molecule library reveals potent MELK inhibitors.  An in-
vitro kinase assay (ADP-Glo™, Promega) was used to measure MELK activity upon exposure to 
53 compounds from a targeted small-molecule library.  All compounds, plus OTS (indicated by a 





Figure 2.4. Novel MELK inhibitors impair PC cell proliferation.  A, MIA PaCa-2 cells were 
exposed to inhibitors for 72h, in technical duplicate, prior to quantification of viability by 
addition of resazurin and measurement of fluorescence.  The 18 compounds shown in Table 2.1 
were tested, and dose-response curves for the 4 most potent inhibitors of cell viability, measured 
by MTS assay, are displayed.  B, PANC-1 cells were exposed to inhibitors for 28 days, before 
being stained with crystal violet dye.  The 3 most potent inhibitors of cell viability, measured by 





Figure 2.5. The kinase selectivity profile of UNC2025 reveals off-target kinase inhibition.  
DMSO or 10, 100, or 1000 nM UNC2025 was incubated for 30 min with equal volumes of lysate 
from PANC-1 cells.  MIB/MS was completed as described in Experimental Procedures to assess 





Figure 2.6. MELK inhibition or knockdown do not sensitize PC cells to gemcitabine.  A, 
MIA PaCa-2 cells were treated with a range of concentrations of gemcitabine (0.3 nM to 10 μM) 
and DMSO or the previously determined IC25 of OTS or UNC2025 (10 nM and 250 nM, 
respectively).  Cells were exposed to compounds for 72h and viability assessed using MTS 
assay, as described previously.  B, MIA PaCa-2 cells were transfected with empty vector or 
shMELK.  After 72h, cells were treated with a range of concentrations of gemcitabine, as in A, 




CHAPTER 3: MASS SPECTROMETRY-BASED SELECTIVITY PROFILING 
IDENTIFIES A HIGHLY SELECTIVE INHIBITOR OF THE KINASE MELK THAT 
DELAYS MITOTIC ENTRY IN CANCER CELLS2 
 
Introduction 
 The maternal embryonic leucine zipper kinase (MELK), also known as MPK38 or pEg3, 
is a highly conserved member of the AMPK family of kinases (1, 86).  The proposed role of 
MELK in regulation of cell growth has been controversial.  MELK expression is increased in 
cancer relative to normal tissue (5), and high levels of MELK are correlated with tumor grade, 
poor prognosis, radioresistance, and recurrence in multiple cancers (6, 17, 20–22, 24, 25).  
RNAi-mediated depletion of MELK has been shown to cause impaired proliferation in a variety 
of cancers, including basal-like breast (17), glioma (6), acute myeloid leukemia (11), high-risk 
neuroblastoma (24), and hepatocellular carcinoma (25).  In triple-negative breast cancer (TNBC), 
knockdown of MELK caused shrinking and radiosensitization of xenografts (17, 21).  
Significantly, numerous studies have shown that RNAi effects on growth are due specifically to 
MELK depletion by demonstrating rescue with ectopic MELK expression (6, 17, 22, 25, 36, 37).  
Complicating the interpretation of these findings, the requirement of MELK for cancer cell 
proliferation has been challenged by studies showing that genomic deletion of MELK with 
CRISPR/Cas9 caused no growth effects (16, 18, 44).  Other studies contend that genomic MELK 
 
2This chapter was originally published in the Journal of Biological Chemistry.  The original citation is as follows: 
McDonald, I. M., Grant, G. D., East, M. P., Gilbert, T. S., Wilkerson, E. M., Goldfarb, D., Beri, J., Herring, L. E., 
Vaziri, C., Cook, J. G., Emanuele, M. J., and Graves, L. M. (2020) Mass spectrometry-based selectivity profiling 
identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells. J. Biol. Chem. 
295, 2359–2374 
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deletion does cause impaired proliferation of cancer cells (35), although this effect may only 
manifest under certain growth conditions (19).   
The discordant results between acute MELK knockdown and longer-term genetic 
inactivation is reminiscent of other key cell cycle proteins whose essential roles are evident in 
experiments following acute inactivation by RNAi or with small-molecules, but less clear in 
knockout experiments.  Two examples in particular illustrate this phenomenon.  First, the cyclin 
D-CDK4/6 complex is non-essential for proliferation in knockout cell lines and virtually all 
mouse tissue (139, 140), but chemical inhibitors halt progression into S phase in cell lines with a 
functional retinoblastoma protein (141).  This example is particularly relevant given the growing 
clinical use of CDK4/6 inhibitors for the treatment of cancer (142).  Second, recent results using 
CRISPR/Cas9 gene editing suggest Bub1 is non-essential for mitotic spindle checkpoint function 
in humans (143, 144), but it was later shown that these “knockout” cells express low levels of a 
truncated Bub1 protein, accounting for the negative results and lack of a phenotype (46–48).  
Together, these results highlight the importance of examining protein function using multiple, 
orthogonal approaches and for using caution in interpreting negative results from gene knockout 
experiments.  
 The recent controversy concerning the requirement of MELK in cancer has underscored 
the need for a more comprehensive understanding of MELK function.  MELK has been reported 
to function in a multitude of processes including cell cycle progression (5, 17, 74), maintenance 
of cancer cell stemness (6, 72, 81), protein synthesis (75), and apoptosis, (7, 22, 67, 82).  Many 
of the functional studies of MELK have focused on the role of this kinase in the cell cycle.  
MELK mRNA is cell cycle regulated, and accordingly, protein levels of MELK oscillate 
throughout the cell cycle, with expression reaching a maximum in G2/mitosis (M) phase, before 
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declining upon mitotic exit (17, 49, 50).  Depletion of MELK has been shown to cause a G2/M 
arrest in cells (5, 17, 35, 41).  Some studies have attributed this effect to a role for MELK in the 
G2/M DNA damage checkpoint, potentially mediated through interaction with CDC25B, a 
phosphatase that regulates CDK1 activity at the G2/M checkpoint (73).  Additionally, loss of 
MELK activity may cause activation of the ATM/Chk2 DNA damage response (39).  Other 
studies indicate that MELK knockdown specifically impairs mitotic progression.  A circular 
relationship between MELK and FoxM1 has been described, whereby MELK expression is both 
regulated by this mitotic transcription factor, and phosphorylation by MELK regulates the 
activity and expression of FoxM1 (39, 74).  MELK may also regulate synthesis of the anti-
apoptotic protein MCL1 in M via interaction with eIF4B (75).  Overall, while a number of 
studies have uncovered putative functions of MELK at G2/M, a comprehensive understanding of 
the role of MELK at these phases of the cell cycle remains elusive. 
 One of the key challenges in studying the biological functions of MELK has been the 
lack of a selective inhibitor.  The most commonly used MELK inhibitor, OTSSP167 (OTS), also 
referred to as OTS167, has shown potent antiproliferative and apoptotic effects against multiple 
cancer types, including TNBC, acute myeloid leukemia, and high-risk neuroblastoma (10, 11, 17, 
24, 28).  Consequently, OTS is currently in multiple phase I clinical trials for the treatment of 
patients with advanced TNBC and refractory or relapsed leukemia (NCT01910545, 
NCT02795520, NCT02768519, NCT02926690).  While an effective inhibitor of cancer cell 
viability, OTS is poorly selective for MELK.  Recent publications have shown that OTS is a 
broad-spectrum inhibitor that inhibits numerous kinases that are vital for proliferation, including 
multiple mitotic kinases (13, 15).  A number of studies have relied upon OTS as a means to 
investigate the biological function of MELK; however, these results must be interpreted with 
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caution due to the poor selectivity of this inhibitor.  More recently, additional MELK inhibitors 
have been developed, including MELK-T1 (39), NVS-MELK8a (8a) (38), HTH-01-091 (HTH) 
(16), IN17 (40), and others  (22, 65).  8a and HTH in particular appear to have more favorable 
selectivity profiles than OTS based upon kinase activity profiling assays (16, 38).   
 The key objectives of this study were to evaluate the selectivity profiles of three MELK 
inhibitors, 8a, HTH, and OTS, using a cell-based assay, in order to identify a highly selective 
inhibitor to subsequently investigate MELK function.  To this end, we utilized a chemical 
proteomics approach called multiplexed kinase inhibitor beads/mass spectrometry (MIB/MS) to 
characterize the selectivity of these MELK inhibitors in TNBC cells (127, 130).  OTS was 
observed to be highly non-selective, in agreement with previous studies, and HTH did not 
effectively inhibit MELK in cells.  In contrast, we found the inhibitor 8a to be highly selective 
for MELK, providing the first reliable alternative to OTS for functional MELK studies.  Using 
8a as a tool compound to probe the function of MELK, we observed that MELK inhibition 
perturbed cell cycle progression by delaying entry into M, without an induction of apoptosis.  
Collectively, our results provide a rationale to utilize 8a for functional MELK studies as an 
orthogonal approach to knockdown and knockout techniques, and provide insight into the role of 
MELK in cell cycle progression, specifically at the G2/M checkpoint. 
 
Results 
Identification of a selective MELK inhibitor by MIB/MS kinome profiling 
MIB/MS is a proteomics technology used for enriching kinases from complex samples 
(127, 128).  This technique can be used for selectivity profiling of inhibitors in a cell-based 
fashion, an application termed competition MIB/MS (see Fig. 3.1 for detailed description of 
technology) (130).  Selectivity can also be assessed using MIB/MS by adding inhibitors directly 
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to lysates.  A similar chemical proteomics approach, using kinobeads and MS, was recently 
employed by Klaeger et al. to comprehensively define the selectivity of all clinical and FDA-
approved kinase inhibitors, validating the use of this approach for measuring inhibitor selectivity 
in cells (13).  We used the competition MIB/MS approach to profile the selectivity of 8a and 
HTH in an effort to identify a highly selective MELK inhibitor suitable for functional studies.   
We first determined the kinase target landscape of OTS, HTH, and 8a at a single 
concentration.  MDA-MB-468 cells were selected for initial experiments, as many previous 
studies utilized this and other TNBC cell lines.  MDA-MB-468 cells were treated with 1 μM of 
each putative MELK inhibitor or DMSO for 30 minutes.  Lysates from DMSO- or inhibitor-
treated cells were flowed over columns packed with MIBs.  Kinases bound to MIBs in the 
absence or presence of inhibitors were eluted and quantified by MS using label-free 
quantification in MaxQuant with integrated Andromeda search engine.  The specificity of each 
inhibitor was analyzed for a total of 235 protein kinases quantified in this assay (Fig. S3.1).  
Examining the 20 protein kinases detected in lowest abundance after OTS, HTH, or 8a treatment 
of cells (i.e. most prevented from binding to MIBs), relative to DMSO treatment, revealed stark 
differences in the selectivity and potency of these three compounds (Fig. 3.2A).  As previously 
reported, OTS exhibited broad specificity, with 52 protein kinases including MELK captured by 
MIBs with at least 4-fold decreased abundance relative to DMSO (OTS / DMSO <0.25).  
Moreover, OTS decreased the binding of a number of kinases to MIBs more effectively than 
MELK.  This finding is in agreement with previous studies, confirming that OTS has very poor 
selectivity, despite high potency for MELK (13, 15).  HTH was found to have a much narrower 
selectivity profile, with only 5 protein kinases captured with at least 4-fold decreased abundance 
relative to DMSO, but surprisingly MELK binding was largely unaffected by this compound.  
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These results suggest that HTH did not effectively inhibit MELK in this cell-based assay, 
inconsistent with in vitro enzyme assay data (16).  By contrast, the target landscape of 8a was 
observed to be extremely narrow, with MELK being the only protein kinase captured with at 
least 4-fold decreased abundance relative to DMSO.  These results indicated that 8a is the most 
selective of the three MELK inhibitors profiled using MIB/MS.   
Due to the striking specificity and potency differences between 8a and HTH, we sought 
to further validate these results in biological triplicate, again at a single concentration of 1 μM.  
Subsequent competition MIB/MS results are displayed as volcano plots to assess both kinase 
fold-change magnitude and significance (Fig. 3.2B).  With 8a treatment, MELK was the only 
kinase that displayed statistically significant decreased binding to MIBs, confirming the high 
selectivity of this compound.  As observed previously (Fig. 3.2A), HTH treatment did not 
significantly decrease MELK capture, whereas binding of GAK, CSNK2A2, CSNK2B, 
CSNK2A1, PIP4K2C, and RIPK2 were significantly decreased.  These results further confirm 
that 8a is a highly selective MELK inhibitor in cells, and underscore the importance of 
determining compound selectivity in a cellular context prior to biological studies. 
Competition MIB/MS was next used to profile the selectivity of 8a at 10, 100, and 1000 
nM.  As expected, we observed a dose-dependent decrease in MELK binding to MIBs, with no 
major off-target inhibition over this concentration range (Fig. S3.2).  While high selectivity was 
maintained at 1 μM 8a, we did not observe greater than 90% loss of MELK binding to MIBs, 
suggesting incomplete inhibition.  Since the percent inhibition of MELK required to elicit a 
phenotype is not well-defined, we tested higher concentrations of 8a (3 and 10 μM), with the 
goal of assessing selectivity at concentrations required for near-total inhibition of binding to 
MIBs.  Following MIB/MS, 221 protein kinases were quantified by label-free quantification as 
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above (Fig. S3.3), and the data were filtered to remove any protein kinases that did not exhibit 
reduced binding at all three concentrations, in a dose-dependent manner.  The 32 protein kinases 
that met these criteria are displayed in a heat map (Fig. 3.2C).  At 1 μM, 8a was again observed 
to be highly selective for MELK, with only MELK, STK11, and MAP2K4 captured with 4-fold 
less abundance, relative to DMSO.  Notably, competition MIB/MS results indicated that MELK 
was not detected at quantifiable levels following 3 μM 8a treatment, suggesting total loss of 
MELK binding to MIBs, while maintaining a high level of selectivity at this concentration.  At 
10 μM, however, the specificity of 8a was decreased, with robust off-target kinase inhibition 
observed.   
While STK11 and MAP2K4 appear to exhibit decreased binding in a somewhat dose-
dependent manner, it should be noted that neither exhibited significantly reduced binding with 1 
μM 8a treatment in biological triplicate (Fig. 3.2B).  We further tested the binding affinity of 8a 
for these kinases using the Eurofins DiscoverX KINOMEscan™ assay, which quantitatively 
measures the ability of an inhibitor to compete with a kinase ligand.  8a was found to have no 
detectable binding affinity for STK11 (Kd > 30 μM) or MAP2K4 (Kd = 17 μM) at 3 μM or 
lower, while high affinity for MELK was observed (Kd = 14 nM) (Fig. S3.4).  Taken together, 
results from this cell-based selectivity profiling assay indicate that treatment of cells with 8a at 1 
μM to 3 μM concentrations are sufficient for moderately strong levels of inhibition to near-total 
inhibition of MELK, respectively, while maintaining high selectivity for this kinase. 
 
Effects of MELK inhibition on TNBC cell viability 
MELK has been reported to play a role in TNBC proliferation and radioresistance (17, 
20, 21).  In TNBC and other cancers, RNAi-mediated depletion of this kinase impairs growth, an 
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effect that can be reversed with exogenous MELK rescue, indicating MELK may be an attractive 
therapeutic target (6, 17, 21, 22, 36, 37).  Recent results demonstrating that genetic knockout of 
MELK may cause no growth phenotype have called into question the approach of inhibiting this 
kinase as a cancer monotherapy (16, 18).  In light of these disparate results, we sought to test 
whether selective MELK inhibition with 8a impaired the proliferation of two TNBC cell lines.  
Treatment of MDA-MB-231 and MDA-MB-468 cells with 8a for 72 hours caused decreased cell 
viability, as measured by resazurin assay, with an IC50 of 1.7 μM +/- 0.4 and 2.3 μM +/- 0.4, 
respectively (Fig. 3.3A).  We further measured the viability effects of 8a using long-term crystal 
violet cell staining assays.  MDA-MB-231 and MDA-MB-468 cells were treated with 8a for 8 or 
14 days, respectively, prior to staining with crystal violet.  Similar IC50 values of between 1 and 
3 μM were obtained for both cell lines (Fig. 3.3B), in agreement with shorter-term resazurin 
assay results.  Notably, this inhibition of cell viability was observed at the same concentrations 
found to result in selective, moderately strong to near-total inhibition of MELK (Fig. 3.2C).   
 We next examined whether reduced cell viability was mediated through the induction of 
apoptosis or perturbation of cell cycle progression.  MDA-MB-468 cells were treated with 0.5, 1, 
or 3 μM 8a, or DMSO vehicle control, and cells were collected over a 24h time course.  Samples 
were immunoblotted for PARP/cleaved PARP, cyclins E1, A2, and B1, and p-Histone H3 (S10), 
to measure effects on apoptosis and cell cycle distribution (Fig. 3.3C).  PARP cleavage was not 
observed at any concentration or timepoint, indicating that 8a did not induce apoptosis.  8a 
treatment also had no effect on the abundance of the measured cyclins, but there was a dose-
dependent decrease in p-H3 (S10), a marker of M that is induced in G2 and dephosphorylated 
upon mitotic exit.  This decrease was observed as early as 1h post-treatment and maintained 
through 24h. 
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Histone H3 is phosphorylated at Ser10 by Aurora B (145).  To be certain that the 
observed decrease in p-H3 (S10) was not due to direct inhibition of the Aurora kinases, we 
utilized the Thermo Fisher SelectScreen kinase assay to test the effects of 8a on Aurora A and B 
activity.  Concentrations below 10 μM 8a did not inhibit Aurora A.  The IC50 for inhibition of 
Aurora B was 24 μM, and only 10% and 21% inhibition was observed with 1.2 and 3.7 μM 8a 
treatment, respectively.  The potency of 8a for the Aurora kinases was 1000-fold lower than that 
observed for MELK (IC50 = 17 nM) (Fig. S3.5), indicating that 8a does not significantly inhibit 
Aurora A and B.  It should also be noted that these data were from a cell-free enzymatic assay, 
so inhibition in cells is likely to be considerably weaker at these concentrations.  In agreement 
with this, we did not observe substantial decreases in Aurora A or B binding to MIBs with 3 μM 
8a or lower (Figs. S3.1 and S3.3).  Collectively, these results show that MELK inhibition with 8a 
caused decreased viability through impaired cell cycle progression, specifically in G2/M phases. 
 
MELK inhibition results in delayed mitotic entry mediated through delayed activation of 
Aurora A, Aurora B, and CDK1 
 
 Our results prompted further investigation into the effects of MELK inhibition on cell 
cycle progression.  For subsequent experiments, HeLaS3 cells were used because of their robust 
and well-characterized response to cell cycle synchronization methods.  We first confirmed that 
HeLaS3 cells exhibit similar sensitivity to 8a (IC50 of 1.9 μM +/- 0.5) as TNBC cell lines (Fig. 
S3.6A).  We further observed that 8a treatment caused the same dose-dependent decrease in p-
H3 (S10), with no effect on PARP cleavage or abundance of the measured cyclins, in HeLaS3 
cells as in MDA-MB-468 cells (Fig. S3.6B).  MELK expression levels were found to be similar 
between HeLaS3, U2OS, and TNBC cell lines as well (Fig. S3.6C). 
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 To specifically examine effects on progression through G2 and M, HeLaS3 cells were 
synchronized with double thymidine block and released into media containing DMSO, 1 μM, or 
3 μM 8a, and harvested every 2h over a 12h time course.  Samples were immunoblotted for cell 
cycle markers to determine the effect of 8a treatment on progression through S phase and into M 
(Fig. 3.4A).  No differences in cyclin E1 or A2 abundance were observed after 8a treatment from 
0h to 8h, indicating that S phase progression was unaffected by MELK inhibition.  At 8h post-
release, p-H3 (S10) abundance was lower in 3 μM 8a-treated cells relative to DMSO- and 1 μM 
8a-treated cells.  Further, at 10h post-release, cyclins A2 and B1, and p-H3 (S10) abundances 
were greater with 3 μM 8a treatment, indicating that entry into and progression through M was 
delayed (Fig. 3.4B).  At the 12h timepoint, cells appeared to have completed M, evident by 
major decreases in signal for cyclins E1, A2, and B1, and p-H3 (S10).  Cyclin E1 abundance was 
decreased by 3 μM 8a at 12h, relative to other conditions, suggesting the effects of mitotic delay 
may persist after M.  Treatment with 1 μM 8a had little effect on cell cycle progression as 
measured using this thymidine synchronization technique.  Therefore, 3 μM 8a was used in 
subsequent synchronization experiments. 
 To further investigate this apparent delay in mitotic entry, we completed another double 
thymidine synchronization experiment with more frequent collections around M (8-12h post-
release).  Cells were not collected between 0h and 6h post-release, as no differences were 
observed with 8a over this timeframe in the previous experiment (Fig. 3.4A).  Additionally, we 
sought to investigate the mechanism underlying this mitotic delay further by expanding the 
number of cell cycle proteins that were measured by immunoblotting.  Aurora A and B have 
critical roles in mitotic entry and progression, and their activity is regulated by 
autophosphorylation at T288 and T232, respectively (146, 147).  CDK1, regarded as the key 
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kinase for promoting M, is activated by cyclin binding and dephosphorylation of Y15 and T14.  
These regulatory sites are phosphorylated by Wee1 and Myt1 in interphase, respectively, and are 
dephosphorylated by CDC25B (148).  We immunoblotted for Aurora A and B and their 
regulatory phosphorylation sites, CDK1 and its regulatory phosphorylation sites, Myt1, Wee1, 
CDC25B, and the cell cycle markers used previously (Fig. 3.5).   
With more frequent timepoints, the delay in onset of M caused by 3 μM 8a was even 
more apparent than in the previous experiment.  This was evident by delayed degradation of 
cyclins A2 and B1, delayed accumulation of the mitotic marker p-H3 (S10), delayed 
phosphorylation and activation of Aurora A and B, and delayed activation of CDK1 by 
dephosphorylation of Y15 and T14.  In control cells, cyclin A2 accumulation peaked at 7h post-
release and persisted through 8.5h, after which it was rapidly degraded.  In 3 μM 8a-treated cells, 
cyclin A2 accumulated similarly, but expression persisted through 11h.  Cyclin B1 accumulation 
was also unaffected by 8a, but its degradation upon mitotic exit was delayed by approximately 
3h, beginning at 9h in control cells and 12h in 8a-treated cells.  Consistent with this, p-H3 (S10) 
accumulation began at 8h and decreased after 10h in control cells, compared to accumulation 
beginning at 9h, peaking at 11h, and persisting at high levels through 12h in 8a-treated cells.  
The activation of Aurora A and B by autophosphorylation was also delayed, correlating precisely 
with p-H3 (S10) patterns.  CDK1 activation by dephosphorylation of Y15 and T14 began at 8.5h 
in control cells, compared to 11h in 8a-treated cells, while CDK1 expression was unaffected.  
Interestingly, the dynamics of Wee1 expression appeared mostly unchanged between control and 
8a conditions, while inactivation of Myt1 by hyperphosphorylation (slower migrating band on 
gel) mirrors the delayed dephosphorylation pattern observed with CDK1 T14 and Y15.  Finally, 
the accumulation pattern of CDC25B may also be unaffected by MELK inhibition, though peak 
65 
levels of CDC25B may be decreased relative to control.  These results indicate that MELK 
inhibition results in delayed mitotic entry due to a delay in activation of multiple kinases 
essential for this process, namely Aurora A and B, and CDK1.   
 
MELK inhibition does not impair mitotic completion 
 After observing that MELK inhibition results in a delay in mitotic entry, we next asked 
whether it also had an effect on mitotic progression and completion.  Following the previously 
described synchronization/release approach, cells were collected over a 20h time course and 
immunoblotted for the same cell cycle markers (Fig. 3.6).  Again, degradation of cyclins A2 and 
B1, and induction of p-H3 (S10) were delayed by 3 μM 8a treatment, correlating with delayed 
activation of Aurora A and B and CDK1.  Despite this delay, cells treated with 3 μM 8a appeared 
to progress through and complete M in a similar amount of time, once M began.  This was 
evident by a return of p-H3 (S10) to steady-state levels at 14h, compared to 12h for DMSO, and 
dephosphorylation of Myt1, resulting in a faster migrating band relative to hyperphosphorylated 
mitotic Myt1.  MELK expression also decreased rapidly immediately following completion of 
M, as described in other studies (17, 49).  HeLaS3 cells treated with 3 μM 8a re-entered the 
subsequent cell cycle, as observed by an induction of cyclin E1 at 14h, compared to 12h for 
DMSO.  Levels of this G1/S phase cyclin peak at ~16-18h with 3 μM 8a treatment, which is 2h 
later than control cells, where cyclin E1 peaks at 14-16h.  These results indicate that the length of 
M appears to be largely unaffected by MELK inhibition, despite mitotic entry being delayed.  
These observations, along with delayed activation of Aurora A and B and CDK1 are consistent 
with activation of the G2/M checkpoint (149).  Since M occurs quite rapidly (~30 min), we 
sought to further examine these results using live-cell imaging for greater temporal resolution. 
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Live-cell imaging quantifies the mitotic entry delay caused by MELK inhibition 
 To more precisely measure the lengths of G2 and M phases in response to 8a treatment, 
we conducted live-cell imaging of U2OS osteosarcoma cells stably expressing a fluorescent cell 
cycle reporter based on PCNA localization (150).  U2OS cells are routinely used for cell cycle 
studies, particularly with imaging methods, and our results indicate that MELK expression is 
similar between U2OS and TNBC cells (Fig. S3.6C).  This live-cell imaging approach employs 
tracking of individual cells from an unperturbed, asynchronous population.  Fluorescent PCNA 
delineated the start and end of S phase, while nuclear envelope breakdown and cytokinesis 
delineated the start and end of M.  Cells were treated with DMSO, 1 or 3 μM 8a, and G2 length 
was measured.  We observed significant, dose-dependent G2 lengthening in cells treated with 
either 1 μM or 3 μM 8a, compared to DMSO-treated cells (Fig. 3.7A).  In contrast to the lower 
time resolution immunoblotting experiments with synchronized cells (Fig. 3.4), the increased 
sensitivity of live-cell imaging revealed that G2 was indeed significantly lengthened by 1 μM 8a 
treatment (~30% increase, 81 min).  Following 3 μM 8a treatment, median G2 length was 
markedly increased (>250% increase, 426 min) compared to untreated cells (Fig 3.7C). 
 Live-cell imaging was next used to quantify the length of M phase.  While no significant 
difference in time to complete M was observed between cells treated with DMSO and 1 μM 8a, 3 
μM 8a caused detectable lengthening of M in two of three replicates (Figs. 3.7B and S3.7).  This 
increase in mitotic length from 24 minutes in control cells to 36 minutes in 3 μM 8a-treated cells 
was much smaller in magnitude than the observed increase in G2 (Fig. 3.7C), which likely 
explains why it was not detected using synchronization methods.  An increase in G2 length 
appears to be the predominant phenotype resulting from MELK inhibition.  Taken together, our 
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results indicate that selective MELK inhibition causes a delay in mitotic entry that is consistent 
with transient G2 arrest. 
 
Discussion 
Currently, one of the main questions in the MELK field is how to rectify the seemingly 
disparate observations that RNAi-mediated MELK depletion and pharmacological inhibition 
cause a strong growth defect in cancer cells (5, 6, 17, 25, 36, 38, 39, 41, 74, 75), whereas 
CRISPR/Cas9 knockout of MELK may have conditional or no effect on proliferation (16, 18, 19, 
35, 44).  It is vital to recognize that genomic knockout techniques are not identical to RNAi-
mediated knockdown or inhibition, but rather that all are valuable orthogonal approaches.  Thus, 
divergent results should be interpreted as evidence that the functional role of the protein being 
investigated is likely complex, rather than evidence that one set of results is incorrect in its 
entirety.  It is quite possible that the total loss of protein expression and activity, via knockout, 
could have different effects than partial inhibition of activity with unperturbed expression, via 
pharmacological inhibition.  Further, and because of the inherent differences between these 
techniques, it is also possible that genomic knockout could result in cellular reprogramming of 
signaling networks such that compensation for growth defects occurs, whereas partial inhibition 
or depletion of the same enzyme may not result in the same changes.  As described in the 
introduction, divergent phenotypes have been observed, but not yet fully explained, between 
cyclin D-CDK4/6 knockout and inhibition, demonstrating that this phenomenon is not 
constrained solely to MELK (139–141).  At this point, these potential explanations are purely 
speculative, but this will undoubtedly be an important area of investigation for future MELK 
studies. 
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This controversy has underscored the fact that our understanding of the function of 
MELK in cancer is still lacking.  As a further complication, functional studies of MELK have 
long relied upon OTS, an inhibitor with a remarkable lack of selectivity, to complement results 
obtained using knockdown and other techniques.  While RNAi-mediated knockdown and 
genomic knockout approaches obviously have their merits, the use of a pharmacological 
inhibitor has distinct advantages as well.  First, pharmacological inhibition generally allows for 
much tighter temporal control than other techniques, such that effects can be measured on a short 
timescale before significant changes in signaling networks occur.  Second, inhibition of kinase 
activity often does not directly affect expression of the inhibited kinase, which allows for 
differentiation between activity-dependent and -independent functions.  Thus, a selective MELK 
inhibitor would clearly be a valuable addition to the toolkit available for studying the 
mechanistic underpinnings of this kinase in cancer. 
In an effort to identify a selective MELK inhibitor, we used competition MIB/MS 
technology to evaluate the selectivity profiles of OTS, HTH, and 8a.  Our results (Fig. 3.2A) are 
in agreement with other studies in demonstrating that OTS is highly non-selective, and therefore 
is unsuitable for mechanistic studies of MELK biology (13, 15).  In contrast to published enzyme 
assay data demonstrating HTH to be a potent MELK inhibitor, we found that this inhibitor did 
not significantly affect MELK binding to MIBs (Fig. 3.2, A and B) (16).  This illustrates the 
disparate results that can be observed between enzyme- and cell-based selectivity profiling 
methods, emphasizing the importance of evaluating compound selectivity in a cellular context.  
Our results indicating that 8a exhibits high selectivity for MELK (Fig. 3.2, A-C) are the first to 
characterize an exquisitely selective MELK inhibitor in cells, and thus rationalize the use of 8a 
for future functional studies.  Since thoroughly validated MELK substrates are lacking, one 
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intriguing possibility is to use MS to compare the phosphoproteome of cells treated with 8a to 
control cells, in an effort to identify novel MELK substrates.  Such studies could serve to 
establish a much-needed cellular readout for MELK activity, and to further elucidate the role of 
MELK in the cell cycle and cancer.  To date, MELK phosphoproteomics studies have only been 
completed using a mutant null allele of the MELK homolog in Caenorhabditis elegans (pig-1) 
(93), or with OTS treatment (37).  
As previously described, 8a treatment caused decreased viability of TNBC cells (Fig. 3.3, 
A and B) at concentration ranges that significantly prevented MELK binding to MIBs (Fig. 3.2C) 
(38).  We did not observe an induction of apoptosis with 8a (Fig. 3.3C), despite some others 
describing this effect as a result of MELK knockdown (17, 25, 35, 75).  It is possible that the 
longest time point used in our study (24h) is not sufficient for induction of apoptosis with 8a, and 
that the observed cell cycle perturbation precedes apoptosis.  Both pro-survival and pro-apoptotic 
roles have been attributed to MELK, and the specific contexts that determine these opposing 
functions remain to be elucidated (67).   
While many studies describe a role for MELK in cell cycle progression, the precise 
details of this role are not well understood.  In response to MELK silencing with RNAi, 
numerous studies have reported an accumulation of cells in G2/M phases (5, 9, 35, 38, 41).  It 
should be noted that due to the methods used (quantification of cellular DNA by flow cytometry) 
these particular studies were not able to differentiate between an accumulation in G2 versus M.  
Paradoxically, overexpression of MELK may induce a G2/M accumulation of cells as well (5, 
73).  Other studies have used more specific techniques to differentiate between G2 and M phase 
effects.  MELK knockdown has been reported to impair mitotic progression by varied 
mechanisms, including by decreasing activity and expression of the oncogenic mitotic 
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transcription factor FoxM1 (39, 74), by regulating MCL1 synthesis in M (75), by inducing 
mitotic catastrophe (22), and by causing cytokinetic defects (17, 76, 77).  A role for MELK in 
G2, distinct from M, has been described as well.  Davezac et al. observed that ectopic expression 
of MELK (formerly known as pEg3) caused an accumulation of cells in G2, which could be 
rescued by co-expression of CDC25B.  MELK was found to directly interact with CDC25B in 
Xenopus, and phosphorylate this phosphatase in vitro, leading the authors to hypothesize that 
MELK negatively regulates the G2/M checkpoint through interaction with CDC25B (73).   
As there is no clear consensus as to whether MELK plays a role in G2, M, or both, we 
used 8a, as an alternative to RNAi knockdown, to further investigate the cell cycle function of 
MELK.  Time-lapse microscopy experiments (Fig. 3.7) indicated that MELK inhibition caused a 
major, significant lengthening of G2 phase.  Of note, we observed many cells that delayed in G2 
phase after exposure to 8a within that same cell cycle, suggesting that the G2 delay phenotype is 
proximal to MELK inhibition.  An additional minor delay in mitotic progression was observed, 
warranting further investigation in light of previous studies indicating that MELK has mitotic 
functions.  However, we focused on the more predominant delay in mitotic entry.  Using 
thymidine synchronization techniques (Figs. 3.4-3.6), we observed that MELK inhibition caused 
delayed mitotic entry, likely mediated through delayed activation of CDK1, which was 
ultimately overcome to allow cells to complete M and begin the subsequent cell cycle.  These 
observations are consistent with a transient activation of the G2/M checkpoint (149).  Further 
studies are required to elucidate the underlying mechanism, though it is possible to speculate 
based upon the work of others.   
One potential explanation for the observed G2 delay phenotype is that MELK positively 
regulates CDC25B in G2, such that inhibition of MELK causes CDC25B to be unable to 
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dephosphorylate and activate CDK1, thereby delaying mitotic entry.  MELK phosphorylates 
multiple sites on CDC25B to regulate both progression through the G2/M checkpoint, and 
CDC25B localization to centrosomes during M (73, 113).  Importantly, this putative interaction 
has never been examined in the context of cancer.  A possible interaction with CDC25C, which 
has a critical role at the G2/M checkpoint and shares high sequence homology with CDC25B, 
has not been explored either.  Additional studies are needed to more clearly define the interaction 
between MELK and the CDC25 phosphatases in cancer.  An alternative hypothesis is that 
MELK inhibition causes DNA damage, which subsequently activates the G2/M checkpoint.  A 
study by Beke et al. found that MELK inhibition with MELK-T1 caused replication stress in 
MCF-7 cells, manifesting in replication fork stalling and DNA double strand breaks.  This 
resulted in activation of the ATM/Chk2 DNA damage repair pathway, which stimulates the 
G2/M checkpoint (39, 151).  While this pathway would certainly explain the putative checkpoint 
activation, one would also expect strong ATM activation to lengthen S phase, which was not 
observed in our study (Fig. 3.4).   
In conclusion, we have validated 8a as a highly selective MELK inhibitor suitable for 
functional studies, and have shown that MELK inhibition causes a mitotic delay consistent with 
activation of the G2/M checkpoint. 
 
Experimental Procedures 
Antibodies and reagents 
MELK-8a hydrochloride was purchased from MedChemExpress (HY-100368A).  
OTSSP167 was purchased from Selleck Chemicals (S7159).  HTH-01-091 was a generous gift 
from Dr. Nathanael Gray (Harvard).  The following primary antibodies were used in this study.  
Aurora A (14475, 1:1000), Aurora B (3094, 1:1000), CDC25B (9525, 1:1000), cyclin A2 (4656, 
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1:2000), cyclin E1 (4129, 1:2500), MELK (2274, 1:1000), Myt1 (4282, 1:1000), PARP (9532, 
1:1000), p-Aurora A/B/C (2914, 1:1000), p-CDK1 (T14) (2543, 1:1000), p-CDK1 (Y15) (4539, 
1:1000), and p-Histone H3 (S10) (9701, 1:1000) were purchased from Cell Signaling 
Technology.  β-actin (SC47778, 1:500) was purchased from Santa Cruz Biotechnology.  CDK1 
(MAB8878, 1:2000) was purchased from Millipore.  Cyclin B1 (ab32053, 1:10000) was 
purchased from Abcam. 
 
Cell culture and viability assays 
MDA-MB-468 and MDA-MB-231 cells were kindly provided by Dr. Gary Johnson 
(UNC).  These cell lines were cultured in RPMI 1640 (Gibco) supplemented with 10% fetal 
bovine serum (FBS, Millipore) and 1% antibiotic-antimycotic (Sigma).  HeLaS3 cells were 
kindly provided by Dr. Michael Emanuele (UNC), and were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM), high glucose (Gibco) supplemented with 10% FBS and 1% antibiotic-
antimycotic.   
Resazurin assays were completed as described previously (152).  Briefly, MDA-MB-231 
(1500 cells/well), MDA-MB-468 (4000 cells/well), or HeLaS3 (1000 cells/well) cells were 
plated on a 96-well plate.  After 24h, media was aspirated and replaced with fresh media 
containing 8a at concentrations ranging from 1 nM to 30 µM, or DMSO (negative control).  Each 
treatment condition was tested in technical quadruplicate.  Cells were incubated in media with 8a 
or DMSO for 72h prior to addition of resazurin dye (0.6 mM, Acros Organics 62758-13-8).  
After color change was observed (3h for MDA-MB-231, 2h for MDA-MB-468, 0.75h for 
HeLaS3), signaling that measurable reduction of resazurin to resorufin had occurred, 
fluorescence intensity was measured using a PHERAstar (BMG Labtech) plate reader with 
73 
fluorescence module (FI: 540-20, 590-20).  Dose-response curves were created and IC50 values 
calculated using GraphPad Prism version 8. 
For crystal violet assays, MDA-MB-231 and MDA-MB-468 cells were seeded at a 
density of 5000 and 10000 cells per well, respectively, on each well of a cell culture-treated 6-
well plate (Corning).  The following day, media was aspirated from all wells and replaced with 
media supplemented with either DMSO or 0.1, 0.3, 1, 3, or 10 µM 8a.  Every 2 days throughout 
the course of the assay, media was replaced on all wells with fresh media containing 8a or 
DMSO.  Cells were observed daily using a bright-field microscope and confluency was noted.  
The assay was continued until cells in the DMSO well were observed to be near-confluent (~8d 
for MDA-MB-231, and ~14d for MDA-MB-468).  Media was then aspirated from all wells, and 
cells were washed gently with ice-cold phosphate buffered saline (PBS, Gibco).  Next, 2 mL 
crystal violet stain (0.5% crystal violet (w/v) (Sigma), 20% methanol (Fisher)) was gently added 
to each well and plates incubated for 10 minutes at room temperature.  Wells were subsequently 
washed three times with water, allowed to dry, and plates were imaged with a Canon LiDE 110 
document scanner. 
 
Double thymidine synchronization 
HeLaS3 cells were seeded on 6 cm plates and allowed to adhere overnight.  During this 
and all subsequent incubation steps, cells were maintained in a humidified chamber with 5% CO2 
at 37°C.  DMEM was aspirated from all plates (except for asynchronous control plates, which 
were maintained in an incubator until the end of the assay) and replaced with media 
supplemented with 2 mM thymidine (Sigma).  16h after thymidine block, media was aspirated, 
plates were washed with warm PBS (1x) and warm DMEM (2x), and fresh media was added for 
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release from block.  Plates were incubated for 9h, at which point media was aspirated and again 
replaced with DMEM supplemented with 2 mM thymidine and incubated for 16h.  Media was 
aspirated and cells washed as above, and released from thymidine block into DMEM 
supplemented with 8a or DMSO.  0h timepoints were collected at the time of release, and 
subsequent collections were completed at the timepoints shown in figures.  Cells were collected 
by scraping in media and cell suspension was transferred to a 15 mL conical.  Cells were pelleted 
at 3000 rcf in a centrifuge with swinging bucket rotor, washed with cold PBS, and stored at -
80°C.  After all timepoints were collected, cell pellets were lysed and prepared for 
immunoblotting as described below. 
 
Immunoblotting 
HeLaS3 cells were plated in 6-well plates and treated with DMSO or 0.5, 1, or 3 µM 8a 
for 1h, 2h, 4h, 8h, 12h, or 24h.  Cells were collected as described above for double thymidine 
synchronization protocol.  Pellets from asynchronous and synchronized experiments were lysed 
by addition of RIPA buffer (20 mM Tris pH 7.4, 137 mM NaCl, 10% glycerol, 0.5% sodium 
deoxycholate, 1% Nonidet P-40 substitute (Fluka), 0.1% sodium dodecyl sulfate, 2 mM EDTA) 
supplemented with protease and phosphatase inhibitors (2 mM Na(VO3)4, 10 mM NaF, 0.0125 
µM calyculin A, and cOmplete EDTA-free Protease Inhibitor Cocktail (Roche).  Benzonase was 
added to each lysate (42 units/sample) and samples were incubated on ice for 10 minutes.  
Lysates were clarified by centrifugation at 21000 rcf, 4°C for 15 minutes.  Protein concentrations 
were normalized by Bradford assay (Bio-Rad), and prepared for SDS-PAGE by addition of 4x 
Laemmli sample buffer (250 mM Tris pH 6.8, 40% glycerol, 8% sodium dodecyl sulfate, 8% β-
mercaptoethanol, 0.4% bromophenol blue).  Samples (10-30 µg) were applied to a 10% SDS-
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PAGE gel for separation of proteins, after which proteins were transferred to a PVDF membrane 
(Bio-Rad).  Membranes were blocked for 1h with 5% non-fat dry milk or 5% bovine serum 
albumin (BSA, for phospho-specific antibodies) in TBS-T (20 mM Tris pH 7.6, 137 mM NaCl, 
0.05% Tween-20).  Membranes were incubated in primary antibody dilutions (described above) 
in 5% BSA made in TBS-T, at 4°C with gentle shaking.  Following overnight incubation, 
membranes were washed with TBS-T three times and incubated for 1h at room temperature with 
anti-mouse or -rabbit IgG-HRP conjugated secondary antibody (Promega) dilutions in 5% milk 
in TBS-T.  Membranes were again washed three times in TBS-T, and bands imaged using a 
Chemi-Doc Touch Imaging System (Bio-Rad) after addition of Clarity ECL reagent (Bio-Rad). 
 
MIB/MS selectivity profiling sample preparation 
The selectivity of MELK inhibitors for kinase targets was profiled using competition 
MIB/MS.  MDA-MB-468 cells were treated with MELK inhibitor, at concentrations listed in 
figure legends, or DMSO for 30 minutes.  This timepoint is sufficient for kinase engagement and 
inhibition by compound, but insufficient for major expression-level changes.  Cells were then 
washed twice with ice-cold PBS before being scrape-harvested in PBS.  Cell lysis, sample 
preparation, and MIB kinase enrichment was completed as previously described (138), with the 
exception of the composition of the kinase inhibitor mix used for enrichment.  To enrich for 
kinases in each sample, a 350 µL volume of the following kinase inhibitors, immobilized on 
beads, was applied to one Poly-Prep® chromatography column (Bio-Rad) per sample: CTx-





Samples were analyzed by LC-MS/MS using a Thermo Easy nLC 1200 coupled to an 
Orbitrap Q Exactive HF mass spectrometer equipped with an EasySpray nano source.  Samples 
were loaded onto an EasySpray C18 column (75 µm ID X 25cm, 2 µm particle size) and eluted 
over a 120 min method.  The gradient for separation consisted 5-40% B at a 250 nL/min flow 
rate, where mobile phase A [water, 0.1% formic acid] and mobile phase B [80% acetonitrile, 
0.1% formic acid].  The Q Exactive HF was operated in data-dependent mode where the 15 most 
intense precursors were selected for subsequent fragmentation.  Resolution for the precursor scan 
(m/z 350–1700) was set to 120,000 with a target value of 3 × 106 ions, 100 ms max IT.  MS/MS 
scans resolution was set to 15,000 with a target value of 1 × 105 ions, 75 ms max IT. The 
normalized collision energy was set to 27% for HCD.  Dynamic exclusion was set to 30 s and 
precursors with unknown charge or a charge state of 1 and ≥ 8 were excluded. 
 
MS data analysis 
Data was processed using the MaxQuant software suite (version 1.6.1.0) (153, 154).  The 
data were searched against a reviewed Uniprot human database (downloaded in February 2018) 
containing 20,245 sequences.  Precursor mass tolerance was set to 4.5 ppm and fragment mass 
tolerance was set to 20 ppm.  A maximum of two missed tryptic cleavages were allowed. The 
fixed modification specified was carbamidomethylation of cysteine residues.  The variable 
modification specified was oxidation of methionine.  A default protein false discovery rate 
(FDR) of 1% was used to filter all data within MaxQuant.  Proteins were quantified across all 
samples using MaxLFQ (155).  Matching between runs was allowed with the default retention 
time window.  Kinases were parsed from the dataset and those with >1 unique peptide were 
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quantified using label-free quantification (LFQ).  Kinases with >50% missing values were 
removed and LFQ intensities for the missing values were imputed using a constant value 
(average lower 10% of all LFQ intensities).  The ratio of the LFQ intensity for each kinase in 
MELK inhibitor conditions to that kinase in DMSO control was computed.  GraphPad Prism 
version 8 was used to generate bar plots and heat maps.  For data used to generate volcano plots, 
kinases that were not quantified in all three replicates in at least one condition within each 
analysis were removed.  Missing LFQ values were then imputed by randomly sampling from a 
normal distribution with a mean of 1.8 standard deviations lower than the mean in the original 
data, and a standard deviation of 0.3 times the standard deviation in the original data.  Data were 
Log2 transformed and moderated t-tests were computed using the Limma package (156). Briefly, 
a linear model predicting signal intensity given treatment condition was fit for each kinase, 
followed by t-statistics calculated by empirical Bayes moderation of standard errors towards the 
standard error estimated from all kinases. Multiple test correction was performed using the 
Benjamini-Hochberg method to control for a 5% FDR (157).  The mass spectrometry proteomics 
data have been deposited to the ProteomeXchange Consortium via the PRIDE (158) partner 
repository with the dataset identifier PXD016022. 
 
Live-cell imaging 
U2OS cells were a gift from Dr. Michael Whitfield (Dartmouth College) and maintained 
in DMEM (Sigma) supplemented with 10% FBS (Sigma), 1x penicillin-streptomycin, and 4 mM 
L-glutamine and incubated at 5% CO2.  Cells were transduced with fluorescent PCNA (pLenti-
Hyg-turq2-PCNA) and histone H2B (pBabe-Puro-mCh-H2B) using standard techniques, as 
described previously (150).  One day prior to imaging, cells were plated on #1.5 glass-bottom 
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plates (Cellvis) in FluoroBrite DMEM (Gibco) supplemented with FBS, penicillin-streptomycin, 
and L-glutamine, as above.  Imaging was performed on a Nikon Ti Eclipse inverted microscope 
using a 40x (NA 0.95) Plan Apochromat dry objective lens and the Nikon Perfect Focus System.  
Still images were captured using an Andor Zyla 4.2 sCMOS detector with 12-bit resolution.  
During imaging cells were maintained in a humidified chamber with 5% CO2 at 37°C.  Filter sets 
were CFP - 436/20 nm; 455 nm; 480/40 nm (excitation; beam splitter; emission filter) and 
mCherry - 560/40 nm; 585 nm; 630/75 nm (Chroma).  Images were obtained every 6 minutes 
using NIS-Elements AR software.  No photobleaching or phototoxicity was observed in cells 
imaged with this protocol.  
 8a or DMSO (negative control) was added 24 hours after the beginning of the imaging 
run as described in the figure legends.  Cells were manually tracked and scored.  The onset and 
end of S phase were determined visually using the DNA replication associated patterns of PCNA 
localization in the nucleus.  Mitosis length was defined visually by the length of time between 
nuclear envelope breakdown and cytokinesis.  Three individual biological replicates were 
imaged with 50 cells counted per condition per replicate.  Cells that traveled out of the field of 






Figure 3.1. Schematic of competition MIB/MS workflow and sample selectivity output data.  
MDA-MB-468 cells were treated with DMSO (negative control) or MELK inhibitor for 30 
minutes.  This timepoint allows sufficient time for inhibitors to penetrate cells and engage kinase 
targets, but not for significant expression-level changes.  After harvest, cell lysates were flowed 
over columns containing kinase inhibitors immobilized on Sepharose® beads, which bind 
kinases in the cell lysates (top).  Kinases bound to the added MELK inhibitor are unable to bind 
to the MIBs beads, and thus are not captured.  Following wash steps to remove non-specific 
binders, kinases were subsequently eluted and quantified by MS using label-free quantification.  
Kinases detected in lower abundance in MELK inhibitor conditions relative to DMSO control 






Figure 3.2. 8a is a highly selective MELK inhibitor.  A, MDA-MB-468 cells were treated for 
30 minutes with either DMSO or 1 µM 8a, HTH, or OTS.  Cells were harvested and competition 
MIB/MS was completed, as described in Experimental Procedures, to determine the selectivity 
profile of each MELK inhibitor.  The 20 kinases detected in lowest abundance, relative to 
DMSO control, are displayed for each inhibitor.  Arrows indicate the bar corresponding to 
MELK in each selectivity profile.  Results shown are from one experiment.  B, MDA-MB-468 
cells were treated for 30 minutes with either DMSO, 1 µM 8a, or 1 µM HTH in three biological 
replicates (distinct from the replicate shown in A).  Competition MIB/MS was used to determine 
selectivity as in A, and results displayed as volcano plots to show both the fold-change and 
significance of the quantified changes in kinase abundance.  Kinases with high significance and 
log2 fold-change < -1 are colored red and labeled.  Kinases with only log2 fold-change < -1 are 
colored yellow.  Kinases with log2 fold-change > -1 and non-significance are colored gray.  T-
statistics were calculated by empirical Bayes moderation of standard errors towards the standard 
error estimated from all kinases (156).  The Benjamini-Hochberg method was used for multiple 
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test correction with a 5% false discovery rate (157).  C, MDA-MB-468 cells were treated with 
DMSO or 1, 3, or 10 μM 8a for 30 minutes.  Cells were harvested and lysates subjected to 
competition MIB/MS as in A.  Data were filtered for kinases that showed decreased binding at all 
three concentrations in a dose-dependent manner.  The 32 kinases that met these criteria are 
displayed in a heat map, with a double-gradient color scheme ranging from dark blue (near-total 






Figure 3.3. Treatment with 8a causes decreased viability and decreased phosphorylation of 
Histone H3 (S10) in TNBC cells.  A, MDA-MB-231 (left) and MDA-MB-468 (right) cells were 
treated with DMSO or 8a at concentrations ranging from 1 nM to 30 μM.  Cells were exposed to 
8a for 72h before viability was measured using a resazurin assay.  Three biological replicates 
were completed for each cell line, and representative dose-response curves are displayed here.  
B, MDA-MB-231 and MDA-MB-468 cells were treated with DMSO or 8a at indicated 
concentrations.  The medium was changed and fresh inhibitor added every two to three days.  
Cells were monitored until near-confluent in the DMSO condition (about 8 or 14 days, 
respectively), at which point they were stained with crystal violet and imaged.  Three (MDA-
MB-231) or two (MDA-MB-468) biological replicates were completed, and representative 
images are shown here.  C, asynchronous MDA-MB-468 cells were treated with DMSO or 0.5, 
1, or 3 μM 8a for 1, 6, or 24h.  Cells were harvested and immunoblotted with the indicated 





Figure 3.4. MELK inhibition with 3 μM 8a causes delayed mitotic entry.  A, HeLaS3 cells 
were synchronized at G1/S with double thymidine block and released into DMSO, 1 μM, or 3 
μM 8a.  Cells were collected every 2h over a 12h timecourse.  Cells were lysed and 
immunoblotted with the indicated antibodies.  The splits in the image indicate that the samples 
from DMSO, 1 μM, and 3 μM 8a conditions were immunoblotted separately due to space 
constraints.  Asynchronous HeLaS3 lysate was loaded in the lanes labeled “A” in order to 
normalize among the blots.  The data shown here are representative of three independent 
experiments.  B, the signal intensity of the cyclins E1, A2, and B1, and p-H3 (S10) bands was 
quantified for the replicate shown in A using Bio-Rad Image Lab™ software.  The ratio of the 
quantified signal intensity at each timepoint relative to the 0h timepoint was computed for each 
condition.  The resulting ratios are plotted as bar charts for each protein, with 1.0 indicating no 





Figure 3.5. Delayed mitotic entry caused by 8a is associated with delayed activation of 
Aurora A, Aurora B, and CDK1.  HeLaS3 cells were synchronized at G1/S with double 
thymidine block and released into DMSO or 3 μM 8a.  Cells were collected starting at 6h post-
release, with subsequent collections completed every 0.5 or 1h, over a 12h timecourse.  Cells 
were lysed and immunoblotted with the indicated antibodies.  The split in the image indicates 
that the samples from DMSO and 3 μM 8a conditions were blotted separately due to space 
constraints.  Asynchronous HeLaS3 lysate was loaded in the lanes labeled “A” in order to 
normalize among the blots.  The data shown here are representative of two independent 





Figure 3.6. HeLaS3 cells treated with 8a complete mitosis and begin the subsequent cell 
cycle following delayed mitotic entry.  HeLaS3 cells were synchronized at G1/S with double 
thymidine block and released into DMSO or 3 μM 8a.  Cells were collected starting at 6h post-
release, with subsequent collections completed every 2h over a 20h timecourse.  Cells were lysed 
and immunoblotted with the indicated antibodies.  The split in the image indicates that the 
samples from DMSO and 3 μM 8a conditions were blotted separately due to space constraints.  
Asynchronous HeLaS3 lysate was loaded in the lanes labeled “A” in order to normalize among 





Figure 3.7. 8a causes a major, dose-dependent increase in G2 length.  A, asynchronous 
U2OS cells harboring fluorescent PCNA were treated with DMSO, 1 μM, or 3 μM 8a.  
Microscopy images were acquired every 6 minutes over the course of 72h.  Cells were manually 
tracked, and the length of G2 was calculated by measuring the amount of time between 
disappearance of PCNA foci (end of S phase) and nuclear envelope breakdown (start of M).  For 
each of three biological replicates, 50 cells were tracked per condition.  Kaplan-Meier curves 
were generated and significance calculated in GraphPad Prism using the log-rank test for 
survival curves.  Representative data are shown here, and results from additional replicates are 
shown in Fig. S3.7.  B, the length of M was manually calculated in the cells in A by measuring 
the amount of time between nuclear envelope breakdown (start of mitosis) and cytokinesis (end 
of mitosis).  For each of three biological replicates, 50 cells were tracked per condition.  Curves 
were generated and significance calculated as in A.  Data shown here, indicating M to be 
significantly lengthened by 3 μM 8a, are representative of 2 out of 3 biological replicates.  
Additional experiments (Fig. S3.7) indicate that M was not significantly lengthened in one 
replicate.  C, median length of G2 and M, in minutes.  The displayed cell cycle phase lengths 





Figure S3.1. Full competition MIB/MS selectivity profiles for 1 μM 8a, HTH, and OTS.  
MDA-MB-468 cells were treated with 1μM 8a, HTH, or OTS, and competition MIB/MS was 
completed as in Fig. 3.2A.  All 235 protein kinases that were quantified by MS are displayed.  





Figure S3.2. Full competition MIB/MS selectivity profiles for 10, 100, and 1000 nM 8a.  
MDA-MB-468 cells were treated with 10, 100, or 1000 nM 8a, and competition MIB/MS was 
completed as in Fig. 3.2A.  All 235 protein kinases that were quantified by MS are displayed.  





Figure S3.3. Full competition MIB/MS selectivity profiles for 1, 3, and 10 µM 8a.  MDA-
MB-468 cells were treated with 10, 100, or 1000 nM 8a, and competition MIB/MS was 
completed as in Fig. 3.2A.  All 221 protein kinases that were quantified by MS are displayed.  





Figure S3.4. 8a has no detectable affinity for STK11 or MAP2K4 at 3 µM.  The Eurofins 
DiscoverX cell-free assay platform was used to determine the binding affinity of 8a for STK11, 
MAP2K4, and MELK.  Results shown here are indicative of two biological replicates.  The 





Figure S3.5. Aurora A and B are minimally inhibited by 8a in cell-free kinase assays.  The 
Thermo SelectScreen kinase assay service was used to determine the percent inhibition of 
Aurora A and B upon exposure to 8a at concentrations ranging from 5 nM to 100 μM.  Results 





Figure S3.6. Treatment with 8a causes decreased viability in HeLaS3 cells.  A, HeLaS3 cells 
were treated with DMSO or 8a at concentrations ranging from 1 nM to 30 μM.  Cells were 
exposed to 8a for 72h before viability was measured using a resazurin assay.  Two biological 
replicates were completed, and representative results are displayed here.  B, asynchronous 
HeLaS3 cells were treated with DMSO or 0.5, 1, or 3 μM 8a for 1, 2, 4, 8, 12, or 24h.  Cells were 
harvested and immunoblotted with the indicated antibodies.  The split in the center of the image 
indicates that the 1, 2, and 4h samples were immunoblotted separately from the 8, 12, and 24h 
samples, due to space constraints.  Three biological replicates were completed. Data displayed 
here are representative results.  C, asynchronous HeLaS3, U2OS, MDA-MB-231, and MDA-
MB-468 cells were harvested and immunoblotted with the indicated antibodies.  The displayed 





Figure S3.7. Additional replicates of live-cell imaging experiment measuring G2 and M 
phase lengths.  Asynchronous U2OS cells harboring fluorescent PCNA were treated with 
DMSO, 1 μM, or 3 μM 8a and G2 and M phase lengths were measured as described in Fig 3.7. A 
and B.  Three independent experiments were completed, and representative results are shown in 
Fig. 3.7.  Curves for G2 length (top), M length (middle), and quantified cell cycle phase lengths 




CHAPTER 4: INVESTIGATION OF PUTATIVE MELK INTERACTORS AND 
COMBINATORIAL STRATEGIES TO INCREASE MELK-8A POTENCY3 
 
Introduction 
In chapter 3, we demonstrated that MELK inhibition with 8a causes delayed mitotic 
entry, and that cells ultimately overcome this delay to enter and progress through mitosis.  This 
phenotype is consistent with transient activation of the G2/M DNA damage checkpoint.  DNA 
damage can occur in cells through various means, resulting in activation of the DNA damage 
response (DDR).  Two of the main forms of DNA damage are single-strand and double-strand 
breaks (DSBs), which canonically result in activation of the ATR/Chk1 and ATM/Chk2 
pathways, respectively.  Activation of these pathways induces the phosphorylation of a multitude 
of substrates, including p53 and its stability regulators MDM2 and MDMX, BRCA1 and -2, 
histone H2A.X, and CDC25 phosphatases, enabling the DDR to slow or halt cell cycle 
progression and repair the damage (159). 
The list of known MELK substrates is short and generally not well-validated, but some 
putative interactors play a role in the DDR and cell cycle progression, specifically G2/M 
checkpoint function, including FoxM1, CDC25B, and p53 (67).  FoxM1, a transcription factor 
that regulates key mitotic genes, has been shown to both induce MELK expression and to be 
phosphorylated by MELK in glioma cells, regulating its transcriptional activity in a PLK1-
 
3A portion of this chapter, including Fig. 4.1 and descriptions of the BioID technique, was previously published in 
the Journal of Cellular Biochemistry.  The original citation is as follows: Cann, M. L., McDonald, I. M., East, M. P., 
Johnson, G. L., and Graves, L. M. (2017) Measuring Kinase Activity-A Global Challenge. J. Cell. Biochem. 118, 
3595–3606. 
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dependent manner (74).  CDC25B is among the first proteins to be recognized as a MELK 
substrate.  This interaction has only been studied in Xenopus, where it was shown that MELK 
phosphorylates CDC25B to modulate its phosphatase activity, thereby contributing to regulation 
of mitotic progression through CDK1 activation (73, 113).  MELK has been shown to 
phosphorylate p53, driving increased association with positive regulators and enhanced stability, 
thus increasing expression of p53 target genes (83).  Moreover, it was recently demonstrated that 
mutant p53 regulates MELK expression by controlling FoxM1 expression, further suggesting 
that MELK is a regulator of the DDR and cell cycle progression (71).  While these putative 
substrate interactions provide some clues regarding potential mechanisms underlying the 
observed mitotic delay phenotype, none have been extensively studied, and no unified model of 
MELK function exists, either globally or in the specific processes of DDR and G2/M checkpoint 
function. 
It is clear that a more comprehensive understanding of MELK interactors and substrates 
will be required to elucidate the function of MELK in various processes.  Classical affinity-based 
interaction studies such as immunoprecipitation (IP)/MS are widely used to study protein-protein 
interactions.  However, it can be challenging to identify kinase substrates using these methods 
due to the transient nature of phosphorylation reactions.  For this reason, more recently 
developed proximity biotinylation approaches such as BioID and APEX have gained popularity 
for probing the interactome of kinases and protein complexes (160).  The BioID (proximity-
dependent biotin identification) technique relies on the fusion of the kinase being studied to a 
mutated, promiscuous form of BirA, a biotin ligase from Escherichia coli (161).  The BirA gene 
used for BioID has a point mutation that results in a ligase (BirA-R118G (BirA*)) with 
decreased affinity for biotinyl-5’-AMP, the highly reactive intermediate of the biotinylation 
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reaction (162).  When a BirA*-kinase fusion protein is expressed in cells grown in media 
supplemented with biotin, the biotinyl-5’-AMP molecule is released by BirA* and irreversibly 
biotinylates lysine residues on proximal proteins (within ~10 nm), with no required biotinylation 
consensus sequence (Fig. 4.1) (163, 164).  Biotinylated proteins can then be captured with 
streptavidin Sepharose and identified by MS, to ultimately identify proximal proteins and 
candidate kinase substrates. 
Another well-established approach for substrate identification and characterization is 
phosphoproteomics/MS.  The coupling of phosphopeptide enrichment strategies to MS allows 
for the identification and quantification of phosphate modifications on proteins, thereby enabling 
varied analyses, from examining global phosphoproteome dynamics to mapping phosphorylation 
sites on a specific protein of interest (165, 166).  In the latter scenario, phosphorylation site 
mapping in combination with either overexpression or selective inhibition of a kinase of interest 
enables the phosphorylation of specific residues to be attributed to a particular kinase (167).  
This can be a powerful approach when probing kinase-substrate interactions, and often serves as 
a starting point for mechanistic studies of this nature. 
The validation of 8a as the first highly selective MELK inhibitor (chapter 3) provides a 
valuable tool compound for functional studies of MELK.  Further, this molecule can also be used 
to revisit the therapeutic potential of MELK inhibitors for cancer treatment.  The leading MELK 
inhibitor OTS has shown some pre-clinical promise (10–12, 35, 41), spawning multiple clinical 
trials, but it has also been demonstrated to be non-selective for MELK (13–15, 17).  Thus, the 
clinical fate of this inhibitor will not ultimately settle the dispute concerning whether or not 
MELK is an attractive therapeutic target in cancer.  In addition to single-agent therapeutic 
studies with 8a, drug synergy studies could be used to identify efficacious drug combinations.  
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Indeed, the therapeutic use of drug combinations to leverage polypharmacology, particularly 
involving epigenetic modulation, has proven to be an attractive approach to improve efficacy 
relative to single-agent therapies (168–170).  The elucidation of synergistic relationships has also 
aided in the investigation of the mechanism of action of drugs and the functional characterization 
of drug targets (171–173). 
In this chapter, we further investigate the mechanism underlying the delay in mitotic 
entry, observed in chapter 3, as a result of MELK inhibition with 8a.  We found that 8a treatment 
causes dose-dependent induction of the DNA damage marker p-H2A.X (S139) and activation of 
Checkpoint kinase 2 (Chk2), suggesting that MELK inhibition delays mitotic entry by activating 
the G2/M DNA damage checkpoint.  We next revisited past results in an effort to shed light on 
the mechanistic link between MELK inhibition and activation of the DDR.  The BioID 
technology was used to identify putative MELK interactors, which included the MCM complex, 
CDK1/cyclin B1, p53, and other proteins involved in cell cycle and DDR-related processes.  
Phosphoproteomics/MS techniques were used to probe the MELK-FoxM1 relationship.  Our 
results demonstrated that FoxM1-S481 is a candidate MELK phosphorylation site, and 
phosphomimetic mutation of this residue was observed to slightly increase FoxM1 
transcriptional activity.  Finally, we conducted an unbiased screen for kinase inhibitors and 
epigenetic regulators that synergize with 8a in TNBC cells.  The goal of this screen was two-
fold; first, we aimed to identify drug combinations that would potentially be clinically 
actionable, and second, we aimed to gain insight into the function of MELK by examining the 
targets of synergistic compounds.  We identified three epigenetic regulators, namely UNC0642, 
OTX015, and UNC1999, that may exhibit favorable combinatorial effects with 8a.  While the 
results presented in this chapter are generally incomplete, they potentially lay the groundwork for 
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future MELK interaction studies and investigations of combinatorial drug strategies involving 
the MELK inhibitor 8a. 
 
Results 
MELK inhibition activates the Chk2 pathway 
DNA DSBs are the most deleterious form of DNA damage.  ATM kinase is activated in 
response to DSBs, resulting in activation of Chk2 by phosphorylation of threonine 68 and 
phosphorylation of serine 139 of the histone variant H2A.X, at the sites of DSBs, which 
facilitates the recruitment of repair machinery to these sites (151).  We treated HeLaS3 cells with 
DMSO or 0.5, 1, or 3 μM 8a, for times ranging from 1h to 24h, and immunoblotted for Chk2, p-
Chk2 (T68), and p-H2A.X (S139) (Fig. 4.2A).  Treatment with 8a caused a dose-dependent 
increase in p-H2A.X (S139), a marker of DNA damage, at all measured timepoints.  This 
phosphorylation correlated precisely with increased activation of Chk2, as measured by p-Chk2 
(T68), while total Chk2 expression remained largely unchanged.  These observations suggest that 
the delay in mitotic entry caused by MELK inhibition is likely mediated by activation of the 
Chk2 DNA damage pathway.   
Given these results, we hypothesized that DNA damage occurs in cells following MELK 
inhibition.  To test this hypothesis, we examined whether DNA damage repair-deficient cells 
were more sensitive to 8a than normal cells.  RNF168 is an E3 ubiquitin ligase whose 
ubiquitination activity is essential for the DDR to DSBs (174).  For these experiments, we 
utilized RNF168 knockout U2OS cells that were generated via CRISPR-mediated genomic 
knockout by the Cyrus Vaziri lab (UNC).  The viability of wild-type and RNF168 knockout 
U2OS cells was measured following 72h 8a treatment using an MTS assay (Fig. 4.2B).  Both 
control cells and RNF168 knockout U2OS cells exhibited equal sensitivity to 8a (IC50 = 1 μM), 
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demonstrating that deficiency in the DDR caused by RNF168 loss does not confer increased 
sensitivity to MELK inhibition. 
While the results of these experiments provided some mechanistic insight into the mitotic 
delay phenotype observed in chapter 3, they did not fully elucidate the steps linking MELK 
inhibition to Chk2 activation and delayed mitotic entry.  In the remainder of this chapter, we 
revisit previous results in search of a deeper mechanistic understanding of this phenotype.   
 
BioID identifies novel putative MELK interacting proteins 
 As noted previously throughout this work, the function of MELK in cancer is poorly 
understood, which is in part due to a dearth of well-validated MELK interactors and substrates 
(67).  To identify novel putative MELK interacting proteins, we utilized BioID.  Because of the 
small labeling radius inherent to BioID, it is important to carefully consider whether to fuse 
BirA* to the N- or C-terminus of the protein of interest, as these two strategies are likely to 
reveal different proximal proteins (175).  Our main goal was to identify novel MELK substrates, 
so we chose to fuse BirA* to the N-terminus of MELK, where the kinase domain is located (Fig. 
4.3A).  In an effort to maintain unperturbed substrate binding to MELK, we incorporated a 15-
amino acid linker between BirA* and MELK.  It is known that linker composition can affect the 
protein-protein interactions and activity of fusion proteins.  To account for this possibility, we 
designed two different MELK BioID constructs: one bearing a flexible linker (3 x GGGGS), 
referred to as BirA*-FL-MELK, and one bearing a rigid linker (3 x EAAAK), referred to as 
BirA*-RL-MELK (Fig. 4.3B) (176, 177).   
 We first verified that the BirA*-MELK fusions labeled proteins with biotin in cells.  
HEK293T cells were transfected with BirA* (control), BirA*-FL-MELK, or BirA*-RL-MELK, 
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and 3h after transfection, media was supplemented with 50 μM biotin.  Cells were incubated in 
media containing biotin for 16h before being harvested for immunoblot.  BirA* and BirA*-
MELK samples were resolved by SDS-PAGE, transferred to PVDF membranes, and detected 
using streptavidin-HRP (Fig. 4.4).  We observed high levels of auto-biotinylation of BirA*, 
BirA*-FL-MELK, and BirA*-RL-MELK, as anticipated with this technique, revealing that both 
BirA* (37 kDa) and the BirA*-MELK fusions (115 kDa) were of the expected size.  Longer 
exposures revealed apparent differences in proximal protein biotinylation between the BirA* 
control and BirA*-MELK samples.  These differences were observed around 42-60 kDa, though 
interestingly the biotinylation patterns of BirA*-FL-MELK and BirA*-RL-MELK were not 
noticeably different from one another.  These results indicated that the BirA*-MELK fusion 
proteins labeled proteins with biotin as expected.  We next proceeded to analyze the MELK 
BioID samples using MS to identify specific differentially biotinylated proteins. 
 HEK293T cells were again transfected with control or MELK BioID constructs and 
exposed to biotin for 16h.  Cells were collected and lysed, and biotinylated proteins were 
captured from cell lysates with streptavidin agarose.  On-bead trypsin digestion of proteins and 
MS analysis were completed as described in Experimental Procedures.  A total of two biological 
replicates were completed.  For both MELK BioID constructs, the ratio of the abundance of each 
protein quantified in the BirA*-MELK sample to the abundance of that protein in the BirA* 
control sample was calculated, and this value was averaged between the two biological 
replicates.  Proteins with a ratio of abundance ≤ 1.5 (BirA*-MELK to BirA*) were filtered from 
the data, and the remaining proteins were analyzed using Ingenuity Pathway Analysis (IPA) 
software (QIAGEN) (178).  In total, 376 and 522 proteins met these cutoffs for BirA*-FL-
MELK and BirA*-RL-MELK, respectively. 
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When we used IPA to analyze the diseases and disorders that most overlapped with the 
MELK BioID data, cancer was identified as the top disease (Fig. 4.5A).  This result was in 
agreement with previous studies that have extensively linked MELK to cancer, more frequently 
than any other disease (67).  Next, we used IPA to score the data according to the overlap of 
identified proteins with canonical pathways.  The top three pathways identified for both BirA*-
MELK fusions were eIF2 signaling, regulation of eIF4 and p70S6K signaling, and mTOR 
signaling (Fig. 4.5B).  Notably, the proteins from our data that were assigned to these pathways 
were exclusively ribosomal proteins and translation initiation factors.  These are known 
contaminants in BioID datasets when using N-terminal BirA* fusions, ostensibly because the 
functional BirA* domain is synthesized and kept in close proximity to the ribosome while the 
remainder of the fusion protein is synthesized (179).  We therefore omitted these pathways and 
proteins from further analysis.  There was a large degree of overlap between the remaining top 
canonical pathways identified in the BirA*-FL-MELK and BirA*-RL-MELK data.  The two cell 
cycle pathways, G2/M DNA damage checkpoint regulation and control of chromosomal 
replication, were of particular note because of the results from chapter 3.  We further analyzed 
the specific proteins from our BioID data that were assigned to these pathways. 
 The proteins found more highly biotinylated by BirA*-MELK fusions in the G2/M DNA 
damage checkpoint pathway were TP53 (p53), CDK1, CCNB1/CCNB2 (cyclin B1/B2), and 
multiple 14-3-3 proteins (Fig. 4.6A).  The interaction with p53 is in agreement with previous 
work that showed MELK directly binds and phosphorylates p53 (83).  CDK1, along with its 
activator cyclin B1, is considered the master regulator of mitotic entry and progression (140).  
The 14-3-3 proteins, which bind phosphorylated serine and threonine residues, are known to be 
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involved in hundreds of protein-protein interactions, facilitating a multitude of processes (180–
182). 
 Within the chromosomal replication pathway, MCM2-7, PCNA, RPA1, and TOP2A were 
identified as being highly biotinylated by BirA*-MELK fusions (Fig. 4.6B).  None of these 
proteins have previously been identified as MELK interactors.  MCM2-7 comprise the 
minichromosome maintenance (MCM) complex, the core component of the eukaryotic 
replicative helicase, which is essential for the initiation and elongation of DNA replication (183–
185).  PCNA, RPA1, and TOP2A are additional vital parts of the replication machinery.  PCNA 
acts as a DNA clamp, tethering polymerases to DNA and serving as a binding site for numerous 
proteins, which enables the high processivity inherent to DNA replication (186).  RPA1 binds to 
and stabilizes single-stranded DNA during normal DNA replication and the repair of DNA 
damage (187).  TOP2A is a type 2 topoisomerase that cleaves and unwinds DNA during 
replication to alleviate tension associated with supercoiling (188). 
The interaction with p53 was not pursued further because it has been previously 
investigated, and due to the anticipated difficulty with linking this interaction to one of the 
countless functions of p53.  A putative interaction with 14-3-3 proteins and PCNA has not yet 
been pursued because these proteins are very highly abundant, thus increasing the likelihood of 
these results being false positives when using BioID.  Similarly, the probability of RPA1 and 
TOP2A being bona fide MELK interactors was considered low because biotinylation of these 
proteins was only slightly increased in the BirA*-MELK samples relative to BirA* control.  The 
other proteins (Fig. 4.6C) that were quantified in greater abundance in the BirA*-MELK 
samples, namely SMC2, SUPT16H, MAPRE1, RAN, ARF5, HNRNPH1, VDAC1, and CRK, 
were not analyzed further at this time because of a less obvious connection to the phenotype 
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observed in chapter 3.  We did investigate the putative interaction with the MCM complex, as all 
six subunits of this heteromeric complex were detected in greater abundance in the BirA*-
MELK samples, and there is a clear connection between faithful replication, which requires the 
MCM complex, and activation of the G2/M DNA damage checkpoint.  However, results from 
co-immunoprecipitation (co-IP) experiments were largely negative or inconclusive (data not 
shown).  Finally, we further investigated an interaction between MELK and CDK1/cyclin B1, as 
the role of CDK1 at the G2/M checkpoint and in mitosis provided a clear link with the mitotic 
delay phenotype described in chapter 3.  The likelihood of CDK1 and cyclin B1 being false 
positive interactors was also considered low, as both proteins are found in lower abundance 
relative to many of the other putative interactors identified with BioID. 
 
Investigation of MELK-CDK1/cyclin B1 interaction 
Asynchronous HEK293T cells were transfected with FLAG-MELK and harvested after 
24h for IP.  Mock and FLAG IPs were completed as described in Experimental Procedures.  
Samples were analyzed by immunoblot for MELK, CDK1, and cyclin B1 (Fig. 4.7A).  IP with 
FLAG antibody enriched substantially more MELK than the mock IP.  While CDK1 did not 
seem to co-IP with MELK, more cyclin B1 was detected in the FLAG IP sample than in the 
mock IP sample.  These results suggested that MELK and cyclin B1 may physically interact in 
cells.  However, a second replicate of this experiment did not detect increased cyclin B1 or 
CDK1 abundance in the FLAG IP sample (data not shown). 
We next tested whether MELK depletion or inhibition affected CDK1 activity in mitosis.  
HEK293T cells were either transfected with shMELK42, shMELK46, or an empty vector control 
42h prior to harvest, or they were treated with 1 μM dinaciclib, 1 μM flavopiridol, 0.5 μM 8a, or 
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5 μM 8a 20h prior to harvest.  10 μM 8a treatment was done 1.5h before harvest because of the 
toxicity of 8a at this concentration.  Additionally, all conditions were synchronized in mitosis by 
treatment with 100 ng/mL nocodazole 20h before harvest.  Samples were analyzed by 
immunoblot with MELK, CDK1, CDC25C, cyclin B1, p-H3 (S10), and β-actin antibodies (Fig. 
4.7B).  The CDC25C antibody is routinely used to measure CDK1 activity, as CDK1 
phosphorylates this phosphatase during mitosis, resulting in a slower migration pattern during 
SDS-PAGE separation relative to the unphosphorylated form (189).  As expected, the CDK1 
inhibitors dinaciclib and flavopiridol completely ablated CDK1 activity, as observed by a total 
loss of CDC25C phosphorylation.  Transfection of cells with shMELK42 and -46 resulted in 
high to moderate levels of MELK depletion, respectively, but had no effect on CDK1 activity, as 
measured by the proportion of unphosphorylated to total CDC25C.  CDK1 and cyclin B1 
expression were also unaffected, as was the abundance of p-H3 (S10), a marker for mitosis.  
Likewise, MELK inhibition with 0.5, 5, or 10 μM 8a had no effect on CDK1 activity or 
expression, cyclin B1 expression, or p-H3 (S10) abundance.  Collectively, the results from this 
experiment suggest that MELK depletion or inhibition do not affect CDK1 activity in mitosis. 
 
MELK increases the transcriptional activity of FoxM1 
 One of the more well-validated MELK substrates is FoxM1, an oncogenic transcription 
factor that regulates a multitude of mitotic genes (99, 190).  While it has been shown previously 
that MELK interacts with and phosphorylates FoxM1 to regulate its transcriptional activity, the 
phosphorylation site(s) on FoxM1 that are regulated by MELK are unknown, as is the specific 
mechanism by which MELK phosphorylation increases FoxM1 activity (74).   
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First, we aimed to replicate results showing that MELK and FoxM1 co-IP.  Myc-FoxM1 
and FLAG-MELK were overexpressed in HEK293T cells for 24h.  Cells were lysed and IPs with 
or without Myc antibody were completed, as described in Experimental Procedures.  We 
observed that Myc-FoxM1 IP resulted in co-IP of FLAG-MELK, albeit with low efficiency, 
perhaps suggesting a weak or transient interaction (Fig. 4.8A).  Next, a FoxM1 transcriptional 
reporter assay was completed to test the effects of MELK overexpression on FoxM1 activity.  
HEK293T cells were transfected with Myc-FoxM1 and a FoxM1 transcriptional reporter 
construct (6 x DB), along with varied amounts of the FLAG-MELK construct.  After 48h, cells 
were lysed, and a luciferase assay was completed to quantify the amount of FoxM1 
transcriptional activity in each condition.  FoxM1 activity was increased by MELK 
overexpression, and this effect was potentiated by greater amounts of MELK (Fig. 4.8B).  Both 
the co-IP and transcriptional reporter assay results corroborate published work (74). 
 
Identification of FoxM1-S481 as a putative MELK phosphorylation site 
 Following validation of the MELK-FoxM1 interaction, we aimed to identify specific 
phosphosites on FoxM1 that are regulated by MELK.  We investigated this question with MS, 
using two separate approaches.  Two replicates were completed in which either FoxM1 or 
FoxM1 and MELK were overexpressed in HEK293T cells for 24h.  A third replicate was 
completed in which overexpressed FoxM1 was IPed from HEK293T cell lysate, purified, and 
FoxM1 was incubated with or without active MELK for 1h.  For all replicates, samples were 
resolved by SDS-PAGE, proteins were labeled with Coomassie stain, FoxM1 bands were 
excised, and in-gel trypsin digestion and MS analysis were completed as described in 
Experimental Procedures.  In total, 16 phosphosites were identified by MS analysis, though the 
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abundance of each peptide could not be quantified in all replicates (Table 4.1).  FoxM1-S481 
was the only phosphosite that was quantified in greater abundance in the FoxM1 + MELK 
sample than the control sample in all three replicates, suggesting that MELK phosphorylates this 
residue in FoxM1. 
 FoxM1 is heavily post-translationally modified, including many known phosphorylation 
sites, to regulate its transcriptional activity, localization, and stability (191).  We used the 
PhosphoSitePlus® database to map the phosphorylation sites and relative phosphorylation 
density on FoxM1 (Fig. 4.9A).  Some regions of phosphorylation are well characterized, such as 
the C-terminal transactivator domain (TAD), which is phosphorylated by CDKs and PLK1 to 
modulate FoxM1 activity at different stages of the cell cycle (191).  However, there is a region of 
phosphorylation in the central part of FoxM1, including serine 481, that is not well characterized.  
The phosphorylation of residues in this region of FoxM1 has been detected using high-
throughput techniques, but has not been attributed to any specific kinase, and the effects of this 
phosphorylation is poorly understood.  Serine 481, specifically, has been identified with a 
phosphate group modification by four studies (165, 192–194).  The results of our phosphosite 
identification experiments suggest that MELK may be one of the kinases responsible for 
regulating the phosphorylation of serine 481 of FoxM1. 
 To determine whether phosphorylation of FoxM1 at serine 481 regulates its activity, we 
used site-directed mutagenesis to create FoxM1 mutants that contain either a non-
phosphorylatable alanine, or a phosphomimetic aspartate or glutamate at the 481 position.  A 
luciferase activity assay was conducted to measure the transcriptional activity of wild-type or 
FoxM1-S481A, -D, or -E mutants, in the absence of MELK overexpression (Fig. 4.9B).  The 
FoxM1-S481A mutant exhibited very slightly decreased activity relative to wild-type.  
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Conversely, both of the phosphomimetic mutations resulted in slightly increased FoxM1 activity, 
with the FoxM1-S481D mutant exhibiting a greater increase in activity (~25%), than the -S481E 
mutant (~15%).  Importantly, the modest increases in transcriptional activity observed with 
FoxM1-S481D or -E mutants were much smaller in magnitude than the 250% increase observed 
with high levels of MELK overexpression (Fig. 4.8B), suggesting that MELK phosphorylates 
additional residues, perhaps in the same poorly characterized region of the protein, to further 
activate FoxM1. 
 
Unbiased screen for compounds that synergize with MELK-8a in TNBC cells 
 We conducted an unbiased screen for kinase inhibitors and epigenetic regulators that 
synergize with 8a in TNBC cells.  This screen, henceforth referred to as the synergy screen, was 
completed using MDA-MB-231 and MDA-MB-468 cells, two commonly used TNBC cell lines.  
A schematic of the synergy screen is provided (Fig. 4.10).  Briefly, MDA-MB-231 and MDA-
MB-468 cells were each seeded on 384-well cell culture plates and incubated for 24h to allow for 
cell adherence.  Cells were then treated with either DMSO or 12, 37, 111, 333, 1000, or 3000 nM 
8a, in combination with DMSO or one of 176 compounds (Table 4.2) at a concentration of 3, 10, 
30, 100, 300 or 1000 nM.  Cells were incubated for 96h before viability was measured using the 
CellTiter-Glo® assay. 
 Dose-response curves were generated for 8a in combination with each compound in the 
synergy screen.  High-throughput, objective synergy scoring methods, such as Bliss 
independence, were not calculated because the range of 8a concentrations used in the screen was 
too low, which resulted in dose-response curves with no lower plateau.  Synergy tests using Bliss 
independence and other models were not informative due to the non-normal nature of these data, 
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and thus the curves for each compound had to be manually inspected for potential synergy.  We 
analyzed all dose-response curves, in search of drug combinations for which cell viability was 
substantially lower than what would be expected with single-agent treatment at the same 
concentrations.  For example, the top hit in the synergy screen, UNC0642, appeared to exhibit 
strong synergy with 8a in MDA-MB-468 cells, where 3 μM 8a alone did not decrease viability, 1 
μM UNC0642 alone decreased viability to 80%, and the combination of the two resulted in 0% 
viability (Fig. 4.11A).  These putative synergistic effects were also observed with 1 μM 
UNC0642 in combination with 0.3 and 1 μM 8a, suggesting this effect was not a false positive 
limited to a single datapoint.  Using these manual inspection criteria, the top hits from the 
synergy screen were identified as UNC0642, OTX015, and UNC1999 (Fig. 4.11, A-C).  All of 
these compounds are epigenetic modulators, with known targets identified as G9a/GLP, 
BRD2/3/4, and EZH1/2, respectively. 
 To test the results from the synergy screen using a more optimal range of 8a 
concentrations, we used MTS cell viability assays.  Cells were seeded and incubated for 24h to 
allow for adherence to plates, then exposed to a combination of DMSO or 1 nM to 30 μM 8a, in 
combination with DMSO or 10 nM to 10 μM UNC0642, or 3 nM to 3 μM OTX015 or 
UNC1999.  After 72h, viability was measured as previously described.  Dose-response curves 
were again generated to assess putative synergy (Fig. 4.12, A-C).  No synergistic effects with 8a 
were observed with OTX015 (Fig. 4.12B) or UNC1999 (Fig. 4.12C).  Similarly, no synergy was 
observed between 8a and UNC0642 in MDA-MB-231 cells.  In MDA-MB-468 cells, we 
observed a slight left-shift in the 3 μM UNC0642 dose-response curve (IC50 = 1.5 μM) relative to 
the DMSO and 10 nM to 1 μM curves (IC50 = 3.5 μM) (Fig. 4.12A).  This modest 2-fold increase 
in 8a potency was not observed in a second replicate of this experiment, however (data not 
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shown).  Collectively, the results of the synergy screen demonstrated apparent synergistic effects 
when 8a was combined with UNC0642, OTX015, or UNC1999, but these results were not 
replicated using MTS assays, where these epigenetic regulators had no effect on 8a potency. 
 
Discussion 
 The detection of DNA DSBs triggers a series of events that slow or halt cell cycle 
progression, which is thought to allow time for DNA damage repair.  At the site of DSBs, ATM 
kinase phosphorylates H2A.X at S139, which acts as the site of recruitment for DSB repair 
machinery and initiates the DDR (195).  ATM also phosphorylates multiple substrates to arrest 
cell cycle progression.  When DSBs are detected in G2, ATM activates Chk2 by phosphorylation 
of T68 and other sites.  Chk2 in turn phosphorylates numerous substrates including CDC25C, at 
S216, which is subsequently bound by 14-3-3σ and excluded from the nucleus.  This nuclear 
exclusion prevents CDC25C from dephosphorylating CDK1 at Y15, thereby rendering CDK1 
inactive and arresting cell cycle progression at the G2/M checkpoint (151, 159). 
As an extension of the results shown in chapter 3, we demonstrated that 8a treatment 
caused activation of Chk2 and induced phosphorylation of H2A.X (S139) (Fig. 4.2A), strongly 
suggesting that MELK inhibition delays mitotic entry by activating the G2/M DNA damage 
checkpoint.  Interestingly, other groups have shown that ATM and Chk2 are activated in 
response to MELK knockdown or inhibition with MELK-T1 (26, 39).  To comprehensively test 
activation of the ATM/Chk2 pathway, future studies should measure the activation of ATM (via 
S1981 phosphorylation) and phosphorylation of CDC25C S216 by immunoblot.  This could 
initially be completed in asynchronous cells, as in Fig. 4.2A, but should be extended to 
synchronous experiments like those shown in Figs. 3.4-3.6 to test whether MELK inhibition is 
directly linked to activation of the G2/M checkpoint via the ATM/Chk2 pathway. 
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It was surprising that both wild-type and RNF168 knockout U2OS cells displayed equal 
sensitivity to 8a (Fig. 4.2B), given our findings suggesting that 8a treatment activates the 
ATM/Chk2 DDR pathway.  Our hypothesis could be tested further using alternative cellular 
models with deficiency in DNA damage repair pathways.  Also, while the observation that 8a 
treatment induces p-H2A.X (S139) implies that DNA damage occurred, it does not directly 
provide evidence of DNA lesions.  Future studies should test whether MELK inhibition induces 
DNA damage using comet assays or similar approaches. 
Similar asynchronous (Fig. 4.2A) and synchronous (Figs. 3.4-3.6) approaches to those 
outlined above should also be employed to test for activation of the ATR/Chk1 pathway, which 
is canonically activated in response to replication stress and exposed single-stranded DNA (159, 
195).  The potential observation that MELK inhibition causes activation of the ATM/Chk2 
pathway independent of ATR/Chk1 activation would be surprising and mechanistically 
informative, given that it would suggest that DNA DSBs had formed without prior replication 
stress or single-strand breaks.  A previous study demonstrated that MELK knockdown activates 
the ATM/Chk2 pathway without activating Chk1, though this article was later retracted for 
image duplication (79).  Preliminary results from our lab (data not shown), indicate that Chk1 is 
not activated in asynchronous HeLaS3 cells following 8a treatment, but further investigation is 
required for more definitive evidence. 
The BioID experiments (Figs. 4.4-4.6) identified two intriguing putative MELK 
interactors: the MCM complex and CDK1/cyclin B1.  If a putative MELK-MCM complex 
interaction were to positively regulate normal DNA replication, it could potentially explain how 
MELK inhibition induces the DNA damage markers p-H2A.X (S139) and p-Chk2 (T68).  In this 
instance, one would expect to observe ATR/Chk1 activation due to replication fork stalling, as 
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well as lengthened S phase, which was seemingly not observed with 8a treatment (Fig. 3.4).  
Nonetheless, the MELK-MCM complex relationship should be further investigated with protein-
protein interaction studies beyond the previously attempted co-IP methods.  Candidate 
approaches include proximity ligation assays (PLA) or BRET-based assays, as well as classical 
phosphorylation assays to determine whether MELK can directly phosphorylate the MCM 
complex.  Since 8a has been validated as a highly selective MELK inhibitor, cell-based, 
quantitative flow cytometry assays could also be utilized to determine whether MELK inhibition 
impairs MCM loading onto DNA or S phase progression timing (196). 
An interaction between MELK and CDK1/cyclin B1 could potentially explain the 
observation that MELK inhibition transiently activates the G2/M checkpoint, given that CDK1 
activity is the ultimate control mechanism for mitotic entry.  To date, our experiments have not 
uncovered any mechanistic insight into this interaction; however, the possibilities are numerous.  
MELK may phosphorylate CDK1 directly to regulate its activity.  While our results (Fig. 4.7B) 
suggest this is not the case, the technical aspects of this experiment could be improved, primarily 
by using HeLaS3 cells instead of HEK293T, and by using double thymidine synchronization 
plus 6-8h release to study cells in late G2 instead of cells nocodazole-arrested in mitosis.  An 
additional possibility is that MELK phosphorylates cyclin B1 to regulate its localization, perhaps 
by modulating 14-3-3σ binding, thus indirectly controlling CDK1 activity.  It also cannot be 
ruled out that CDK1 phosphorylates MELK.  Indeed, one study has demonstrated that MPF 
(mitosis-promoting factor, a complex of CDK1 and cyclin B1) phosphorylates MELK to regulate 
its activity in mitosis (197).  It should be noted that this study is one of the earliest in the MELK 
field, was completed solely using Xenopus as a model, and the results were never replicated or 
expanded upon in mammalian cells or in the context of cancer.  To investigate all of these 
112 
possibilities, PLA, BRET, and phosphorylation assays would again be useful.  Secondary 
experiments, supposing positive results, could include microscopy-based cyclin B1 localization 
studies and binding experiments (i.e. co-IP) combined with cell cycle synchronization, as 
previous studies were only completed in asynchronous cells. 
With the exception of p53, our BioID results did not identify any other purported MELK 
substrates such as FoxM1, CDC25B, or eIF4B (73–75).  While there are countless potential 
explanations for these negative results, it may be a worthwhile endeavor to repeat the BioID 
experiments with further technical optimization.  First, HeLaS3 cells should likely be used, given 
that the mitotic delay phenotype has largely been characterized in this cell line.  Second, stable 
cell lines harboring tetracycline-inducible BirA*-MELK fusions should be created and biotin 
exposure timing should be optimized.  Third, the use of BioID2 could be investigated.  This 
upgrade to the original BioID utilizes a BirA protein with additional mutations, which allows for 
much more rapid biotin labeling of proteins in cells (198, 199).  These optimization steps would 
allow for tight temporal control of fusion protein expression and proximal protein biotinylation, 
thereby making it possible to combine cell cycle synchronization with BioID to identify putative 
MELK interactors at specific cell cycle stages (e.g. the G2/M checkpoint).  Optimization of the 
BioID system could be completed in parallel with, or prior to, the aforementioned interaction 
validation studies to refine the list of putative MELK interactors. 
Our phosphoproteomic MS results identified S481 of FoxM1 as a putative MELK 
phosphorylation site (Table 4.1), and we demonstrated slightly increased transcriptional activity 
of the phosphomimetic FoxM1-S481D and -E mutants (Fig. 4.9B).  This increase in activity, 
however, was substantially less than what was observed with high levels of MELK 
overexpression (Fig. 4.8B), suggesting that MELK may phosphorylate additional residues to 
113 
further activate FoxM1, or that the phosphomimetics acted as poor substitutes for actual 
phosphorylation.  To identify additional FoxM1 sites that are phosphorylated by MELK, we 
could repeat the approach employed for replicate 3 of our experiments, in which FoxM1 was 
phosphorylated by MELK in vitro.  A TiO2-based phosphopeptide enrichment strategy could 
also be used to potentially improve FoxM1 sequence coverage.  If these strategies were to reveal 
additional MELK phosphorylation sites, results should be validated using FoxM1 mutation 
studies, as before (Fig. 4.9B).  Upon validation, phosphomimetic mutations of newly identified 
regulatory sites could be made in FoxM1-S481D and -E mutants to determine whether these 
double (or triple, etc.) mutants exhibit activity approaching the levels observed with high levels 
of MELK overexpression (Fig. 4.8B).  Any additional regulatory sites that are identified should 
be characterized to test the effects of phosphorylation of these sites on FoxM1 localization, 
stability, and promoter binding.  Collectively, these experiments would serve to improve our 
understanding of the mechanism by which MELK activates FoxM1 transcriptional activity.  
The synergy screen uncovered three compounds that appeared to enhance the potency of 
8a (Fig. 4.11), but attempts at validation with MTS assays did not replicate these results (Fig. 
4.12).  We do not have a definitive explanation for these divergent findings, but limited evidence 
suggests this effect may in part be due to differences in cell confluency between the synergy 
screen and MTS assays.  One study has demonstrated that MELK knockdown or genomic 
deletion has virtually no effect on viability when assays are completed with near-confluent cells, 
but proliferation is impaired in assays completed with cells plated at low-confluency (19).  We 
tested whether the same effect can be observed with MELK inhibition, and indeed observed that 
the IC50 of 8a in MDA-MB-231 cells varied up to 20-fold in crystal violet cell viability assays 
with differential seeding densities (data not shown).   
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We previously showed that the IC50 of 8a in MTS assays with TNBC cells is around 2 
μM (Fig. 3.3), yet in the synergy screen, when cells were plated at high confluency on a 384-well 
plate, 3 μM 8a alone had essentially no effect on the viability of MDA-MB-231 or MDA-MB-
468 cells.  These results indicate that careful consideration for cell seeding density must be taken 
in future experiments.  The synergy screen could be repeated with optimized cell plating and 8a 
concentration ranges to improve the chances of identifying truly synergistic relationships with 
the kinase inhibitors and epigenetic regulators in this screen.  However, therapeutic interest in 
MELK inhibitors has significantly waned following the publication of studies suggesting that 
MELK is not a cancer dependency (16, 18), so it may be wise to delay future synergy studies 
until the requirement for and functions of MELK in cancer are better characterized. 
 
Experimental Procedures 
Antibodies and reagents 
MELK-8a hydrochloride was purchased from MedChemExpress (HY-100368A).  
Nocodazole was purchased from AdooQ Bioscience (A13219).  Dinaciclib was a gift from the 
Gary Johnson lab (UNC).  Flavopiridol was purchased from MedChemExpress (HY-10005).  
UNC0642 (14604), OTX015 (15947), and UNC1999 (14621) were all purchased from Cayman 
Chemical.  Brilliant Blue G (B1131) was purchased from Sigma.  Myc-tag agarose (3400) was 
purchased from Cell Signaling Technology.  The following primary antibodies were also 
purchased from Cell Signaling Technology: CDC25C (4688, 1:1000), Chk2 (2662, 1:1000), 
MELK (2274, 1:1000), p-Chk2 (T68) (2661, 1:1000), p-H2A.X (S139) (9718, 1:1000), p-H3 
(S10) (9701, 1:1000).  β-actin (sc-47778, 1:500) and FoxM1 (sc-502, 1:2000) antibodies and 
protein A/G PLUS-agarose (sc-2003) were purchased from Santa Cruz Biotechnology.  CDK1 
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(MAB8878, 1:2000) was purchased from Millipore.  Cyclin B1 (ab32053, 1:10000) was 
purchased from Abcam.  FLAG antibody (MA1-91878) was purchased from Thermo. 
The shRNA reagents used in these studies were purchased from Dharmacon™: 
shMELK42 – ID: TRCN0000001642, sequence: 5’-ACAAAGAGACATAGTTAAGAG-3’; 
shMELK46 – ID: TRCN0000001642, sequence: 5’-ATTTCTCTCTTATGCTGGTTC-3’.  The 
pcDNA3 FLAG-MELK construct was a generous gift from the Kevin Dalby lab (UT-Austin).  
The pcDNA3.1 mycBioID plasmid was purchased from Addgene (#35700), for generation of 
BirA*-MELK constructs.  The Myc-FoxM1 and FoxM1 6x-DBE luciferase reporter plasmid 
were generous gifts from the Mike Emanuele lab (UNC) (200).  Myc-FoxM1 mutagenesis 











Cell culture and viability assays 
HEK293T cells were obtained from the ATCC and were cultured in RPMI 1640 (Gibco) 
supplemented with 5% FBS (Millipore) and 1% antibiotic-antimycotic.  Wild-type and RNF168 
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knockout U2OS cells were a generous gift from the Cyrus Vaziri lab (UNC), and were cultured 
in DMEM, high glucose (Gibco) supplemented with 10% FBS and 1% antibiotic-antimycotic.  
MDA-MB-468 and MDA-MB-231 cells were kindly provided by Dr. Gary Johnson (UNC).  
These cell lines were cultured in RPMI 1640 supplemented with 10% FBS and 1% antibiotic-
antimycotic.  All cells were maintained in a humidified chamber with 5% CO2.   
MTS cell viability assays were completed exactly as described previously (referred to as 
resazurin assays) (14). 
 
Immunoblotting 
All immunoblotting was completed exactly as previously described (14). 
 
BioID and mass spectrometry 
The full-length MELK gene was amplified using PCR from the pcDNA3 FLAG-MELK 
plasmid, with XhoI (plus flexible or rigid linker) and BamHI overhangs.  MELK was inserted 
into the pcDNA3.1 myc-BioID plasmid using restriction enzyme cloning to generate the BirA*-
FL-MELK and BirA*-RL-MELK constructs. 
HEK293T cells on 15 cm plates were transfected with BirA* (pcDNA3.1 myc-BioID), 
BirA*-FL-MELK, or BirA*-RL-MELK plasmids using polyethylenimine (Polysciences, 
#24765).  After 3h, medium was aspirated and replaced with complete medium supplemented 
with 50 μM biotin (Sigma, #B4639).  Cells were returned to the humidified incubator for 16h.  
Plates were washed 2 x 10 mL with PBS (Gibco), then cells were harvested on plates using 1 mL 
room temperature BioID lysis buffer (50 mM Tris, pH 7.4, 500 mM NaCl, 0.4% SDS, 5 mM 
EDTA, 1 mM DTT, 1x protease inhibitor cocktail (PIC) (Roche)), to avoid SDS precipitation.  
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Lysate was transferred to 1.5 mL tubes and sonicated 6 x 3 sec at 35% amplitude.  Samples were 
diluted with an equal volume of ice-cold 50 mM Tris, pH 7.4 and 2% Triton X-100 and stored on 
ice.  Samples, now in BioID2 buffer (50 mM Tris, pH 7.4, 250 mM NaCl, 0.2% SDS, 1% Triton 
X-100, 2.5 mM EDTA, 0.5 mM DTT, 0.5x PIC) were again sonicated, on ice, 3 x 10 sec.  
Lysates were then clarified by centrifugation at 21,000 rcf for 30 min at 4ºC.  Clarified lysate 
was either prepared in Laemmli sample buffer and immunoblotted with HRP-streptavidin 
(Thermo, N100, 1:10000), or stored at -80ºC until ready for pulldown with streptavidin agarose. 
For each sample, 60 μL of streptavidin agarose (Thermo, 20347) was pre-washed 2x with 
BioID2 buffer.  Lysates were applied to equilibrated streptavidin agarose, and rotated for 16h at 
4ºC to capture biotinylated proteins.  After overnight incubation, beads were pelleted by low-
speed centrifugation (375 rcf) at 4ºC.  Supernatant was aspirated and beads were subsequently 
washed 2 x 750 μL ice-cold BioID2 buffer, followed by 3 x 750 μL washes with TAP buffer (50 
mM HEPES, pH 8.0, 150 mM NaCl, 10% glycerol, 2 mM EDTA, 0.1% NP-40).  Beads were 
resuspended in 750 μL of 50 mM ammonium bicarbonate, pH 8.0, and transferred to siliconized 
low-retention microfuge tubes.  Beads were washed an additional 2 x 750 μL with ammonium 
bicarbonate, pelleted, and supernatant aspirated.  Beads were then resuspended in 100 μL 
ammonium bicarbonate and 1 μg of sequencing grade trypsin (Promega, V511A) was added.  
Samples were incubated at 37 ºC for 16h with constant shaking at 14,000 rpm using an 
Eppendorf ThermoMixer®.  Following overnight trypsin digestion, an additional 1 μg of trypsin 
was added to each sample and samples were incubated for 1h at 37 ºC.  Agarose beads were 
pelleted by centrifugation at 375 rcf, and supernatant containing digested peptides was 
transferred to new low-retention microfuge tubes.  The beads were resuspended 2x with 100 μL 
MS-grade water, pelleted, and supernatant transferred to microfuge tubes containing the previous 
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supernatant to collect residual peptides.  Samples were extracted with ethyl acetate 4x to remove 
detergents, and peptides were desalted using C-18 spin columns (Pierce, 89870).  Samples were 
subsequently analyzed by LC/MS/MS using a Q Exactive HF mass spectrometer.  Data 
acquisition and search, quantification using MaxQuant label-free quantification, and analysis 
were completed as previously described for MIB/MS experiments (14). 
 
MS Data Analysis 
 Data from BioID MS experiments were analyzed using Ingenuity Pathway Analysis 
(IPA) software (QIAGEN) (178).  For both the BirA*-FL-MELK and BirA*-RL-MELK 
samples, the ratio of the abundance of each protein quantified in the BirA*-MELK sample to the 
abundance of that protein in the BirA* control sample was calculated.  This value was averaged 
between the two biological replicates.  Proteins with a ratio of abundance ≤ 1.5 (BirA*-MELK to 
BirA*) were filtered from the data, and the remaining proteins were submitted to IPA for further 
analysis.  IPA output data were analyzed according to the diseases and disorders associated with 
the proteins in each dataset, and the canonical pathways to which each protein was assigned.  
Ranking was done according to the significance (-log(p-value)) of their overlap with canonical 
pathways, as calculated by IPA. 
 
Immunoprecipitation 
 HEK293T cells were transfected using polyethylenimine with FLAG-MELK or Myc-
FoxM1 as indicated, and lysed for IP after 24h with either CHAPS buffer (40 mM HEPES, pH 
7.5, 120 mM NaCl, 0.5% CHAPS, 2.5 mM Na3VO4, 10 mM NaF, 1x PIC) for FLAG IP, or 
NETN buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 0.5% NP-40, 0.5 mM EDTA, 2.5 mM 
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Na3VO4, 10 mM NaF, 1x PIC) for Myc IP.  Lysates were sonicated 3 x 5 sec on ice, clarified by 
high-speed centrifugation at 4ºC, and protein was quantified by Bradford assay (Bio-Rad).  Equal 
volumes of each sample containing equal amounts of protein (0.5-1 mg) were incubated with 
either 20 μL pre-equilibrated Myc agarose for 3h, or FLAG Ab for 3h followed by 50 μL protein 
A/G beads for 1h.  For mock IPs, samples were incubated with protein A/G beads for equivalent 
times.  All incubations were done at 4ºC with rotation.  Beads were washed 2-3x with 500 μL of 
the appropriate lysis buffer, and pelleted by low-speed centrifugation at 4ºC.  Bound proteins 
were eluted from beads by boiling in Laemmli sample buffer and analyzed by immunoblot. 
 
FoxM1 transcriptional reporter assay 
 HEK293T cells were transfected with a FoxM1 6x-DBE luciferase reporter construct and 
Myc-FoxM1, FoxM1-S481 mutants, or FLAG-MELK as indicated.  After 48h, cells were 
collected and lysed, and a luciferase assay (Promega, #E1500) was completed in a 96-well plate 
according to the manufacturer’s protocol.  Luminescence was measured to quantify 
transcriptional activity. 
 
In-cell and in-vitro phosphorylation of FoxM1 by MELK 
 For replicates 1 and 2, Myc-FoxM1 (control) or Myc-FoxM1 and FLAG-MELK were 
overexpressed in HEK293T cells.  After 24h, cells were lysed and a Myc pulldown was 
completed as previously described.  For replicate 3, Myc-FoxM1 was overexpressed in 
HEK293T cells for 24h, cells were lysed, and pulldown with Myc agarose was completed.  Myc-
FoxM1 bound to beads was incubated, with shaking, for 1h at 30ºC in kinase reaction buffer (40 
mM Tris, pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA, 2.5 mM Na3VO4, 10 mM NaF, 20 mM DTT, 
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150 μM ATP) with or without 100 ng of active MELK (1-340) (SignalChem Lifesciences 
Corporation, M50-11G).  For all replicates, agarose-bound FoxM1 was eluted from beads by 
boiling in sample buffer.  Samples were resolved by SDS-PAGE (120 V, 1h) and gels stained 
with Coomassie stain (0.1% Brilliant Blue G, 50% methanol (v/v), 10% glacial acetic acid (v/v)).  
Gels were destained (10% methanol, 5% glacial acetic acid) and bands corresponding to FoxM1 
were excised and transferred to low-retention microfuge tubes. 
 
In-gel trypsin digestion, MS, and data analysis 
 Gel slices were further destained (50% methanol, 5% glacial acetic acid) by shaking at 
37ºC for 20 min to remove all bound Coomassie.  Gel slices were dehydrated with 1 mL of 100% 
acetonitrile (ACN) for 5 min, ACN was aspirated, and gel slices were dried completely (~10 
min) using a vacuum concentrator (LabConco CentriVap).  The gel slices were rehydrated with 
400 μL of 100 mM ammonium bicarbonate, and proteins reduced by addition of 8 μL of 500 mM 
DTT.  Samples were incubated at room temperature for 30 min, and DTT solution was aspirated.  
A 400 μL volume of 55 mM iodoacetamide (in 50 mM ammonium bicarbonate) was added to 
each tube, and samples were incubated for 30 min at room temperature in the dark.  
Iodoacetamide solution was aspirated, gel slices were washed by addition of 1 mL of 50 mM 
ammonium bicarbonate, and samples were incubated for 10 min at room temperature.  The 
solution was aspirated and gel slices dehydrated with 1 mL ACN for 5 min, rehydrated with 400 
μL of 100 mM ammonium bicarbonate for 10 mins, and dehydrated again with 2 x 800 μL ACN.  
Gel slices were dried using a vacuum concentrator.  A 150 μL volume of ice-cold 50 mM 
ammonium bicarbonate containing 3 μg trypsin was added to each sample.  Tubes were 
incubated on ice for 1h, followed by incubation at 37ºC for 16h. 
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 The trypsin solution, containing trypsinized peptide fragments, was transferred to a new 
low-retention microfuge tube for each sample.  A 200 μL volume of 100 mM ammonium 
bicarbonate was added to each tube containing gel slices, and tubes were vortexed and incubated 
10 min at room temperature.  Ammonium bicarbonate was removed from each sample and 
combined with the previous trypsin solution for that sample.  Peptides were extracted from gel 
slices with 2 x 100 μL of extraction solution (1% trifluoroacetic acid, 50% ACN), tubes 
incubated for 10 min at room temperature, and solutions pooled with peptide solutions from 
previous steps.  Peptides were dried using a vacuum concentrator (~1h), then rehydrated using 
200 μL of 5% ACN, 0.5% trifluoroacetic acid (in MS-grade water) and desalted using C-18 spin 
columns according to the manufacturer’s protocol.  Dried peptide samples were stored at -80ºC 
until ready for MS analysis. 
 LC/MS/MS analysis was completed as described previously (14).  The phosphoRS node 
in Proteome Discoverer™ software was used to assign FoxM1 phosphorylation site localization.  
MS/MS spectra of all phosphorylation sites were manually validated.  The data were normalized 
by calculating the ratio of abundance (area, in Proteome Discoverer™) of FoxM1 in the MELK 
sample compared to the control sample.  The abundance of each quantified phosphopeptide in 




 Cell seeding, drug treatments, and viability measurements by CellTiter-Glo® assay were 
completed as described previously (171).  MELK-8a was screened at 12, 37, 111, 333, 1000, and 
3000 nM in combination with each of 176 compounds, screened at 3, 10, 30, 100, 300, and 1000 
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nM, from a library consisting of kinase inhibitors and epigenetic regulators.  Synergy screens 
were completed in MDA-MB-231 and MDA-MB-468 cell lines.  Dose-response curves were 
generated and IC50 values calculated using GraphPad Prism. 
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Tables and Figures 
Table 4.1. FoxM1 phosphosites identified by MS.  In replicates 1 and 2, either FoxM1 or 
FoxM1 and MELK were overexpressed in HEK293T cells for 24h, prior to collection.  In 
replicate 3, overexpressed FoxM1 was immunoprecipitated from HEK293T lysate, purified, and 
incubated with or without active MELK for 1h.  Samples were prepared for MS and analyzed as 
described in Experimental Procedures.  The ratios of the abundance of each phosphosite 
quantified in the FoxM1 + MELK sample to the abundance in the control sample are shown.  
Missing values indicate that the peptide containing that phosphosite was not identified in either 
sample.  N.Q. indicates that the peptide containing that phosphosite was identified, but not 
quantified in either sample.  A – indicates that the peptide containing that phosphosite was 
quantified only in the control sample.  A + indicates that the peptide containing that phosphosite 





Table 4.2. List of all library compounds used in the synergy screen.  The 176 kinase and 










Figure 4.1. BioID schematic.  BioID schematic with BirA*-MELK fusion protein.  Interacting 
and proximal proteins that fall within the ~10 nm labeling radius (green circle) of BirA*, 
including MELK, will be biotinylated.  Direct interactors may not be biotinylated if they are 




Figure 4.2. Treatment with 8a causes increased phosphorylation of H2A.X (S139) and 
activation of Chk2.  A, asynchronous HeLaS3 cells were treated with DMSO or 0.5, 1, or 3 μM 
8a for 1, 2, 4, 8, 12, or 24h.  Cells were harvested and immunoblotted with the indicated 
antibodies.  B, Wild-type (WT) or RNF168 knockout (KO) U2OS cells were treated with DMSO 
or 8a at concentrations ranging from 1 nM to 30 μM in quadruplicate.  Cells were exposed to 8a 






Figure 4.3. BirA*-MELK fusion protein design.  A, domain structure of MELK.  UBA = 
Ubiquitin-associated domain.  KA1 = Kinase associated domain-1.  B, two BirA*-MELK fusion 





Figure 4.4. Biotinylation of proximal proteins differs between BirA*-MELK constructs and 
BirA* control.  HEK293T cells were transfected with BirA*, BirA*-FL-MELK, or BirA*-RL-
MELK, and 3h after transfection media was supplemented with 50 μM biotin.  Following 16h 
incubation with biotin-supplemented media, cells were harvested for immunoblot.  Biotinylation 
of proteins was detected using streptavidin-HRP.  Short (left) and long (right) exposures are 
displayed.  Regions of apparent differential protein biotinylation between BirA* (blue box) and 





Figure 4.5. Analysis of BirA*-MELK MS data using IPA.  The BioID experiments and MS 
analysis were completed as described in Experimental Procedures.  For both MELK BioID 
constructs, the ratio of the abundance of each protein quantified in the BirA*-MELK sample to 
the abundance of that protein in the BirA* control sample was calculated.  This value was 
averaged between the two biological replicates, and proteins with a ratio of 1.5 or higher were 
submitted to IPA for bioinformatics analysis.  A, the top 5 diseases and disorders predicted from 
IPA analysis of all proteins that passed cutoffs in the BirA*-FL-MELK (left) and BirA*-RL-
MELK (right) datasets are displayed.  B, the proteins in the BirA*-FL-MELK (top) and BirA*-
RL-MELK (bottom) datasets were ranked according to the significance (-log(p-value)) of their 
overlap with canonical pathways, as calculated by IPA analysis.  The top 7 pathways are 





Figure 4.6. BioID and IPA analysis identified putative MELK interactors with roles in cell 
cycle processes.  The ratio of the abundance (BirA*MELK to BirA* control) of each protein 
assigned to the G2/M DNA damage checkpoint pathway (A) and chromosomal replication 
pathway (B) in IPA are displayed.  C, additional proteins with high ratios of abundance 





Figure 4.7. Investigation of a putative MELK-CDK1/cyclin B1 interaction.  A, FLAG-
MELK was overexpressed in HEK293T cells.  Cells were lysed and equal volumes of lysate 
were tumbled with either protein A/G agarose beads (mock IP) or FLAG antibody-linked A/G 
agarose beads (FLAG IP).  Equal volumes of pulldown eluate were immunoblotted with MELK, 
CDK1, and cyclin B1 antibodies.  Images for input, mock, and FLAG IP bands were spliced next 
to one another due to sub-optimal loading conventions.  Images for each target are from the same 
membrane, with identical exposures, except for cyclin B1, input sample (shorter exposure due to 
abundance).  B, HEK293T cells were either transfected with shMELK42, shMELK46, or an 
empty vector 48h before collection, or treated with one of the indicated compounds 20h before 
collection, with the exception of 10 μM 8a (1.5h treatment pre-collection).  Additionally, cells 
were treated with 100 ng/mL nocodazole 20h before collection.  Cells were harvested and lysates 
were analyzed by immunoblot with the indicated antibodies.  Phosphorylated CDC25C, which 
migrates more slowly than unphosphorylated CDC25C, was used as a marker for CDK1 activity.  
The amount of unphosphorylated and phosphorylated CDC25C was quantified by densitometry 
using Bio-Rad Image Lab™ software, and the ratio of unphosphorylated CDC25C to total 




Figure 4.8. MELK interacts with FoxM1 to increase FoxM1 transcriptional activity.  A, 
Myc-FoxM1 and FLAG-MELK were overexpressed in HEK293T cells.  Cells were lysed and 
equal volumes of lysate were tumbled with either protein A/G agarose beads (mock IP) or Myc 
antibody-linked A/G agarose beads (Myc IP).  Equal volumes of pulldown eluate were 
immunoblotted FoxM1 and MELK antibodies.  B, HEK293T cells were transfected with Myc-
FoxM1 and a FoxM1 transcriptional reporter construct (6 x DB).  Cells were additionally 
transfected with varying amounts of FLAG-MELK.  After 48h, cells were lysed and lysates were 
incubated with luciferase assay reagent.  Luminescence was measured to quantify FoxM1 





Figure 4.9. FoxM1-S481A/D/E mutants may display differential transcriptional activity.  A, 
FoxM1 domain structure.  NRD = N-terminal repressor domain.  FKH = Forkhead homology 
domain.  TAD = Transactivator domain.  Binding sites of the APC/C and phosphorylation sites 
of putative (MELK) and established (PLK1 and CDKs) FoxM1 kinases are indicated by pink and 
green arrows/lines, respectively.  Blue lines above the domain structure represent approximate 
phosphorylation density, as collated in the PhosphoSitePlus® database 
(www.phosphosite.org/proteinAction.action?id=2992&showAllSites=true).  B, HEK293T cells 
were transfected with Myc-FoxM1 WT, -S481A, -S481D, or -S481E, and a FoxM1 
transcriptional reporter construct (6 x DB).  After 48h, cells were lysed and lysates were 
incubated with luciferase assay reagent.  Luminescence was measured to quantify FoxM1 





Figure 4.10. Schematic of the screen for compounds that synergize with MELK-8a.  MDA-
MB-231 and MDA-MB-468 cells were seeded on 21 384-well plates each.  24h after seeding, 
cells were treated with either DMSO or one of six concentrations of 8a, in combination with 
DMSO or one of six concentrations of each of 176 library compounds.  Cell viability was 





Figure 4.11. Synergy screen top hits were identified as UNC0642, OTX015, and UNC1999.  
Dose-response curves were generated for each compound in the synergy screen, and top hits 
were identified by manual inspection of all dose-response curves.  The dose-response curves for 
the top three hits, UNC0642 (A), OTX015 (B), and UNC1999 (C), are displayed for both MDA-





Figure 4.12. Secondary cell viability assays indicate no synergy between 8a and UNC0642, 
OTX015, or UNC1999.  Cells were exposed to a combination of 1, 3, 10, 30, 100, 300, 1000, 
3000, 10000, or 30000 nM 8a, or DMSO, and the indicated library compound at 3, 10, 30, 100, 
300, 1000, or 3000 nM, or DMSO, for 72h.  Viability was measured by MTS assay as described 
in Experimental Procedures.  Dose-response curves for UNC0642 (A), OTX015 (B), and 




CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 One of the main strategies used to generate novel cancer treatments is to identify 
molecular targets that cancer cells rely on for growth and survival, moreso than non-neoplastic 
cells, and to develop compounds to inhibit these targets.  While this is somewhat of a simplified 
model, the development of many targeted cancer therapies has taken this general approach.  The 
MELK controversy, on the other hand, demonstrates that the investigation of putative drug 
targets does not always neatly fit this reductionist model.   
MELK was identified as an attractive target in multiple cancers in 2005, in a study that 
showed an upregulation of MELK in cancer and slowed proliferation following MELK silencing 
(5).  Over the subsequent decade, many studies focused on repeating and expanding these 
methods to identify MELK as a target in additional cancer types, without significantly advancing 
our understanding of the function of MELK.  As the list of cancers for which MELK seemed to 
be a viable target grew, inhibitor development efforts were launched with haste.  The first 
inhibitor to be developed and published (OTSSP167) was touted as highly MELK-selective (10).  
Unfortunately, by the time it was first revealed that OTS was actually very poorly selective (13), 
the field had already adopted it as the primary small-molecule tool compound to use in 
functional studies.  Despite the fact that dozens of MELK inhibitors have since been published 
with far superior selectivity profiles, the field has been slow to adopt these alternatives, which 
has further obfuscated our understanding of the functions of MELK in cancer.  More recently, 
CRISPR-based techniques were used to allege that MELK is dispensable for cancer growth, and 
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thus is not a viable cancer target.  Given that there is such a lack of understanding of the 
fundamental functions of MELK, I would argue that the question we should be focused on at the 
moment is not ‘is MELK a requirement in cancer?’ but rather ‘what does MELK do in cancer?’  
By working towards an answer to the latter question, the field should be able to approach an 
answer to the former one. 
In chapter 1, I analyze the evidence on both sides of the controversy concerning the 
requirement for MELK in cancer.  I also discuss MELK inhibitors, processes thought to be 
regulated by MELK, mechanisms of regulation of MELK expression and activity, and reported 
MELK substrates.  While our understanding of the latter three topics is certainly not 
comprehensive, considerable strides have been made since the first CRISPR publications. 
In chapter 2, I show that treatment of pancreatic cancer (PC) cells with gemcitabine 
induces MELK expression, and that MELK knockdown slows PC cell proliferation.  I also detail 
our efforts to identify novel MELK inhibitors.  Multiple lead compounds were identified that 
impair PC cell viability, but the top hit (UNC2025) had only moderate selectivity for MELK and 
failed to sensitize cells to gemcitabine.  While the CRISPR studies cast doubt on whether MELK 
is truly a viable target in pancreatic and other cancers, the observation that gemcitabine 
upregulates MELK expression is compelling.  MELK upregulation has also been observed with 
radiation therapy and treatment with other chemotherapeutics, including 5-fluorouracil.  Future 
studies should further investigate the mechanism underlying this radio- and chemotherapy-
induced upregulation of MELK, as it could serve to improve our understanding of MELK 
function in the DNA damage response. 
In chapter 3, I used the competition MIB/MS technology to evaluate the selectivity of the 
inhibitors OTS, HTH-01-091 (HTH), and NVS-MELK8a (8a) for MELK.  Results showed that 
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OTS is very poorly selective, in agreement with other studies, HTH does not inhibit MELK in 
cells when used at 1 μM, and 8a is highly selective for MELK at 1 and 3 μM.  Impaired TNBC 
cell viability was observed in the 1 to 3 μM 8a range, indicating that antiproliferative effects 
were likely a result of MELK inhibition.  Interestingly, with treatment times up to 24h, an 
induction of apoptosis was not observed, but rather cell cycle progression was perturbed.  I 
further investigated this cell cycle defect, and determined that HeLaS3 cells treated with 8a 
exhibited a delay in mitotic entry, associated with delayed activation of Aurora A, Aurora B, and 
CDK1.  These mitotic kinases were ultimately activated, approximately 2h later than in untreated 
cells, which facilitated delayed mitotic entry and progression through mitosis.  A similar mitotic 
delay phenotype was observed in U2OS cells, along with a less pronounced impairment of 
mitotic progression.  These results suggest that the G2/M DNA damage checkpoint is transiently 
activated in response to MELK inhibition with 8a.   
In chapter 4, I probed for a deeper mechanistic understanding of this mitotic delay 
phenotype.  I found that 8a treatment caused a dose-dependent induction of the DNA DSB 
marker p-H2AX (S139) and activation of Chk2, as measured by phosphorylation of T68.  Using 
BioID to investigate MELK protein-protein interactions, a number of putative interactors that 
participate in the chromosomal replication (MCM complex, PCNA) and G2/M DNA damage 
checkpoint (CDK1, cyclin B1, 14-3-3 proteins, p53) processes were identified.  Attempts at 
validation of these interactions have been inconclusive to date.  The MELK-FoxM1 relationship 
was interrogated with the goal of determining how MELK phosphorylation regulates FoxM1 
transcriptional activity.  I observed a direct interaction between MELK and FoxM1, along with 
increased FoxM1 activity, in agreement with other studies.  Furthermore, a putative FoxM1 
phosphorylation site regulated by MELK was uncovered (S481), and mutation of this site to 
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phosphomimetic or non-phosphorylatable residues may modulate FoxM1 activity.  Finally, I 
used a library of kinase inhibitors and epigenetic regulators to complete a synergy screen with 
the goal of uncovering molecules that synergize with 8a in TNBC cells.  Three compounds 
exhibited apparent synergy with 8a in the screen (UNC0642, G9a/GLP inhibitor; OTX015, 
BRD2/3/4 inhibitor; UNC1999, EZH1/2 inhibitor), but subsequent attempts at validation using 
viability experiments did not replicate these results. 
Future studies should focus on elucidating the mechanism underlying the cell cycle 
phenotypes observed in chapter 3.  With the added information from chapter 4 that the Chk2 
DDR pathway is activated by MELK inhibition, along with an induction of p-H2AX (S139), we 
can begin to form more detailed hypotheses about the role of MELK in the cell cycle.  A putative 
interaction with the MCM complex, identified with BioID, suggests that MELK may regulate 
DNA replication.  Thus, inhibition of MELK may impair faithful replication such that DNA 
DSBs form and the Chk2 DNA damage pathway is activated.  Experiments to assess the effects 
of MELK inhibition on MCM complex loading onto DNA and the timing of S phase progression 
would begin to test this hypothesis.  The effects of MELK inhibition on the G2/M checkpoint 
could potentially be explained by a direct interaction with CDK1 or cyclin B1, thereby 
modulating CDK1 activity, or by regulation of FoxM1 activity, thereby interfering with the 
transcription of genes required for mitotic entry.  Both hypotheses should be investigated, though 
a direct interaction with the CDK1/cyclin B1 complex would be more novel, and could perhaps 
have broader implications for the cell cycle field’s understanding of mitotic entry regulation.  
Basic protein-protein interaction studies should first be used to determine whether a direct 
MELK-CDK1/cyclin B1 interaction occurs in cells, before attempting to elucidate the specific 
mechanistic effects of this interaction in greater detail.  The observed effects of 8a on mitotic 
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progression match what others in the field have reported, and could also be mediated by MELK-
CDK1/cyclin B1 or -FoxM1 interactions.  Precise cell cycle synchronization techniques should 
be used with similar protein-protein interaction studies to probe these relationships in mitosis. 
Collectively, the experiments presented in this dissertation advance our functional 
understanding of MELK in the cell cycle and improve upon the tools available to investigate this 
enigmatic kinase.  Our results, and the results of others, demonstrate definitively that the 
inhibitor OTSSP167 is poorly selective for MELK, and thus should not be used in future 
functional studies.  Instead, NVS-MELK8a should be used in all studies of MELK function, as 
our work has validated the high selectivity of this compound in cells.  The use of 8a in functional 
MELK studies should greatly improve the rigor and reproducibility of future research in this 
field.  Our collective poor understanding of MELK substrates represents a major gap in the field 
that must be addressed.  Specifically, the validation of a reliable measure of MELK activity in 
cells is badly needed.  The measurement of MELK inhibitor-induced MELK degradation as a 
measure of cellular activity has not been well-validated, and the underlying mechanism is 
unclear; thus, this practice has the potential to produce confounding or misleading results.  
Beyond this, the field must place an emphasis on characterizing the functions of MELK in 
cancer.  Much evidence, including some presented in this dissertation, point to an important role 
for MELK in cell cycle progression, particularly in G2 and M phases.  By elucidating the 
functions of MELK in these and other processes, the field will be able to move towards an 
explanation for the disparate cell viability effects observed with RNAi and CRISPR, which 
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